AMENDMENT OF SOUCITATIONIMODIFICATION OF CONTRACT
~MENDMENTIMODIFICA'DON NO. REQ.NO. FO0253
6. ISSUED BY· CODE <.:.:.;:...;.;;:;:.::;..... __-17. ADMINISTERED BY (Ifotlo""than - DCMARAYTHEON U8A8MOCIARSTRAT 5DAPfILE HiLl ORIIIE SMOC-ROC MlST2FR2 POBOX 1800 TEWCllBURY MA 01818 HUNTSIIIU AI.. 3e11D7·3801
8. NAME AND ADDRESS OF CONTRACTOR (No., ~reet, Colllty, ~atc and Zip Code) RAYTHEON COMPANY 360 LOY.aL ST. ANDO\IERMA0181~
10.o\.M2D. OF CONTRACTIORDERNO. ll'ougvo98-c.ooo1
nUnDored lolioilalion ia ~ ..-ut IKth in Item 14. 1hobourond dlla l!*itad "r~p' o~ i. not ClIlDllded. O. nu.1 IckDowledsa ra"pl orlbi ...... 01 ....' priorto tha bour Ind dlla Ipeoiled in tba lolicllalion or _ .-.ncIad by One oftbe 1fI1IowiDS .-thoda: (I) By eOJqlllllinB It_ 8 IIId 15, ..01 retumins ""pi. ortba _dlllml; (b) BylClcnowledsi. reoeipl oftbi. _01_1 OlD ... oopy oflbl 0.,ubnitted; or (e) By lapll1lllleltaror toles_which inelud~ce to die .olicitalion.nd _dillin, nunDln. FAILURE OF YOURACKNOWLEDOMENTTO BE RECEIVED AT1HE PLACE DESIGNA mD FOR 1HE RECElPTOF OFFERS PRIOR '10 lHE HOUR AND DATE SPECIFIBD MAY RESUL TIN REJECTION OF YOUR OFFBR. Ifby virtul ofthil_dllllllt YOII deaiteto chuBe In 0. "rudy .ubnilted, luch chinS. n)' b..... a by Ielesnmor lellar, provided _h talosnunor lottar 1liiie .. ra .....ce to the lolimtatioa .nd Ihilllllllldll'Et, ..d i. received prior to the opllllins hour ud dale epecifed. ACCOUNTING AND APPROPRIATION DATA (lfrequircd)
13. THIS ITEM APPLIES ONLY TO MODIFICA IT MODlFIESTHECONTRACfIORDER THIS CHANGE ORDER IS ISSUED PURSUANT TO: (SPecifY althorlty) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA.
TO REFLECT THE ADMINISTRATIVE \..nIU'I'..E.i> (such as chanlCS in paying P~ANT TOTHE AUTHORITY OF FAR
OTHER (~ecify type of modification and authority)
E. IMPORT ANT: Contractor [!] is not, 0 is required to signlhis II provided hlmn, alii.",. and ocnditioal oftbe doculllDllt reimJced ia IItm9A or lOA, II \. NAME AND TITLE OF SlCIIIER (Type or print) IS8.00NTRACTORIOFFEROR I SC. DATE SIGNED 30·105·04 STANDARD FORM 30 (Rev. 10·83) APPROVED BY OIRM 11-84 Prescribed by GSA OOd.'501 FAR (48 CFR) 53.243 DASG60-98-C-OOO 1 P00253 Page 2 of2 SECTION SF 30 BLOCK 14 CONTINUA nON PAGE (End of Summary of Changes) OO~50~ AMENDMENT OF SOLICITATIONIMODIFICATION OF CONTRACT v DCMA RAYTHEON USASMDClAASTRAT "API'\,,( HIll. ORNE SMOC·RDC PO !lOX 1!Dl ,.,,"'"lEWIS8URY 1M 01878 HUNT$'v1J.£ It. 39107.:311)1 AND AO[)RFS'\OF mNTRACfOR (No .• Sh eet, County, !ialc and Zip Co~ ) RAYTHEON COMP.IHY 3eOlCW'aL.1T. ANOO'JER MA 018'1(l.4O) (SEE ITEM II) l OA. MOO. OF CONTRACfK>ROER NO. 0l.SG60-98-COOO1 lOB. DATED (SEE ITEM 13) I I , , i ...' .... d.d II Hlllnb ;mI ,em 14. ThehourOlld datupacilod brrocclp. " fUji, o iUJllended, D 101l0t e>IIendtd . Oltr ""a. tdno.. ( cod lle '-;pl oflbi • ...,lIdlllmt priono tbo bour IIIId dote . , ,,,,' Ied i. dle.olici, ..i()n Or" ...... ded by one oftb ,l>lIo"'08 _bodt: (0) By ...,,,,,1"'08 II .... , ..01 I ".lIIId reI"",ill8 ___ O(Ipi .. ortbe _dIJo:OI: (b) By ICkQowledaioi rltCelpl ofthi.ln"ClIdmeoot on cICb copy oflbc ob n brritted: or(e) By .epant. letIoror telIS""" .... kkb iBcl,,"" • rri_ to IbuolicilatiOfl W _01""", n ...... , FAILURE OF YOURACXNOWlEOOMllNTlO 8E RECEM!O "TTHE PLACE DESIGNATED FOR 1M!> RECEIPTOf OFfERS PRIO R 10 nil! HOUR AND 010 TE SPECIFIED MA Y RElIU l TIN REEC'nON OF YOUR OFFEL Ifby y;lt"oorth,. omeod .....' yOil d"',..lo ...... lOll 0. 1I....ty ..haiRed , l udl dlq. -.y be...scby 1eI ...... or lemr, pravide:l -=h td q"""'" Ielter .....eo ...... to the oolicilot;"" ..d this _dmtnt. tnd ;1 received prior lO!!Ie opaili>a hour _d dote . pea,*,. See Schedule CII ANGE ORDER ITBM 14 ARE MADE IN THE CONT RAcr ORDER NO. IN ITEM l OA. as changes in payins I THIS SUPPLEMEm AL A Co ntractor isnO I, is reqJiredlo sign this OOCI.IneDI andretWl oop;es to the issuillg offlCC. . DESCRIPTION (Organized by UCF sectioo beadings, incilking solicitationloontract subject matter ""'ere feasible.) Modification Control Number: (b)(6) To issue a change order training due to replacement of sotjiers conductilg the LUT as oulli\ed In a:AM-CAB-B letters, JLENS-2012· 012 and JJ..eS.2012-018, dated Mlrch 30, 2012 and Aprl2S, 2012, respectively. The required trairlng is as foBow s: Genie Man-Lift Trairling, lAah Test and Training Range (LITlRj , 12 students: fight Ci'ector Training, ~ 6 students; and Maintainer Course Training, lJTTR 17 students . . , -toNAME AND TITLE OF SIGlER (Type or print) (b)(6) COm'RACfORlOFFEROR DATE SIGNED I )0 (Rev. 10-83) APPROVED BY OIRM 11-84 Prescribed by GSb. FAR (43 CPR) 53.24) DASG60-98-C-000 1 P00254 Page 2 of12 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES 1. SECTION A - SOLICITATION/CONTRACT FORM The total cost of this contract was increased by $724,879.00 from $1,920,203,430.00 to $1,920,928,309.00. 2. SECTION B - SUPPLIES OR SERVICES AND PRICES SUBCLIN 0017AA The target cost has increased by from to ,:====~ The target profit/fee has increased by from to. 7 The total cost of this line item has increased by $724,879.00 from $1,682.454.983.00 to $1,683,179,862.00. This includes an increase in target cost of :onsisting of cost and a lcrease in facilities capital cost of money, and an increase in target fee target cost less facilities capital cost of money. CLIN 0030 The total cost of this line item has increased by•••• tr,O~J ••••• to t•••••••• • As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 00 17 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. SUBCLIN 003002 is added as follows: ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNlTPRICE AMOUNT 003002 GFEBS Funding for SubCLIN 0017AA CPIF FOB: Destination ACRNMX $719,132.00 CIN: GFEBSOOlO17438300030 B-17. INCENTIVE FEE FOR SUBCLIN 00 17AA1CLIN 0018 (SEEH-19): In accordance with FAR 52.216-7, entitled "Allowable Cost and Payments", and FAR 52.216-10, entitled "Incentive Fee", the total amount for reimbursement of cost and fee for performance under SubCLIN 0017AAlCLlN 0018 are set forth below: Target Cost oo~S04 DASG60-98-C-000 1 P00254 Page 3 of 12 Target Fee (b )(4) Incentive Arrangement: Maximum-- Fee: (b )(4) Minimum Fee: (Share Ratio: Government/Contractor) (b )(4) Underrun: __or the amount by which the total allowable cost is less than the target cost until maximum fee is attained. Overrun: ••• the amount by which the total allowable cost exceeds the target cost until minimum (b) (4) fee is attained. FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows: (e) Fee Payable. (1) The fee payable under this contract shall be the target fee increased b_nts for every dollar that (b )(4) the total allowable cost is less than the target cost or decreased b~ts for every doilail1lat the total allowable cost exceeds the target cost. In no event shall the fee be greater th~ent or less th~cent ofthe target cost. (b )(4) B-18. TARGET COST. TARGET FEE. I'.1INIMUM INCENTIVE FEE. MAXIMUM INCENTIVE FEE. AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA/CLIN 0018: SUBCLIN 0017AA - (Two SDD ]LENS Systems) a. Target cost: (b )(4) b. Target fee: (b )(4) (b )(4) c. Minimum incentive fee: (b )(4) d. Maximum incentive fee: (b )(4) e. Total target cost and target fee: $1,683,179,862 3. SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $719,132.00 from $1,876,986,879.63 to $1,877,706,011.63. SUBCLIN 003002 (GFEBS funding for SubCLIN 00 17AA): Funding on SUBCLlN 003002 is initiated as follows: ACRN:MX elN: GFEBSOOI017438300030 oo~5D5 DASG60-98-C-000 1 P00254 Page 4 of12 Acctng Data: 02120122013204000001 171722550030003242A.0000013.1.1 6100.9000021001 Increase: $719,132.00 Total: $719,132.00 Cost Code: A5XFJ Target Cost, Target Fee, and total for the above increase of$719,132 is distributed as follows and includes an increase in target cost os 7 cost and f facilities capital cost of money) and an increase in target fee of_ Target Cost (b )(4) Target Fee u,)..{ Total llo)LIf: IMPLEMENTATION OF AND EXPLANATION OF THERELATIONSillP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows: SUBCLIN 0017 AA : THIS CUMULATIVE PRIOR MODIFICATION TOTAL· (I) Amount Required for Full Funding, Including Fee: $1,682,454,983 $724,879 $ 1,683,179,862 (2) Amount Allotted Under the LOF Clause for Payment of Costs: $ lb)u(. (3) Amount Separately Obligated for Payment of Fee: l~)L~ (4) Total Amount Allotted and Obligated: $1,643,784,189.27 5719,132 51,644,503,321.27 (5) Net Amount Required for Full Funding $ 38,670,793.73 5 5,747 $ 38,676,540.73 • These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17 AH) 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows: Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraph c., is revised as follows: a. General. SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph the Schedule Incentive. The contrac~riceamount of$I,683,179,862 includes a target cost includes ~f cost of facilities capital cost of money) and «-I~ i~ftarget cost ess facilities capital cost of money. b. Cost Incentive. ill The tariet fee.payable under SubCLIN 0017AA i••• fthe target cost less facilities capital cost of money an amount equal to_ DASG60-98-C-OOO I P00254 Page 5 of 12 (2) The maximum fee payable under SubCLIN 0017AA is~the target cost less facilities capital cost of [h)t§l-) ••In amount equal to ••••, (PJL~) ~ fee payable under SubCLIN 0017 AA ~f the target cost less facilities capital cost of money Qo)i80 ___ anamountequalto_ ' (b)l'k) (4) Fee will be adjusted for actual cost that is less than or more than the target cost stated above using a share ratio o~Government /~ontractor for actual costs less than the target cost, and a ratio o~ovemment / ~ontractor for actual costs greater than the target cost range applied according to Paragraph H-19( c)( I). (5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract. c. Schedule and Performance Incentive. (1) A maximum •••••'''flat zone" will be established at the target cost value oq & iith the conduct of milestones "flat zone" over which the contractor will earn target fee is for eligible costs from $ to the milestones set forth below are conducted. (Note: As of the effective date of P00253, only of the maximwi t zone" has been acknowledged as earned.) (a) fthe maximum benefit of the "flat zone", earned by the conduct of the SOD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that ".,.n.. "n ""'1.U1'''~''''' the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee n .."n.P,,,t Reference letter, (b __fthe maximum benefit of the "flat zone", earned by the conduct of SDD Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Rapheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of 2 Final ~1t determination of incentive fee the "Flat Zone" amount will be made of the contract. Reference letter (9y~) (b~) -(c) _1IIIto of the maximum benefit of the "flat zone", earned by the conduct of the Developmental ~L¥' Test I (DT-I) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDn Contract, Section H-19(c), dated 1111111. (It is hereby acknowledged by the government that Rarheon completed ge requirement for this flat zone and earned a "Flat Zone" schedule incentive of ,( of the available , mFinal determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion 0 t e contract.) maximwn benefit of the "flat zone", earned by the conduct of the Electromagnetic (b )(4) (b)0 Environmental in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 1111111. (e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire (b )(4 )PP)l' Control_S Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19( c), dated 1111111. (f) of the maximum benefit of the "flat zone", earned by the conduct of the Functional (b) (4) I};l ) L l Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c). dated J 111/11. 00;)..507 DASG60-98-C-000 1 P00254 Page 6 of12 (3) For Earned Value and cost reporting purposes, the target cost value of$I,463,647,573 will be used. d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the perfonnance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLlN 0017 are added and exercised. the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision. 5. The following is an update to Modification P00252 showing a summary of funding by ACRN through Modification P00254: ACRN FUNDING AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 OOd.)OV DASG60-98-C-000 1 P00254 Page 7 of12 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU . 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 oo!l50Q DASG60-98-C-000 1 P00254 Page 8 of12 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW $10,000,000.00 MX 553,693,415.00 6. The following is an update to Modification P00252 showing a summary of funding by CLlN by ACRN through Modification P00254: FUNDING AMT CLIN TOTAL CLlN 0001 AA 440,100.00 CLINOOOI AD 0.00 ______440,100.00 CLINOO03 AB 2,298,235.00 CLINOO03 AC 17,832,987.00 CLINOO03 AD 0.00 CLIN 0003 AE 7,500,000.00 CLIN 0003 AF 3,300,000.00 CLINOO03 AG 17,192,400.00 CLIN 0003 AH 700,000.00 CLIN0003 AM 17,045,000.00 CLIN 0003 AN 5,800.00 CLIN 0003 AP 20,779,000.00 CLINOO03 AS 0.00 CLINOO03 AT 6,984,678.52 CLIN 0003 AW 100,000.00 CLIN 0003 AY 550,000.00 ______94,288,100.52 CLIN0005 BA 24,527,878.00 CLIN0005 BB 146,000.00 CLIN0005 BC 72,000.00 CLIN 0005 BD 85,000.00 00&510 DASG60-98-C-OOO 1 P00254 Page 9 of12 CLINOO05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BG 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOO05 BL 0.00 CLINOO05 BZ 0.00 65,025,107.00 CLINOO07AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOO09AA BN 21,315.00 447,966.00 CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINOO09AB BK 3,455.00 CLINOO09AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLINOO09AB BV 9,000.00 869,034.00 CLIN0013 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLINOO13 AY 0.00 CLINOO13 AZ 19,412,000.00 CLINOO13 BI 7,896,673.34 38,674,673.34 CLIN0017 BW 0.00 CLIN0017 KM 0.00 0.00 CLIN0017AA BY 3,880,000.00 CLIN0017AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLIN0017AA BZ 0.00 CLINOO17AA KM 192,793,000.00 CLINOO17AA KN 0.00 CLINOO17AA KQ 66,151.00 ooa511 DASG60-98-C-000 1 P00254 Page 10 of 12 CLINOO17AA KS 0.00 CLINOO17AA KT 386,204,200.00 CLINOOI7AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLINOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 CLINOOl7AA LQ 235,566.00 CLINOOl7AA LS 6,069,616.00 CLINOO17AA LT 530,377.00 CLINOO17AA LU $9,100,000.00 CLINOO17AA LV $1,957,265.00 CLINOOl7AA LW $255,567.00 CLINOOl7AA LX $68,000.00 CLINOO17AA LY $264,807,424.52 CLINOO17AA MB $375,000.00 CLINOOl7AA MC $2,283,481.00 CLINOO17AA MD $8,573.00 CLINOO17AA ME $0.00 CLINOO17AA MF $270,514,880.00 CLINOO17AA MH $213,390.00 CLINOO17AA MJ $858,495.00 CLINOO17AA MK $56,076.00 CLINOO17AA ML $116,044.00 CLINOOl7AA MM $1,618,600.00 CLINOO17AA MN $2,573,000.00 CLINOO17AA MP $250,000.00 CLINOO17AA MQ $691,421.00 CLINOO17AA MR $0.00 CLINOOl7AA MS $700,000.00 CLINOOl7AA MT $16,289,524.00 CLINOO17AA MY $39,921,199.75 CLINOO17AA MW $10,000,000.00 CLINOOl7AA MX $53,693,415.00 1,644,503,321.27 CLIN 0017AB KL 118,250.00 ------118,250.00 DASG60-98-C-OOO 1 POO254 Page 11 of12 CLINOO17AC BZ 190,000.00 190,000.00 CLINOO17AD KN 0.00 CLINOO17AD KS 0.00 0.00 CLINOO17AE LL 173,798.00 173,798.00 CLINOO17AH KT 173,798.00 173,798.00 CLIN0020AA KN 0.00 CLIN0020AA KQ 26,660.00 26,660.00 CLIN0021AA KW 0.00 0.00 CLIN0021AB KV 0.00 CLIN0021AB LB 0.00 CLIN0021AB KX 0.00 CLIN0021AB KY 0.00 0.00 CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00 0.00 CLIN0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLIN0023 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00 297,500.00 CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN0024 KZ 25,000.00 CLIN0024 KW 20,000.00 OOQ.513 DASG60-98-C-000 1 P00254 Page 12 of 12 CLINOO24 LP 83,200.00 203,708.00 CLINOO25 LE 1,173,850.00 CLINOO25 LM 1,080,404.00 CLINOO25 MA 0.00 2,254,254.00 CLINOO26 LN 630,061.00 630,061.00 CLINOO27 LZ 1,751,384.00 1,751,384.00 CLINOO28 LM 329.972.00 CLINOO28 MA 2,982,442.00 CLINOO28 MG 6,262,095.00 CLINOO28 MU $7.864.499 17,439,008.00 CLIN 003001 * MX $52,974,283.00 CLIN003002* MX $719,132.00 * eLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards ot the total contract funding obligated. (End of Summary of Changes) OOQ.51l£ AMENDMENT OF SOLICITATIONIMODIFICAnON OF CONTRACT \MENDMENT/MODIFICAnON NO . EFFECTIVE DATE 4. REQUISITION/PURCHASE REQ. NO. R)0255 6. ISSUED BY CODE 7. ADMlNISlERED BY {Ifotherthan item '------1 OCMA RAYTHEON USASMOC/ARSTRAT 50 APPLE HIU. DRIVE SMOC·ROC MlST2FR2 POBOX 1500 TEW 8. NAME AND ADDRESS OF (No., Street, County, State and Zip Code) RAYTHEON COMPANY 350 LO\I\EU. ST. ANOOVER MA0181o-+KlO lOA. MOD. OF CONTRACT IORDER NO. MSG60-98-C-0001 above nUDbercd solicitation is ammded as set fOrth in Item 14. The hour and date specified ilrreceipt ofO. o i. not e>cIended. 0. 11118t acknowledge receipt ofthi. IIIJlOIldment prior to the hour and date specified in the solicitation or as IIIJlOIlded by one ofth. ililowing methods: (8) By couplcting Itoms 8 and IS, and returning copies oflbe urendment; (b) By acknowledging receipt ofthi. ammdm:nt on each copy oflbe 0. Bubnitted; or (c) By sepllIllte l.tter or telegram wbich includ~ce to the solicitation and IIIIIOndmont nunbers. FAll.URE OF YOURACKNOWLEDGMENTTO BE RECEIVED ATmE PLACE DESIGNATED FOR mE RECEIPT OF OFFERS PRIOR TO THE HOUR AND DAlE SPECIFIED MAY RESULT IN REJECnON OF YOUR OFFER Ifby virtue oflbi. ammdmmt you de.ire to cbange an 01lOr a1roady subnitted, such chang. lIllY be lDIde by telegramor letter, provided each telcgramorletter11llke. ref:rence to tbe solicitation and this amendment, and i. reteived prior to the opening hoursnd date specified. 12. ACCOUNTING AND APPROPRIATION DATA (Ifre~d) See Schedule 13. THIS ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACTS'ORDERS. IT MODIFIES THE CONTRACTIORDERNO. AS DESCRIBED IN ITEM 14. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA. TO REFLECT THE ADMlNISfRATIVE CHANCJES(such as changes in paying IN TO THE AlITHORITY OF FAR . THIS SUPPLEMENT AL AGREEMENT IS ENTERED INTO PURSUANT TO AUTHORITY OF: (Specify type of modification and authority) lERAL: FAR 52.232-22, "Linitation of Funds" E. IMPORT ANT: Contractor 00 is not, 0 is required to sign this Iklcument and return copies to the issuing office. 14. DESCRIPTION OF AMENDMENT !MODIFICATION (Organized by UCF section headings, including solicitation/contract subject matter Vlbere feasible.) Modification Control Number: _ (b )(6) To increase Incremental funding in the armunt'!l!5,747. \. NAME AND TITLE OF SIGNER (Type or print) ISB. CONTRACTOR/OFFEROR ISC. DATE SIGNED 16C. DATE SI{S)(6 24-May-2012 30-105-04 Sf ANDARD FORM 30 (Rev. 10-83) APPROVED BY OIRM 11-84 Prescribed by GSA CX)~515 FAR (48 CFR) 53.243 DASG60-98-C-OOO 1 P00255 Page 2 ofl0 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES 1. SECTION B - SUPPLIES OR SERVICES AND PRICES CLIN0030 The total cost of this line item has increased by $5,747.00 from $53,693,415.00 to $53,699,162.00. * * As stated in Modification P0025l, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. SUBCLIN 003003 is added as follows: ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003003 GFEBS Funding for SubCLIN 0017 CPIF FOB: Destination ACRNMX $5,747.00 CIN: GFEBSOOI017438400030 2. SECTION G - CONTRACT ADMINISTRATION DATA AccoWlting and Appropriation Summary.for the Payment Office As a result of this modification, the total funded amount for this document was increased by $5,747.00 from $1,877,706,011.63 to $1,877,711,758.63. SUBCLIN 003003: Funding on SUBCLIN 003003 is initiated as follows: ACRN:MX CIN: GFEBSOOIOl7438400030 Acctng Data: 02120122013204000001 171722550030003242A.0000013.1.1 6100.9000021001 Increase: $5,747.00 Total: $5,747.00 Cost Code: A5XFJ DASG60-98-C-000 1 P00255 Page 3 of 10 Target Cost, Target Fee, and total for the above increase of istributed as follows and includes an increase in target cost os ~f cost and .-rfacilities capital cost of money) and an increase in target fee of $403. IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows: SUBCLIN 0017AA : TIllS CUMULATIVE PRIOR MODIFICATION TOTAL· (1) Amount Required for Full Funding, Including Fee: $1,683,179,862 $ 0 $ 1,683,179,862 (2) Amount Allotted Under the LOF Clause (b )(4) for Payment of Costs: ~ (3) Amount Separately Obligated for Payment of Fee: (4) Total Amount Allotted and Obligated: $1,644,503,321.27 $1,644,509,068.27 (b}f~) (5) Net Amount Required for Full Funding $ 38,676,540.73 $ 38,670,793.73 * These figures take into consideration the negotiated total value of SubCLIN 00 17 AA (This does not include SubCLIN 17 AH) 3. The following is an update to Modification P00254 showing a summary of funding by ACRN through Modification P00255: FUNDING AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AI 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 OOd.5/7 DASG60~98-C-000 1 P00255 Page 4 of10 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000~00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 U 7,476.00 LK $281,575,897.00 OOa$lg DASG60-98-C-000 1 P00255 Page 5 of 10 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LV $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LV $264,807,424.52 LZ $1,751;384.00 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW $10,000,000.00 MX 553,699,162.00 4. The following is an update to Modification P00254 showing a summary of funding by CLIN by ACRN through Modification P00255: FUNDING AMT CLIN TOTAL CLINOOOI AA 440,100.00 CLINOOOI AD 0.00 ______440,100.00 CUNOOO3 AS 2,298,235.00 CLIN0003 AC 17,832,987.00 CLIN0003 AD 0.00 DAS060-98-C-000 1 P00255 Page 6 of10 CLINOO03 AE 7,500,000.00 CLINOO03 AF 3,300,000.00 CLINOO03 AO 17,192,400.00 CLINOO03 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLINOO03 AN 5,800.00 CLINOO03 AP 20,779,000.00 CLINOO03 AS 0.00 CLINOO03 AT 6,984,678.52 CLIN 0003 AW 100,000.00 CLINOO03 AY 550,000.00 94,288,100.52 CLIN 0005 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLINOO05 BC 72,000.00 CLlNOO05 BD 85,000.00 CLIN 0005 BE 100,000.00 CLINOO05 BF 100,000.00 CLIN 0005 BO 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOO05 BL 0.00 CLINOO05 BZ 0.00 65,025,107.00 CLINOO07AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINoo09AA BK 256,545.00 CLINoo09AA BM 125,000.00 CLINOO09AA BN 21,315.00 447,966.00 CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLfNOO09AB BK 3,455.00 CLfNOO09AB BN 81,685.00 CLfN0009AB BU 350,000.00 CLINOO09AB BV 9,000.00 869,034.00 CLINOO13 AU 7,970,000.00 OO~5aO DASG60-98-C-000 1 P00255 Page 7 of 10 CLIN 0013 AX 3,396,000.00 CLINOO13 AY 0.00 CLINOOl3 AZ 19,412,000.00 CLIN 0013 BJ 7,896,673.34 38,674,673.34 CLINOO17 BW 0.00 CLINOO17 KM 0.00 0.00 CLINOO17AA BY 3,880,000.00 CLINOO17AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLlNOO17AA KM 192,793,000.00 CLINOO17AA KN 0.00 CLINOO17AA KQ 66,151.00 CLINOO17AA KS 0.00 CLINOO17AA KT 386,204,200.00 CLINOO17AA KV 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLlNOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 CLINOO17AA LQ 235,566.00 CLINOO17AA LS 6,069,616.00 CLlNOO17AA LT 530,377.00 CLINOO17AA LV $9,100,000.00 CLINOO17AA LV $1,957,265.00 CLINOO17AA LW $255,567.00 CLINOO17AA LX $68,000.00 CLINOO17AA LY $264,807,424.52 CLINOO17AA MB $375,000.00 CLINOO17AA MC $2,283,481.00 CLINOO17AA MD $8,573.00 CLINOO17AA ME $0.00 CLINOO17AA MF $270,514,880.00 CLINOO17AA MH $213,390.00 CLINOO17AA MJ $858,495.00 CLINOO17AA MK $56,076.00 CLINOO17AA ML $116,044.00 CLINOO17AA MM $1,618,600.00 OO~S~, DASG60-98-C-000 1 P00255 Page 8ofiO CLINOO17AA MN $2,573,000.00 =====-== CLINOO17AA MP $250,000.00 =-======CLINOO17AA MQ $691,421.00 --===-= CLINOO17AA MR $0.00 =====-__ CLINOO17AA MS $700,000.00 _===== CLINOO17AA MT $16,289,524.00 ======CLINOO17AA MY $39,921,199.75 ======CLINOO17AA MW $10,000,000.00 -===== CLINOO17AA MX 553,699,162.00 ====-=== 1,644,509,068.27 CLIN0017AB KL 118,250.00 118,250.00 CLINOO17AC BZ 190,000.00 190,000.00 CLIN0017AD KN 0.00 CLINOO17AD KS 0.00 0.00 CLIN0017AE LL 173,798.00 173,798.00 CLIN0017AH KT 173,798.00 173,798.00 CLIN0020AA KN 0.00 CLIN0020AA KQ 26,660.00 26,660.00 CLIN0021AA KW 0.00 0.00 CLIN0021AB KV 0.00 CLINOO21AB LB 0.00 CLIN0021AB KX 0.00 CLIN0021AB KY 0.00 0.00 CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00 OCd.5~ DASG60-98-C-000 1 P00255 Page 9 ofl0 0.00 CLIN0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLINOO23 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00 297,500.00 CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN0024 KZ 25,000.00 CLIN0024 KW 20,000.00 CLIN0024 LP 83,200.00 203,708.00 CLIN0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00 CLIN0025 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,Q61.00 CLIN0027 LZ 1,751,384.00 1,751,384.00 CLIN 0028 LM 329,972.00 CLIN0028 MA 2,982,442.00 CLIN0028 MG 6,262,095.00 CLIN0028 MU $7,864,499 17,439,008.00 CLIN 003001* MX $52,974,283.00 CLIN003002* MX $719,132.00 eLIN 000303* MX 55,747.00 DASG60-98-C-OOO 1 P00255 Page 10 oflO • CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubC~INs under CUN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017AA and should not be counted twice with regards to the total contract funding obligated. (End of Summary of Changes) PAGES AMENDM~T OF SOLICITATIONIMOnDICATION OF CONTRACT 10 NO. CODE U8A8MDC",RSTRAT &Moe·ROC PO BOX 1111lO HUNTSVIlLE PL. 315807-:1801 8. NAME AND I'UJLI",~OF CONTRACTOR (No., Street, County, State IndZip Code) RAYTH£aII COMPANY 350 LOV.a..L ST. ANDOVER iliA 0181G-4«lO .bov.nlllltNncl.olioitllion i. IIIIIIIdeci u.1t Iblth III Item 14. lh.hourlllddat.lp8Cifed fIr .....pI oro. O"lIIIlt .w.owled., neapt oftbi...... dment prior to the hour IIld daI'opeoiiad in tho .oIloltllioll or U lIIIIaded by oao ofthe flllowi ... lllltbod.}- .• - ... C.) By coapt_II ... Itam B ...d 15.1114 Nlumilll copi .. oflho -m-t; (b) By ",*Ilowl.tains receipt ofthil _4_t 011 eoch copy oftbeo•• ubnittad; or (0) By ••pnl.letterortol ...... whi ... illc1ud~OI to the .olioitlllion IIId _adnlmt n"'" FAR.URE OF YOURACKNOWLBDOMENTTO BE RECEIVED AT1HB pLACH DESIONAll!D POR,1HB RECSIPTOl'OPJIERlI PRIOR TO tHE HOUR AND DAlB SPBCll'IED MAY RESULT IN REJEC'ItON 01' YOU1l0PFBR. [fby virtu. ofthi. _dna! you deal .. to ahaqo III 0."na4y lubniltec!,l1Ioh oh .... ~ b...... by loI"IrIIlIor Iltler. p..,.,idecl eeoh 1I1 ...... or lett. rmIc ...... 00 10 tho .0Ucic-IIon IIld thi. _4... t ....4 Ie roooiTo4 priorto tho opoDiog "0111:1041 datl.pooifad, AND APPROPRIATION See Schedule 13. nns ITEM APPLIES ONLY TO MODIFICATIONS OF CONTRACflVORDERS. IT MODIFIES THE CONTRAer/ORDER NO. AS DESCRIBED IN ITEM 14. THIS CHANGE ORDER IS I~D PURSUANT TO: (*ecify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA. n. \ '>II""U~ type of modification IJId authority) 52.232-22, ·untBtIon or Fundi" Contractor 1Kl ill not, is required to IIign this tbcumcnt lind return copies to tbe ilSlling office. 14. DESCRIPTION OF AMENDMENT /MODIFICATION (Orl!llllized by UCF section headinp. including solicitation/contract suQjcct-mattcr ~cre feuibIe.) Modification Control Number: _ To provide Incranwntal funding In the amount or $16,000,000 . •A. NAME AND TITLE OF !lONER (Type or print) UB. 30-105-04 APPROVED BY OIRM 11-84 OOci.Sa..S DASG60-98-C-OOO 1 P00256 Page 2 ofl0 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES 1. SECTION B - SUPPLIES OR SERVICES AND PRICES CLIN0030 The total cost of this line item has increased by $16,000,000.00 from $53,699,162.00 to $69,699,162.00.* * As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of eLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 00 17AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017AA with associated incentive events and flat zones. SUBCLIN 003004 is added as follows: ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003004 GFEBS Funding for SubCLIN 0017AA CPlF FOB: Destination ACRNMX $16,000,000.00 CIN:GFEBSOOIOI9081700030 2. SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $ I 6,000,000.00 from $1,877,711,758.63 to $1,893,711,758.63. SUBCLIN 003004: Funding on SUBCLIN 003004 is initiated as follows: ACRN:MX CIN: GFEBSOOI019081700030 Acctng Data: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001 Increase: $16,000,000.00 Total: $16,000,000.00 DASG60-98-C-000 1 P00256 Page 3 of 10 Cost Code: A5XFJ Target Cost, Target Fee, and total for the above increase ofl•• is distributed as follows and includes an increase in target cost os 2 t__ f cost facilities capital cost of money) and an increase in target fee of 5 IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph C., is revised to read as follows: SUBCLIN0017AA : THIS CUMULATIVE PRIOR MODIFICATION TOTAL'" (I) Amount Required for Full Funding, Including Fee: $1,683,179,862 $ 0 $ 1,683,179,862 (2) Amount Allotted Under the LOF Clause for Payment of Costs: lbJLf (3) Amount Separately Obligated for • (b )(4) Payment of Fee: $ $ (4) Total Amount Allotted and Obligated: $1,644,509,068.27 $16,000,000 51,660,509,068.27 (b}fd, (5) Net Amount Required for Full Funding $ 38,670,793.73 (516,000,000) $ 22,670,793.73 ... These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include SubCLIN 17 AH) 3. The following is an update to Modification P00255 showing a summary of funding by ACRN through Modification P00256: ACRN FUNDING AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 oo~5~1 DASG60-98-C-000 1 P00256 Page 4 of10 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY ,~ 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 ood5QE DASG60-98-C-OOO 1 P002S6 Page 5 of 10 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MV $39,921,199.75 MW $10,000,000.00 MX $69,699,162.00 4. The following is an update to Modification P00255 showing a summary of funding by CLIN by ACRN through Modification P00256: FUNDING AMT CLIN TOTAL CLINOOOI AA 440,100.00 CLINOOOI AD 0.00 ______440,100.00 CLIN 0003 AB 2,298,235.00 DASG60-98-C-000 1 P00256 Page 6 ofl0 CLINOO03 AC 17,832,987.00 CLINOO03 AD 0.00 CLINOO03 AE 7,500,000.00 CLINOO03 AF 3,300,000.00 CLINOO03 AG 17,192,400.00 CLINOO03 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLIN 0003 AN 5,800.00 CLIN 0003 AP 20,779,000.00 CLINOOO3 AS 0.00 CLINOOO3 AT 6,984,678.52 CLINOO03 AW 100,000.00 CLINOO03 AY 550,000.00 94,288,100.52 CLINOO05 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLINOO05 BC 72,000.00 CLINOO05 BD 85,000.00 CLINOO05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BG 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOO05 BL 0.00 CLINOO05 BZ 0.00 65,025,107.00 CLINOO07AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOO09AA BN 21,315.00 447,966.00 CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOOO9AB AR 35,000.00 CLINOOO9AB BK 3,455.00 CLINOOO9AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLINOOO9AB BV 9,000.00 869,034.00 OO~'53D DASG60-98-C-000 1 P00256 Page 7 oflO CLIN 0013 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLIN 0013 AY 0.00 CLIN 0013 AZ 19,412,000.00 CLIN 0013 BJ 7,896,673.34 38,674,673.34 CLIN 0017 BW 0.00 CLIN 0017 KM 0.00 0.00 CLIN OO17AA BY 3,880,000.00 CLIN 0017AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLIN 0017AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLIN 0017AA KQ 66,151.00 CLIN 0017AA KS 0.00 CLIN 0017AA KT 386,204,200.00 CLINOO17AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLIN 0017AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 CLINOO17AA LQ 235,566.00 CLIN 0017AA LS 6,069,616.00 CLINOO17AA LT 530,377.00 CLIN 0017AA LU $9,100,000.00 CLINOO17AA LV $1,957,265.00 CLINOO17AA LW $255,567.00 CLINOO17AA LX $68,000.00 CLIN 0017AA LY $264,807,424.52 CLIN 0017AA MB $375,000.00 CLINOO17AA MC $2,283,481.00 CLINOO17AA MD $8,573.00 CLINOO17AA ME $0.00 CLINOO17AA MF $270,514,880.00 CLINOO17AA MH $213,390.00 CLINOO17AA MJ $858,495.00 CLINOO17AA MK $56,076.00 OO~531 DASG60-98-C..QOO 1 P00256 Page 8 of 10 CLlNOO17AA ML $116,044.00 ======CLlNOO17AA MM $1,618,600.00 ======CLINOO17AA MN $2,573,000.00 ======CLIN0017AA MP $250,000.00 =_==-===== CLIN 0017AA MQ $691,421.00 -==--==== CLINOO17AA MR $0.00 ...... -======CLINOO17AA MS $700,000.00 ======CLINOO17AA MT $16,289,524.00 ======CLINOO17AA MY $39,921,199.75 ======-_ CLIN00l7AA MW $10,000,000.00 ======CLINOO17AA MX 569,699,162.00 ======1,660,509,068.27 CLINOOl7AB KL 118,250.00 118,250.00 CLINOO17AC BZ 190,000.00 190,000.00 CLINOO17AD KN 0.00 CLINOO17AD KS 0.00 0.00 CLINOO17AE LL 173,798.00 173,798.00 CLINOO17AH KT 173,798.00 173,798.00 CLINOO20AA KN 0.00 CLIN0020AA KQ 26,660.00 26,660.00 CLINOO21AA KW 0.00 0.00 CLIN0021AB KV 0.00 CLIN0021AB LB 0.00 CLIN0021AB KX 0.00 CLIN0021AB KY 0.00 0.00 OO~S3~ DASG60-98-C-OOO I P00256 Page 9 of 10 CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00 0.00 CLIN0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLINOO23 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00 297,500.00 CLINOO24 LA 13,508.00 CLIN0024 LG 62,000.00 CLINOO24 KZ 25,000.00 CLIN0024 KW 20,000.00 CLIN0024 LP 83,200.00 203,708.00 CLIN0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00 CLIN0025 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,061.00 CLIN0027 LZ 1,751,384.00 1,751,384.00 CLIN0028 LM 329,972.00 CLIN0028 MA 2,982,442.00 CLIN0028 MG 6,262,095.00 CLIN0028 MU $7,864,499 17,439,008.00 CLIN 003001* MX $52,974,283.00 CLIN003002* MX $719,132.00 CLIN 000303* MX $5,747.00 eLIN 000304* MX $16,000,000.00 69,699,162.00 QOd-5:33 DASG60-98-C-000l P00256 Page 10 oflO • CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated. (End of Summary of Changes) AM 53'-1 PM. AMENDMBN'l' OF SOUClTA110NIMOODlCA110N OJ' CONTltACI' 16 ulle.... 1111 ...... nlI. n.'" De...,...... a... I ...... 'I.,. .. ~ ...... dII ....I ... III' ...... ,_ ••• n ...... : (ll)1Iy ....I8a ...... "...... eap'•• fllle-'-'r...... , ...... -'-IOII...... , ...... • r(e)., ...... IIIW., ...... IuIa~•• I.. IIIIIakIIIaa ..___ III ..... 'AIWUOPYOU.ACKNOWUDGMINT1Oaa ItICEMaJAT'IIIIIPLAaD... NAUDIIOII.11I.8KIIPTO'0fRIII .... 1011IIHClURANDDAlIi.IaPllDMAYRllULTIN ua:no.. OFYOUACJFIIB.llllyv.... ' ..,...... ,...... ct-.• .,...... , ...... , ...... , ... _I...... __...... Jc1IM ...... pdar ...... IIoUrIId ...... -ahIaIII in payin. 14. DBICRInION OF AMENDMENTIMODIFICATION (0riIaiIIII1Ir to __ hIIdInII. ~•• lcilatlolllcon .. "'" 1Ml_ ...... ) . MocIIIcMlan OmtIOI H_E • lbprclVldlthli.'..... f\Jrdvtl ..1IIIUIt Df.te,ooo.lIOO; IDrtlVlle8eclDnff.1t.taNllYERES'IRJCI\EAN)MVII!NI'PDRa.N CIOt1. 8V8IB'tII~ AtGIIMNnM'IDII(8DD) fD nadPi ..1IIt.pat hllnlMtcdlrla lDeIII. _ PllfarftWlOe CIIR from IbIl..... "-0mIId (Jq .-1It.. Ainotlanlll ~AudI(FQ\)'" eMntmilD ...... __ lnalnllrecdlrllfD __.. IIIt.patlncldlna~ In """'rec ... 1D ..... IlclalnJDhiJde ...... _ ...... ~ .... nwlHmlD~"~ Ult(aR.)B1J1)4. Alot.-...... CGi ....,..,u,."..... P..mr.dlly CB\ FAR('" a'R) 53.243 DASG60-98-C-000 1 P00257 Page 2 of 15 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES 1. SECTION B - SUPPLIES OR SERVICES AND PRICES CLIN 0030 The total cost of this line item has increased by $16,000,000.00 from $69,699,162.00 to $85,699,162.00.* • As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 00 17 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. SUBCLIN 003005 is added as follows: ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003005 GFEBS Funding for SubCLIN 0017 AA CPIF FOB: Destination ACRNMX $16,000,000.00 CIN: GFEBSOOI015913300030 2. SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $16,000,000.00 from $1,893,711,758.63 to $1,909,711,758.63. SUBCLIN 003005: Funding on SUBCLIN 003005 is initiated as follows: ACRN:MX eIN: GFEBSOOI015913300030 Acctng Data: 0212012201320400000 1171722550030003242A.OOOOO 13.1.1 6100.9000021001 Increase: $16,000,000.00 Total: $16,000,000.00 OASG60-98-C-000 1 P00257 Page 3 of 15 Cost Code: A5XFJ Target Cost, Target Fee, and total for the above ~~'=lliiS.d~istributed as follows and includes an increase in target cost os lSI • facilities capital cost of money) and an increase in target fee of Target Cost Target Fee Total IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSIDP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows: SUBCLIN 0017AA : THIS CUMULATIVE PRIOR MODIFICAnON TOTAL· (I) Amount Required for Full Funding, Including Fee: $1,683,179,862 $ 0 $ 1,683,179,862 (2) Amount Allotted Under the LOF Clause for Payment of Costs: ~)(4) (3) Amount Separately Obligated for Payment of Fee: $ b)(4) (4) Total Amount Allotted and Obligated: $1,660,509,068.27 516,000,000.. 51,676,509,068.27 (5) Net Amount Required for Full Funding $ 22,670,793.73 (516,000,000) 5 6,670,793.73 * These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include SubCLIN 17AH) 3. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows: Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017, SYSTEM DEVELOPMENT AND DEMONSTRATION (SOD), subparagraph C., is revised as follows: c. Schedule and Performance Incentive. (1) A maximum 'flat zone" will be established at the estimated cost value of with the (b)( 4 ) conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from _to nce the program milestones set forth below are conducted. (Note: As of the (b)( 4 ) effective date of Modification P002S7, only ofthe maximum flat zone" has been acknowledged as earned.) (a) 2 . ,-.of the maximum benefit of the "flat zone", earned by the conduct of the SOD System (b )(4) Functional Review NLT2iid Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that : • 1 •.• I • II' . ted the requirement for this flat zone and earned the "Flat Zone" schedule incentive of Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 5 March 2007 from [b')..l£;) lQlD) (b) S ,~fthe maximum benefit of the "flat zone", earned by the conduct ofSOO Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon Cb~) completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive Final (],1t> determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the0_. conclusion of the ooaS3'7 DASG60-98-C-OOO 1 P00257 Page 4 of 15 contract. Reference letter, dated 12 January 2009, from l~l~) 2 - a ~l0 (c) I of the maximum benefit of the "flat zone", earned by the conduct ofthe Developmental ~f-v Test 1 (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Perfonnance Criteria for JLENS SOD Contract, Section H-19{c), dated 081t0/12. (It is hereby acknowledged by the government that Raytheon co:teted the requirement for this flat zone and earned a "Flat Zone" schedule incentive of $ , or of the available Final detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) (d) of the maximum benefit ofthe "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government ~n completed tbe requirement for this flat zone and earned a "Flat Zone" schedule incentive of"'-oi ofthe available j • Final determination of incentive fee (0)Ll£) payment utilizing the "Flat Zone" will be at the conclusion of the *NOTE: Tbe u:>'itf) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (t) 7· -. of the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) # 1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDn Contract, Section H-19(c), dated 08/10/12. *Note: has been10 Sec 130 (a)(b) (b)(3)(A) (g) _ of the maximum benefit of the "flat zone", earned bytbe conduct of (i)&Title Lb){~ Developmental Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled F1at10 Sec 130 Zone Performance Criteria for JLENS SDn Contract, Section H-19(c), dated 08110/12. • (a)(b) (h) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Early User u,)Ltf) Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. * (i) -. of the maximum benefit of the "flat zone", earned by the conduct of the Final Lb)l<1:) Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19{c), dated 08110/12. • • These additional incentives are added to the contract contingent upon agreement to a pending contract ceiling increase. Should the parties not be able to reach agreement on such increase, the Government reserves the right to rescind the incentives. (3) For Earned Value and cost reporting purposes, the estimated cost value o_illbe used. d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to DASG60-98-C-OOO 1 P00257 Page 5 of 15 the Option will be incorporated in accordance with the incentive fee structure of this provision. 4. SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS The following has been revised: #OFPAGES Contract Security Classification Specification (DD Form 254), 14 Apr 11 13 Revision 13 (Added per Modification P0023S) JLENS Software Source Code Specifically Negotiated License, 04 Sep 08 8 License Number lLENS-SWLA-OI (Added per Modification POO 166) CLINOOI7: JLENS System Development and Demonstration 30Nov06- 37 (SDD) Program Statement of Work (Revised by Revised 20 Feb 07 Incorporating CSDR Plans dated 20 Febr 2007 in Appendix C per Modification P00136) JLENS System Development and Demonstration Revised 06 Apr 09 38 (SDD) Program Statement of Work (Added per Modification POO 187) JLENS System Development and Demonstration Revised 09 Mar 10 36 (SDD) Program Statement of Work, Revision 2 (Added per Modification P00207) JLENS System Development and Demonstration Revised 01 Sep 11 36 (SOD) Program Statement of Work, Revision 3 (Added per Modification P00239) JLENS System Development and Demonstration Revised 26 Sep 11 36 (SOD) Program Statement of Work (Added per Modification P00240) March 08 (b )(3) (A) (i)&Title lO Sec 130 (a)(b) Contract Data Requirements List (DD Form 1423) 01 Dec 06 63 Exhibit A with Distribution List & Data Item Nos. BOOI through B062 (Replace Data Item Nos. B026 and B027, only Revised 05 Apr 07 Per Modification P00136) (Replace Data Item Nos. B048 and B049, only Revised 24 Oct 07 Per Modification P00143 & to add statement in Section A of Modification POOI43) (Replace Data Item No. B033 only, per Revised 11 JuI 08 Modification POO 161) Contract Data Requirements List (DD Form 1423) Revised 07 May 09 2 Exhibit A. Data Item Nos. BOOI and BOl4 (Added per Modification POO 187) DASG60-98-C-000I P00257 Page 6 of 15 ( Contract Data Requirements List (DO Fonn 1423) Revised 20 Mar 09 60 Exhibit A, Data Item Nos. 8002 through B062 (less 80 [4 ) (Added per Modification POD 187) Contract Data Requirements List (DO Fonn 1423) Revised 30 Aug 11 2 Exhibit At Data Item Nos. BOOI and BOl4 (Added per Modification POD239) Contract Data Requirements List (DO Form 1423) Reviscd,31 Jul12 Exbibit A, Data Item Nos. 8004 (Added per Modification PO02S7) "Added statement below to address weekendsIHoJidays: 24 October 07 (In Mod POO143) ·Per a mutual agreement between Raytheon and JLENS Product Office all Contract Data Requirements List (CDRL's) (DO Fonn 1423) are due on the next business day after the required due date if the due date falls on Saturday. Sunday or a Government Holiday, In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the conuncnts on a Friday. the time frame for resuhmittal will begin on the next business day, Statement added in Mod POD 143 on 24 Oct. 2007, GFElGFP/GFS List for SOD 28 Nov 06 2 Replaced with Rev. B List 15 Oct 07 6 ( "Add items below Revised 22 Oct 07 For record-keeping purposes (Per Mod POO143) Replaced with Revision C List 09 Mar 09 12 (per Modification POOl 83) Replaced with Revision 0 List 23 Feb 10 1 1 (Per Modification P00207) •• Per the,DCMA is authorized rent tree use on a non-interference use of the equipment listed below on JLENS Fire Control Radar Prime Contract DASG60-98-C- (b)(4) 0001 for the period from 19 April 2007 through 30 September 2011. (b)(3) (A) ( Originated in Basic Contract: , Government Furnished Equipment - Spiral I 20 Jun 03 1 List (Spiral 1 Equipment Transferred to Government 25 Mar 07* 34 pages DASG60·98·C·000I POO257 Page7ofl5 1149 (attached) (Revised 21 Nov 07)'" 34 pages (b)(6) (b)(4) *NOTE: (terns 1·1060 transferred to Contract DASG60...(){)..c;-0091 per revised GFE list dated 21 Nov 07. Items 1061 - 1116 GFE items retained on Contract DASG60-98·C-000 I for Spiral 2 per GFE list dated 25 Mar 07. JLENS Perfonnance Specification, MIS·PRF·55628, 27 Jun 08 136 Revision A (Added by reference per Modification POO 168) Annex A to the JLENS Perfonnance Specification, 27 Jun 08 10 MIS-PRF.55628, Revision A (Added by reference per Modification POO 168) JLENS SOO 00250 Plan II Dec 09 5 (Added per Modification P00207) Engineering Change Proposal (ECP) MI·N3893, 15 Nov 10 IS Revision 2, CDRL B039·oo5b Engineering Cbange Proposal (ECP) MI-N3894. 18 Aug JO 16 CDRL 9039-006 Engineering Change Proposal (ECP) MI-N3895, 28 Sep to 50 CORL 8039-007 Engineering Change Proposal (ECP) JL 1359 20 Jun II 7 (Added per Modification P00240) Flat Zone Perfonnance Criteria for JLENS SOD 01 Nov I I 4 Contract, Section H·19(c) (Added per Modification P00242) Revised Flat Zone Performance Criteria ror JLENS SOD 10 Aug 12 7 Contraet, Section H·I9(e) (Added per Modifieation P002S?) Test Spares List Undated 8 (Added per Modification P00247) CLINs 0023 and 0024 JLENS Simulation Support 28 January 2008 2 SOW dat d 28 J 2008 (b)(3) (A) > •. , >,., .~ ... (Added per Mod POOI60) CLIN 0025 JLENS Integrated Fire Control Demonstration Program 14 Sep 09 3 DASG60-98-C-000 1 P002S7 Page 8 of15 Statement of Work, Revision 5 (Added per Modification P002Il) JLENS Integrated Fire Control Demonstration Program 30 Mar 10 26 Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00211) Contract Data Requirements List (DD Form 1423) 16 Oct 07 19 Exhibit B, Data Items Nos. BOO 1 through B004, with Data Item Descriptions (Added per Modification POO 165) Contract Data Requirements List (DD Form 1423), 16Iun 10 6 CLIN 0028, Exhibit B, Data Item Nos. BOOI through B006 (Added per Modification P002Il) CLIN0027 JLENS System Integration Lab (SIL) Undated 6 Equipment List (Added per Modification P00196) Revision to System Integration Lab (SIL) 02 Aug 10 6 Equipment List (Added per Modification P002I7) 5. The following is an update to Modification P00256 showing a summary of funding by ACRN through Modification P00257: ACRN FUNDING AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AI 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 OOaS4a DASG60-98-C-000 1 P00257 Page 9 of15 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018j 908.00 BJ 7,896;673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 U 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 C'()~j4 3 DASG60-98-C-OOO 1 P002S7 Page 10 of15 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW $10,000,000.00 MX $85,699,161.00 6. The following is an update to Modification P00256 showing a summary of funding by CLIN by ACRN through Modification P00257: FUNDING AMT CLIN TOTAL CLINOOOI AA 440,100.00 CLINOOOI AD 0.00 ______440,100.00 CLIN0003 AB 2,298,235.00 CLIN0003 AC 17,832,987.00 CLINOOO3 AD 0.00 CLINOOO3 AE 7,500,000.00 CLIN0003 AF 3,300,000.00 DASG60-98-C-000 1 P00257 Page 11 of15 CLINOO03 AG 17,192,400.00 CLINOO03 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLINOOO3 AN 5,800.00 CLINOO03 AP 20,779,000.00 CLINOO03 AS 0.00 CLINOOO3 AT 6,984,678.52 CLINoo03 AW 100,000.00 CLINOO03 AY 550,000.00 94,288,100.52 CLINOOO5 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLINOO05 BC 72,000.00 CLINOO05 BD 85,000.00 CLINoo05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BG 1,975,321.00 CLINOO05 BH 38,018,908.00 CLINOOO5 BL 0.00 CLINOO05 BZ 0.00 65,025,107.00 CLINOO07AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLIN0009AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOOO9AA BN 21,315.00 447,966.00 CLINOOO9AB AI 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINoo09AB BK 3,455.00 CLINOOO9AB BN 81,685.00 CLINOOO9AB BU 350,000.00 CLINOO09AB BV 9,000.00 869,034.00 CLIN 0013 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLIN0013 AY 0.00 OO~545 DASG60-98-C-000 1 P00257 Page 12 of15 CLINOOI3 AZ 19,412,000.00 CLINOO13 BJ 7,896,673.34 38,674,673.34 CLIN 0017 BW 0.00 CLINOO17 K.M 0.00 0.00 CLINOO17AA BY 3,880,000.00 CLIN 0017AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLINOO17AA K.M 192,793,000.00 CLINOO17AA KN 0.00 CLINOO17AA KQ 66,151.00 CLINOO17AA KS 0.00 CLINOO17AA KT 386,204,200.00 CLINOO17AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLINOO17AA LC 200,000.00 CLINOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 CLINOO17AA LQ 235,566.00 CLINOO17AA LS 6,069,616.00 CLINOO17AA LT 530,377.00 CLINOO17AA LU $9,100,000.00 CLINOO17AA LV $1,957,265.00 CLINOO17AA LW $255,567.00 CLINOO17AA LX $68,000.00 CLINOO17AA LY $264,807,424.52 CLIN 0017AA MB $375,000.00 CLINOO17AA MC $2,283,481.00 CLINOO17AA MD $8,573.00 CLINOO17AA ME $0.00 CLINOO17AA MF $270,514,880.00 CLINOO17AA MH $213,390.00 CLINOO17AA MJ $858,495.00 CLINOO17AA MK $56,076.00 CLINOO17AA ML $116,044.00 CLINOO17AA MM $1,618,600.00 CLINOO17AA MN $2,573,000.00 CLINOO17AA MP $250,000.00 ~54lQ DASG60-98-C-OOO 1 P00257 Page 13 of 15 CLINOO17AA MQ $691,421.00 -====...... _=== CLINOO17AA MR $0.00 -==-...... _==== CLINOO17AA MS $700,000.00 ======CLINOO17AA MT $16,289,524.00 _====-=== CLINOO17AA MY $39,921,199.75 ______CLINOO17AA MW $10,000,000.00 ======...... CLINOO17AA MX $85,699,162.00 ======1,676,509,068.27 CLINOO17AB KL 118,250.00 118,250.00 CLINOO17AC BZ 190,000.00 190,000.00 CLINOO17AD KN 0.00 CLINOO17AD KS 0.00 0.00 CLINOO17AE LL 173,798.00 173,798.00 CLINOO17AH KT 173,798.00 173,798.00 C[IN0020AA KN 0.00 CLIN 0020AA KQ 26,660.00 26,660.00 CLIN0021AA KW 0.00 0.00 CLIN0021AB KV 0.00 CLIN0021AB LB 0.00 CLIN0021AB KX 0.00 CLIN 002 lAB KY 0.00 0.00 CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00 0.00 coa.54'J DASG60-98-C-000 1 P00257 Page 14 of 15 CLIN 0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLIN 0023 KY 25,000.00 CLIN0023 KV 65,000.00 CLlN0023 LB 12,500.00 CLIN 0023 LF 10,000.00 CLIN 0023 LR $125,000.00 297,500.00 CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLlN0024 KZ 25,000.00 CLIN0024 KW 20,000.00 CLlN0024 LP 83,200.00 203,708.00 CLIN0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00 CLIN 0025 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,061.00 CLIN0027 LZ 1,751,384.00 1,751,384.00 CLIN0028 LM 329,972.00 CLIN0028 MA 2,982,442.00 CLIN0028 MG 6,262,095.00 CLIN0028 MU $7,864,499 17,439,008.00 CLIN 003001 * MX $52,974,283.00 CLIN003002* MX $719,132.00 CLIN 000303* MX $5,747.00 eLIN 000304· MX 516,000,000.00 85,699,162.00 * CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For proposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated. DASG60-98-C-OOO I P00257 Page 15 of15 (End of Summary of Changes) lorA .... INSERT IN SECT.B OO~S50 ,---, T SPOT INCENTIVE CRITERIA FOR JLENS SOD (y '\RACT, SECTION H-19(C), DATED 10 AUG 1; 8 $V (J1 -CIt 'T SPOT INCENTIVE CRITERIA FOR JLENS SOD' r r---~TRACTI SECTION H-19(C)1 DATED 10 AUG 1: I::!::w I - .-- -T SPOT INCENTIVE CRITERIA FORJlENS SOD c: ';RACT, SECTION H-19(C), DATED 10 AUG 1: ------.. . ~ T SPOT INCENTIVE CRITERIA FOR JLENS SOD. (" ""RACT, SECTION H-19(C), DATED 10,AUG 1: G>~ ...- 0- ...... - ...... ~ L~)ff~ ---'TSPOT INCENTIVE CRITERIA FORJLENSSDD r "fRACT, SECTION H":19(C), DATED 10 AUG 1: T SPOT INCENTIVE CRITERIA FOR JLENS SOD ( TRACT; SECTION H-19(C)1 DATED 10 AUG 17 1===' - .- ·.... T SPOT INCENTIVE CRITERIA FOR-JLENS SODCr ~RACT,.sECTION Hr.19(C), DATED 10 AUG 1: ,=::1 __ d PA AND ADDRESS OF CONTRAcrOR (No .• !it recto COIIIty. &lIe ud Zip Code) RAYTHEON CCMPNrf 311DLOE.L8r. MOOU!iJ'IMAOI81004«lO _.. abo""'~ solldlalon I• ...cIed as 111II1II11 ... 1_14. 11M hDllr .... dale IpCCiIed IItNCdpl oro. 0 I. _ded. Is __ended O._leeknowled..... pl Dfdrill8alll_1 prior 10 IIIcbOllf'IIId ~qNlClhd I. IIMsoIlcilallaa or as ..-dcd by _ oRlle 1»11ow1 .. lII:lhods: (I'll)' caap,..... ,..... mIlIS ••d Rlumilll copM oldie MaId_: (II)BJ ldlnowled.lq _lpI Df.. 111 """_1011 acb copy onlle oltr lu""'"ed: or(c:) By .._lanaror ICIqnmwblcb hld~lo lIIolCllld"'oo II1II ...... nntJcn. FA R.U RE OF YOUR ACXNOWLEOOMBNTlO BE REa!JVED AT1HE PLACE DBSIONAlED fOR lIIE REaJPTOFOfFERS PRlOR1011I8 HOU1AHD DAlE SPECIFIED Nt.Y RESULTIN REJEC'JlON OP YOUR OfFER. Ilby "111 ..0 .....1.--..1 you dalMIO ..... III ...... J lubnflled.sucll ell .... n.)' buaddy ...... or 'e"•• pIO\'IdId~IeI._hmer""' __ IDIII.. oIlri .. IORudchl.~.ORdII.-lwedpriorlal"" ...I·lbour""dllClped.ed. 12. A ,,","'''.~ (SQCh IS cblllFS In pa)'lnl IMPORT ANT: Conlr8CIor 0 is 1101. is required 10 Ii.... Ibis cb:umenl IIDd ret.,. c:opies 10 ahe issuing office. 14. DEDIPTION OF AMENDMENTIMODIFICATION (Orpnized by OCFscc:tion heMinp. includinl solicilltionlcontrac:t suI!Iec:t mluer lIofIere fasible.) " . ModiflCltion Control Number: ••••••• The PI.II'JIOS8 d ..II trodflcallon Is to hlreae the esttratad cost 0/ SlbCl.fi 0017AA tAle to a cos1 overrun resuDlg from 1he delayad s1art elate d Deve/cpmBn1a1 Test 2 (DT·2) and to provide Incremental furdlg II tie arrounI 0/ $38,266,043. AI oller tem'8 and ccndlllon8 AII1IIt"I unchlngad. 30·105-04 Sf ANDARD FORM:30 (Rev. 10.13) APPROVED BY OIRM 11·84 Prescribed by C&\ FAR (48 CPR) 53.243 DASG60-98-C-OOO 1 P00258 Page 2 of 13 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES 1. SECTION A - SOLICITATION/CONTRACT FORM The total cost of this contract was increased by $34,309,700.00 from $1,920,928,309.00 to $1,955,238,009.00. 2. SECTION B - SUPPLIES OR SERVICES AND PRICES SUBCLIN 0017AA The estimated cost has increased The estimated fee has decreased The total estimated cost plus fee of to $1,717,489,562.00. rlhis includes an increase in estimated cost 0 7000 consisting of in cost and _ increase in facilities capital cost of money, and a decrease in estimated fee These estimated values incorporate the Integrated Fire Control (IFC) incentive recognized in Modification P00257. The target cost and target fee set forth in the table below reflects the negotiated Section B values prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between the Estimated Cost values provided above in Section B and the Target Cost values shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee values provided above in Section B and the Target Fee values shown on the table below are a result of reductions based on current share ratio impacts to the Target Fee and do not include any allocation for yet to be earned incentives as set forth in Section H-I9. As of the date of this modification, the target cost and target fee are as follows: The Target Cost is •••••,consisting o ••••••n cost and ••••tt, facilities capital cost of money. TotalThe Target Target Fee Cost is ~~~~==~plus Fee is •••. Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance. The table below provides 'a summary of the target cost, target fee, and total: (~)(~ \$J'{If) ~i't) l'-->1f) CLIN 0030 The total cost of this line item has increased by $38,000,000.00 from $85,699,162.00 to $123,699,162.00. SUBCLIN 003006 is added as follows: DASG60-98-C-000 1 P00258 Page 3 of 13 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003006 GFEBS funding for SubCLlN 0017 AA CPIF FOB: Destination ACRNMX $38,000,000.00 CIN: GFEBSOOI019081700030 • As stated in Modification P002S1, CLlN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLlNOO 17, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. B-17. INCENTNE FEE FOR SUBCLIN 00 17AA1CLIN 0018 (SEE H-19): In accordance with FAR 52.216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017 AAlCLIN 0018 are set forth below: Target Cost Target Fee Incentive Arrangement: Maximum Fee: Minimum Fee: (Share Ratio: Government/Contractor) Underrun: _or the amount by which the total allowable cost is less than the estimated cost until maximum fee is attained. Overrun: ~r the amount by which the total allowable cost exceeds the estimated cost until minimum fee is attained. FAR 52.216-10, INCENTIVE, paragraph (e)(1), is stated as follows: (e) Fee Payable. (1) The fee payable under this contract shall be the target fee increased b_ents for every dollar that the total allowable cost is less than the estimated cost or decreased b_ents for every dollar that the total allowable cost exceeds the estimated cost. In no event shall the fee be greater th~rcentt (Maximum fee) or less th~ percent (Minimum fee) of the estimated cost. B-18. ESTIMATED COST, ESTIMATED INCENTIVE FEE, MINIMUM INCENTIVE FEE, MAXIMUM INCENTIVE FEE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017AA1CLIN 0018: SUBCLIN0017AA-ITwo SDDJLENS Systems) DASG60-98-C-000 1 P00258 Page 4 of13 a. Estimated cost: (b )(4) b. Estimated fee: • (b )(4) c. Minimum incentive fee: (b )(4) .... (b )(4) d. Maximum incentive fee: .-- e. Total estimated cost and estimated fee: 51,717,489,562 3. SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $38,266,043.00 from $1,909,711,758.63 to $1,947,977,801.63. SUBCLIN 0017AA: MF: 21 12040 5L 5L68 Pl72419E555L 255Y 4MIJ730000 S010214MIJ730000/14MJLEl4M5 was increased by $266,043.00 from $270,514,880.00 to $270,780,923.00 Estimated Cost, Estimated Fee, and Estimated total for the above increase distributed as follows and (b )(4) includes an increase in estimated co_stof $£ 3 _ofcost and IllCllllUI=S capital cost of money) and an increase in estimated fee oti SUBCLIN 003006 (GFEBS Funding for SubCI,.IN 0017AA): Funding on SUBCLIN 003006 is initiated as follows: ACRN:MX CIN: GFEBSOOI019081700030 Acctng Data: 0212012201320400000 I 171722550030003242A.OOOOO 13.1.1 6100.9000021001 Increase: $38,000,000.00 Total: $38,000,000.00 Cost Code: A5XFJ (b )(4) Estimated (b )(4) Cost Estimated Fee Total IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS DASG60-98-C-000 1 P00258 Page 5 of 13 (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph C., is revised to read as follows: SUBCLIN 0017AA : THIS CUMULATIVE PRIOR MODIFICATION TOTAL· (1) Amount Required for Full Funding, Including Fee: $1,683,179,862 534,309,700 51,717,489,562 (2) Amount Allotted Under the LOF Clause for Payment of Costs: &,1Y (3) Amount Separately Obligated for Payment of Fee: lb~_ (4) Total Amount Allotted and Obligated: $1,676,509,068.27 538,266,043 51,714,775,111.27 (5) Net Amount Required for Full Funding $ 6,670,793.73 ($ 3,956,343) 5 2,714,450.73 • These figures take into consideration the negotiated total value of SubCLIN 00 17 AA (This does not include SubCLIN 17 AH) 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows: ParagraphH-19, INCENTIVE FEE STRUCTURE AND PAYMENT FORCLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraphs a., b., and C., are revised as follows: a. General. SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The contract price r ount If $lfS,OOS,39S includes a target cost 0 (which includes cost alid facilities capital cost of money) and a target incentive fee of of estimated cost less facilities capital cost of money. b. Cost Incentive. (I) The tarlilfee ranle under SUbCLIN._0.O.17•• estimated cost less facilities capital cost of ~iL{) money an amount equall~ Q;,)4) (2) Th~e under SubCLIN 0017AA it Iof the estimated cost less facilities capital cost of l>)l~) money~ount equal to LbJl.#) (3) Th~able under SubCL~fthe estimated cost less facilities capital cost of ~)(t.t) mone~an amount equal to __ L\o.)[1-' (4) Fee will be adjusted for ac!1 cost that is less than or more than the estimated cost stated above using a share ratio 0 overnment :ontractor for actual costs less than the estimated cost, and a ratio of. Government ~ontractor for actual costs greater than the estimated cost range applied according to Paragraph H-19(c)(l); (5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract. c. Schedule and Performance Incentive. (1) A maximum flat zone" will be established at the estimated cost value of-. with the conduct of milestones below. The "flat zone" over which the contractor will earn target fee IS for eligible costs from DASG60-98-C-OOO 1 P00258 Page 6 of13 (8) I of the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NL T 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of •••••, Final determination of incentive fee payment the "Flat Zone" amount will be made at the (7)(1{) ~ct. Reference letter, dated 5 March 2007 L'Ox-~: O'J)lG-.- (I Df the maximum benefit of the "fl~t zone", earned by the conduct of SDD Orbit Critical O:;.~) Design review NL T 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of $' Final C!;>)L1f; determination of incentive fee payment utilizing the "Flat will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, frOI•• (bX-IQ) C1~: (c) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Developmental \D"j..", Test I (DT-1) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10112. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of ? 01 of the available Final determination of incentive fee p~yment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) (d) 1 of the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Lb)O() Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (e) , _ of the maximum benefit of the ''flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a f'Flat Zone" schedule incentive of ."••• or _ of the available .• Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the ·NOTE: Th ..... "' . ,: , ., .- ... , from to movement of the for (b)(3)(A) (i)&Title (f) • the maximum benefit of the "flat zone", earned by the conduct of the Functional if 10 Sec Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone 130 (a)(b) Performance Criteria for JLENS SOD Contract, Section H-19(c), 08110/12. ·Note: (b)(3)(A) (i)&Titie 10 Sec 130 (g) _ ~ of the maxinium benefit of the "flat zone", earned by the conduct of Developmentaia)(b) Lb)L.'1) Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10112. • (h) of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test ~ )LIIJ (previously as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDO Contract, Section H-19(c), dated 08/10112. * OASG60-98-C-000 1 P00258 Page 7 of 13 (i) _ of the maximum benefit of the ".flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Perfonnance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10112 .... (3) For Earned Value and cost reporting purposes, the estimated cost value of be used. d. Changes is.sued under FAR 52.243-2, Changes - Cost Reimbursement In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the perfonnance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedulelperfonnance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision. 5. The following is an update to Modification P00257 showing a summary of funding by ACRN through Modification P00258: ACRN FUNDING AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AI( 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 roa5loY DASG60-98-C-000 1 POO258 Page 8 ofl3 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 .KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 (X)~5105 DASG60-98-C-000 1 POO258 Page 9 of 13 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,780,923.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MY $39,921,199.75 MW S.10,OOO,OOO.00 MX $123, 699,162.00 6. The following is an update to Modification P00257 showing a summary of funding by CLIN by ACRN through Modification P00258: FUNDING AMT CLIN TOTAL CLINOOOI AA 440,100.00 CLINOOOI AD 0.00 ______440,100.00 CLINOO03 AB 2,298,235.00 CLINOO03 AC 17,832,987.00 CLINOO03 AD 0.00 CLINOO03 AE 7,500,000.00 CLINOO03 AF 3,300,000.00 CLINOO03 AG 17,192,400.00 CLINOO03 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLINOO03 AN 5,800.00 CLIN 0003 AP 20,779,000.00 CLINOO03 AS 0.00 CLINOO03 AT 6,984,678.52 CLIN0003 AW 100,000.00 CLINOO03 AY 550,000.00 ______94,288,100.52 DAS060-98-C-000 1 P00258 Page 10 of 13 CLINOO05 BA 24,521,818.00 CLIN 0005 BB 146,000.00 CLINOO05 BC 12,000.00 CLINOO05 BD 85,000.00 CLINOO05 BE 100,000.00 CLINOO05 BF 100,000.00 CLINOO05 BO 1,915,321.00 CLIN 0005 BH 38,018,908.00 CLIN 0005 BL 0.00 CLINOO05 BZ 0.00 65,025,101.00 CLINOO07AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOO09AA BN 21,315.00 447,966.00 CLINOO09AB AI 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINOO09AB BK 3,455.00 CLINOO09AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLINOO09AB BV 9,000.00 869,034.00 CLINOO13 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLINOO13 AY 0.00 CLIN 0013 AZ 19,412,000.00 CLINOO13 BJ 7,896,673.34 38,674,673.34 CLIN 0017 BW 0.00 CLINOO17 KM 0.00 0.00 CLINOO17AA BY 3,880,000.00 CLINOO17AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 (J:)Q'Sb1 DASG60-98-C-000 1 P00258 Page 11 of 13 CLIN 0017AA BZ 0.00 CLIN 0017AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLINOO17AA KQ 66,151.00 CLINOO17AA KS 0.00 CUN 0017AA KT 386,204,200.00 CLINOO17AA KU 2,203,183.00 CLINOOI7AA KY 0.00 CLINOO17AA LC 200,000.00 CLINOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 CLINOOl7AA LQ 235,566.00 CLINOO17AA LS 6,069,616.00 CLINOO17AA LT 530,377.00 CLINOO17AA LU $9,100,000.00 CLINOOl7AA LV $1,957,265;00 CLINOO17AA LW $255,567.00 CLINOO17AA LX $68,000.00 CLINOO17AA LY $264,807,424.52 CLINOO17AA MB $375,000.00 CLINOO17AA MC $2,283,481.00 CLIN 0017AA MD $8,573.00 CLINOOl7AA ME $0.00 CLINOOl7AA MF $270,780,923.00 CLINOO17AA MH $213,390.00 CLINOO17AA MJ $858,495.00 CLIN 0017AA MK $56,076.00 CLINOO17AA ML $116,044.00 CLINOO17AA MM $1,618,600.00 CLINOO17AA MN $2,573,000.00 CLINOO17AA MP $250,000.00 CLINOO17AA MQ $691,421.00 CLINOO17AA MR $0.00 CLINOO17AA MS $700,000.00 CLINOO17AA MT $16,289,524.00 CLIN 00 I 7AA MV $39,921,199.75 CLIN 0017AA MW $10,000,000.00 CLINOO17AA MX 5123,699,162.00 1,714,775,111.27 DASG60-98-C-000 1 P00258 Page 12 of 13 CLIN0017AB KL 118,250.00 118,250.00 CLINOO17AC BZ 190,000.00 190,000.00 CLINOO17AD KN 0.00 CLINOO17AD KS 0.00 0.00 CLIN0017AE LL 173,798.00 173,798.00 CLIN0017AH KT 173,798.00 173,798.00 CLIN0020AA KN 0.00 CLIN0020AA KQ 26,660.00 26,660.00 CLIN0021AA KW 0.00 0.00 CLINOO21AB KV 0.00 CLIN0021AB LB 0.00 CLINOO2lAB KX 0.00 CLINOO21AB KY 0.00 0.00 CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00 0.00 CLIN0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLINOO23 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00 297,500.00 ())~5109 DASG60-98-C-000 1 P00258 Page 13 of 13 CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN0024 KZ 25,000.00 CLlN0024 KW 20,000.00 CLIN0024 LP 83,200.00 203,708.00 CLIN0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00 CLIN0025 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,061.00 CLIN0027 LZ 1,751,384.00 1,751,384.00 CLIN0028 LM 329,972.00 CLIN0028 MA 2,982,442.00 CLIN0028 MG 6,262,095.00 CLIN0028 MU $7,864,499 17,439,008.00 CLIN 003001 * MX $52;974,283.00 CLIN003002* MX $719,132.00 CLIN 000303* MX $5,747.00 CLIN 000304* MX $16,000,000.00 CLIN 000305* MX $16,000,000.00 eLIN 003006* MX 538,000,000.00 123!699,162.00 ... CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated. (End of Summary of Changes) ~S70 PAGES AMENDMENT OF SOUCITATIONIMODIFICATION OF CONTRACT 20 ADMINISTERED BV (If'oIhcrtbua ltan6) DCMARAYTHalN SI N'FLE HIJ.DRM! t.MS13'R2 ~NAInIJ8 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, Cowly, Stlde and Zip Code) RA'miEDN COMPANY 3IIIl.CMI!lLsr. AI'IO(M!Il MA01I1~ I. not P1a1cicd. oerlJllltacknow!odaeleCdPl orthi..... ftIIlpriDl'IO thclaounnd doIe.pcdlcd In IhClOllcUI.loIIoru _lied by oneor.Iae ..UowIDI acchods; II) By co .... IClln.I...... snd IS ...... -Ina copies 1Ifl1le._dln"u: (II) By ICknowled,;n,lB:dp! anh" .-ndmenl on ..... copy anbcal:rlu~"'ncd; or(c) By ••me letlerortel.... wbl~ l..chldes--;;;ti ... cc 10 \lie solicitation ud --"'11I\IatJcn. FAILUR!! OF YOUR ACKNOWLI!DOMENTTO BE RECEIVED ATnll! PLACE DESIONA TED FOR nil! Rl!CElPTOFOFfERS PRIOR 10 nil! ROUP. AND DA 11: SPEClfll!D MA VIlI!IlULT IN IlI!JECOON OF VOUR OFfI!R. lilly vlltueonhl. ~'fOll desl.to ct.acMloeulMCly 1IIbni\l" llIel1 cblnp ...y be ndcby JeI....,...r 1.. 1 .... PlDylded cecil ...... orletler ..ka ...... to dtcHllclhtlon.ad"1t ...... I.aad Is IeCdved plio. to tlIcapeR1nll h_InddMespcclled. 12. ACCOUNTING AND APPROPRIATION DATA (lfrequked) a.. Sch.dule 13. THIS ITEM APPLIES ONLY TO MODIflCATIONSOFCONTRACTS'ORDERS. IT MODlFJESTHE CONTRACTIORDERNO. AS DElDUBED IN ITEM 14. . A. THIS CHANGE ORDER IS I~D PURSUANT TO: (lipeci/Y ...hority) THE CHANCES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA. TO REFLECT THE ADMINlSfRATIVE ~""""lJ=(lIICh u chlftFS mpayma TOTHE AUTHORITY OF E.IMPOKTANT: Contractor Is required to sian this documeal and retwn copies 10 the iauinloffic:e. 14. DESCItJPTION OF AMENDMENTIMODlFlCATION (Orpizedby UCF section headings, includingsoHcillltionlconlncl sul!iec:t mailer v.tacre feasible.) MacUle.lion Control Number. •••••• ) See OJntlnuallon Page IIIIu. aad COtIdllloM 0"_ dOCIIlllltlt rdnmcId ID 1I1III9A or lOA. u hClClO .... Sl'ANDARD FORM 30 (Rev. 10-83) APPROVED BYOIRM 11-84 Prs:ribed by CBA COcl. S '11 FAR(48 CFR) 51.243 DASG60-98-C-OOO 1 P00259 Page 2 of20 SECTION SF 30 BLOCK 14 CONTINUATION PAGE The purpose of this modification is: 1. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00236 for JLENS 14 Day Endurance Test. The target cost, target fee,and total contract value will be adjusted as follows to account for the difference in the order value and the final negotiated amount: target cost decreased b~get fee decreased . total contract value decreased by $640,600. 2. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00239 to delete paragraph 3.12.4, System Capability Reviews, from the System Development and Demonstration (SOD) Program Statement of Work, SW-JLENS-SDD-2006. The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order Wue and the final negotiated amount for costs incurred: target cost increased by target fee increased b. and total contract value (b )(4) ~1( increased by $660,095. 3. (b)(3)(A) P00246 i (i)&Title 10 The target cost, Sec 130 (a) (b) target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount: target cost decreased by ~get fee decreased ~ and total contract value decreased by $199,804. 4. Settlement of the proposal submitted by the contractor in response to Change Order Modification P00247 tor JLENS System Development and Demonstration (SDD) Spares. The target cost, target fee, and total contract value will be adjusted as follows to account for the difference in the change order value and the final negotiated amount: target cost decreased b~ target fee decreased by _ and total contract value decreased by $600,733. 5. Settlement of the proposal submitted by the contractor in response to Directorate B, Contract Operations Division 2, letter JLENS-2012-001, dated Januray 19,2012, subject: Contract DASG60-98-C-OOOI, "Joint Land Attack Cruise Missile Defense Elevated Netted Sensor (JLENS)," for de-scope offour functionalities from MIS-PRF-55628, Revision B, dated 18 August 2009. The target cost; target fee, and value will be adjusted as follows to account for the final negotiated amount: target cost decreased by target fee decreased by and total contract value decreased by $931,707. 6. Settlement of the proposal submitted by the contractor in response to Directorate B, Contract Operations Division 2, letter JLENS-2011-036, dated July 1,2011, requesting an update to Contract Data Requirements List (CDRL) BOI7, Integrated Support Plan, Sub-Plan entitled Deployment Transition Plan. The target cost, target fee, and total contract value will be adjusted as follows to account for the fmal negotiated amount: target cost increased by £ 3target fee increased by _ and total contract value increased by $2,091,048. 7. To provide incremental funding in the amount of$I,096,I96. SUMMARY OF CHANGES 1. SECTION A - SOLICITATION/CONTRACT FORM DASG60-98-C-000 1 P00259 Page 3 of20 The total cost of this contract was increased by $378,299.00 from $1,955,238,009.00 to $1,955,616,308.00. 2. SECTION B - SUPPLIES OR SERVICES AND PRICES SUBCLIN 0017 AA The target cost has increased by ••••om ••••••'0 ••••••• The target fee has increased by The total target cost plus fee of this line item has increased by $378,299.00 from $1,595,005,395.00 to $1,595,383,694.00. This includes an increase in target cost of consisting of __1r.rl'!lI'1.l'! in cost and ••• increase in facilities capital cost of money, and an increase in target fee The target cost and target fee set forth above and in the table below reflects the negotiated ~ection B values prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between the Estimated Cost values provided below and the Target Cost values provided above and shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee values provided below and the Target Fee values provided above and shown on the table below are a result of reductions based on current share ratio impacts to the Target Fee and do not include any allocation for yet to be earned incentives as set forth in Section H-19. As oftl:}e date of this modification, the estimated cost and estimated ~~asfu~~: • The Estimated Cost is ••••••consisting of $•••• 1 in cost and ••••lm facilities capital cost of money. The Estimated Fee is •••••• Total Estimated Cost plus Fee is $1,717,867,861. Pursuant to FAR 16.405-1, the target cost and target fee will be finally determined and adjusted after contract performance. The table below provides a summary of the target cost, target fee, and total: eLIN MOD TARGET COST FQCM TARGET FEE $1,594,280,516.00 lb~A 17AA \\?)L~ 17AA P00254 ,005,395.00 l'C')L ~: 17AA P00258 1,595,005,395.00 09)L{ 17AA P00259 1,595,383,694.00 ~)L~ oo~5'73 DASG60-98-C-000 I P00259 Page 4 of20 CLIN 0030 The total cost of this line item has increased by $1,096,196.00 from $123,699,162.00 to $124,795,358.00. SUBCLIN 003007 is added as follows: ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003007 GFEBS Funding for SubCLIN 0017AA CPIF FOB: Destination ACRNMX $1,096,196.00 CIN: GFEBSOOI021201300030 ... As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for perfonnance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, analyzed, or reported separately from SubCLINOO 17, including EVMS: All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. B-17. INCENTIVE FEE FOR SUBCLIN OOI7AA1CLIN 0018 (SEE H-19): In accordance with FAR 52.216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017 AAlCLIN 0018 are set forth below: Target Cost Target Fee Incentive Arrangement: Maximum Fee: Minimum Fee: --- (Share Ratio: Government/Contractor) - Underrun: _or the amount by which the total allowable cost is less than the estimated cost until maximum fee is attained. Overrun: _or the amount by which the total allowable cost exceeds the estimated cost until minimum fee is attained. FAR 52.216-10, INCENTIVE, paragraph (e)(I), is stated as follows: DASG60-98-C-000I P00259 Page 5 of20 (e) Fee Payable. (I) The fee payable under this contract shall be the target fee increased by_or every dollar that the total allowable cost is less than the estimated cost or decreased b) every dollar that the total allowable cost exceeds the estimated cost. In no event shall the fee be greater than t 1aximum fee) or less th~ inimum fee) of the estimated cost. B-18. ESTIMATED COST. ESTIMATED INCENTIVE FEE. MINIMUM INCENTIVE FEE. MAXIMUM INCENTIVE FEE. AND INCENTIVE ARRANGEMENT FOR SUBCLIN 0017 AAlCLlN 0018: SUBCLIN 0017 AA - ITwo SDD JLENS Systems) a. Estimated cost: ~)lq b. Estimated fee: ~i~J c; Minimum incentive fee: ~1t£ d. Maximum incentive fee: $--- s ~t~ e. Total estimated cost and estimated fee: 51,717,867,861 3. SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $1,096,196.00 from $1,947,977,801.63 to $1,949,073,997.63. SUBCLIN 003007: Funding on SUBCLIN 003007 is initiated as follows: ACRN:MX CIN: GFEBSOOI021201300030 Acctng Data: 02120122013204000001 171722550030003242A.0000013. 1.1 6100.9000021001 Increase: $1,096,196.00 Total: $1,096,196.00 Cost Code: A5XFJ Estimated Cost, Estimated Fee, and Estimated total for the above increase of $1 ,096, 196 is distributed as fo lIows (b)~) and includes an increase in estimated cost of_(_ of cost an~ facilities capital cost of money) and an increase in estimated fee ~ 'rJ~ oo~'5 '75 DASG60-98-C-000 1 P00259 Page 6 of20 Estimated Cost Estimated Fee Total ,096,196 IMPLEMENTATION OF AND EXPLANATION OF THE RELATIONSlllP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows: SUBCLIN 0017 AA : THIS CUMULATIVE PRIOR MODIFICATION TOTAL'" (1) Amount Required for Full Funding, (b )(4) Including Fee: ltll (2) Amount Allotted Under the LOF Clause - (b )(4) for Payment of Costs: \.\;l)~ (3) Amount Separately Obligated for (b )(4) Payment of Fee: S lV.>~ (4) Total Amount Allotted and Obligated: $1,714,775,111.27 51,096,196 $1,715,871,307.27 (5) Net Amount Required for Full Funding $ 2,714,450.73 ($ 717,897) $ 1,996,553.73 ... These figures take into consideration the negotiated total value of SubCLIN 0017AA (This does not include SubCLIN 17 AH) 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows: Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SDD), subparagraph a., b., and c., are revised as follows: a. General. SubCLIN 0017AA, System Development and Demonstration (SDD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and Paragraph H-19(c) applies only to the Schedule Incentive. The target contract price amount 0($1,595,383,694 (b )(4) includes a target cost of which includes & of cost and 5 facilities capital .2 »f (b)C DASG60-98-C-OOO I P00259 Page 7 of20 cost of money) and a target incentive fee of.S•••• 'which is.oftarget cost less facilities capital cost of money. b. Cost Incentive. (1) The target fee payable under SubCLIN 0017 AA estimated cost less facilities capital cost of mOlley an amount equal under SubCLIN 0017 AA is8 of the estimated cost less facilities capital cost of money an amount equal to_ (3) The minimum fee payable under SubCLIN 0017AA is "'the estimated cost less facilities capital cost of ~)C'f an amount equal ~ , (4) Fee will be adjusted for actual cost that is less than or more than the estimated cost stated above u~ share ratio o~ovenunent ~ontractor for actual costs less than the estimated cost, and a ratio o~ ~1 Government _ Contractor for actual costs greater than the estimated cost range applied according to Paragraph 1 H-19(c)(1). Q?1 (5) Nothing stated in this clause shall take precedence over the clause 52.216-10 - Incentive Fee contained in this contract, c. Schedule and Perfonnance Incentive. (1) A maximum "flat zone" will be established at the target cost value of 'lith the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from S to $ once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00259, onl~fthe maximwi "flat zone" has been acknowledged as earned.) (a) , ~fthe maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NLT 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of .Ii•••• Final detemiination of incentive fee payment the "Flat Zone" amount will be made at the \])'0 conclusion of the contract. Reference letter, dated 5 March 2007 U)i(g) (nLIq) (b) of the maximum benefit of the "flat zone", earned by the conduct of SDD Orbit Critical ~t't Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive a Final 0D)~ detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 12 January 2009, front...... (PX1o 7 ~lo) (c) 2 _ of the Inaximum benefit of the "flat zone", earned by the conduct of the Developmental Test I (DT -I) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance (b)(~' Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112. ([t is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of ••••• or of the available Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) DASG60-98-C-OOO I P00259 Page 8 of20 (d) ,fthe maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08110/12. (e) • _ of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone PerfoI'IIlance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of the available S____ inal determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) ·NOTE: The potential has been decreased from _ lue to movement of the centive for "JLENS tracks interceptor when it enters the FCR Field-of-View (FOV)" from the IFC event to the FCA #1 event (f) 7 ~ of the maximum benefit of the "flat zone", earned by the conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19( c), dated 08/10112. ·Note: The potential has been increased frOIl to 'ue to movement of the ncentive for "JLENS tracks interceptor when it enters the FCR Field-of-View (FOV)" from the IFC event to the FCA # 1 event. (g) , ~ of the maximum benefit of the "flat zone", earned by the conduct of Developmental Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12 .... (h) l _ofthe maximum benefit of the "flat zone", earned by the conduct of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112 .... (i) ,_of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional l'o)L~ Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. • (3) For Earned Value and cost reporting purposes, the estimated cost value of $1,464,660,290 will be used. d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision. 5. The following is an update to Modification P00258 showing a summary of funding by ACRN through Modification P00259: FUNDING OO~57R DASG60·98·C-OOO 1 P00259 Page 9 of20 AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 OO~ rs79 DASG60-98-C-Ooo 1 P00259 Page 10 of20 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 12~,()()O.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 (joci5iO DASG60-98-C-000 1 P00259 Page II of20 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 00 aes«J DASG60-98-C-000 1 P00259 Page 12 of20 MA $2,982,442.00 MB $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,780,923.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 .ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7 ,864,499.00 MY $39,921,199.75 MW $10,000,000.00 MX SI14,795,358.00 6. The following is an update to Modification P00258 showing a summary of funding by CLIN by ACRN through Modification P00259: DASG60-98-C-OOOI P00259 Page 13 of20 FUNDING AMT CLIN TOTAL CLIN 0001 AA 440,100.00 CLINooOI AD 0.00 440,100.00 CLIN 0003 AB 2,298,235.00 CLINOO03 AC 17,832,987.00 CLINOO03 AD 0.00 CLINOO03 AE 7,500,000.00 CLINOOO3 AF 3,300,000.00 CLINOO03 AG 17,192,400.00 CLINOOO3 AH 700,000.00 CLINOOO3 AM 17,045,000.00 CLINOOO3 AN 5,800.00 CLINOO03 AP 20,779,000.00 CLINOOO3 AS 0.00 CLINOOO3 AT 6,984,678.52 CLINOOO3 AW 100,000.00 CLINOO03 AY 550,000.00 94,288,100.52 CLINOO05 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLIN 0005 BC 72,000.00 CLINOO05 BD 85,000.00 CLIN 0005 BE 100,000.00 OOd..583 DASG60-98-C-OOO 1 P00259 Page 14 of20 CLIN0005 BF 100,000.00 CLIN0005 BO 1,975,321.00 CLIN0005 BH 38,018,908.00 CLINOO05 BL 0.00 CLIN0005 BZ 0.00 65,025,107.00 CLIN0007AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLINOOO9AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOO09AA BN 21,315.00 447,966.00 CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLlNOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINOO09AB BK 3,455.00 CLINOO09AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLINOO09AB BV 9,000.00 oo~~~tt DASG60-98-C-000 1 P00259 Page 15 of20 869,034.00 CLINOO13 AU 7,970,000.00 CLINOO13 AX 3,396,000.00 CLIN 0013 AY 0.00 CLINOO13 AZ 19,412,000.00 CLIN 0013 BJ 7,896,673.34 38,674,673.34 CLIN 0017 BW 0.00 CLIN0017 KM 0.00 0.00 CLINoo17AA BY 3,880,000.00 CLINOOl7AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLINOO17AA KM 192,793,000.00 CLINOO17AA KN 0.00 CLINOO17AA KQ 66,151.00 CLINOO17AA KS 0.00 CLINOOl7AA KT 386,204,200.00 CLINOO17AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLINoo17AA LC 200,000.00 CLINOO17AA LD 7,943,648.00 CLINOO17AA LE 0.00 CO~5 CLINOO17AA LH 400,000.00 CLINOO17AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 CLINOO17AA LQ 235,566.00 CLINOO17AA LS 6,069,616.00 CLINOO17AA LT 530,377.00 CLINOO17AA LV $9,100,000.00 CLINOO17AA LV $1,957,265.00 CLINOO17AA LW $255,567.00 CLINOO17AA LX $68,000.00 CLINOO17AA LY $264,807,424.52 CLINOO17AA MB $375,000.00 CLINOO17AA MC $2,283,481.00 CLINOO17AA MD $8,573.00 CLINOO17AA ME $0.00 CLINOO17AA MF $270,780,923.00 CLINOO17AA MH $213,390.00 CLINOO17AA MJ $858,495.00 CLINOO17AA MK $56,076.00 CLINOO17AA ML $116,044.00 CLINOO17AA MM $1,618,600.00 CLINOO17AA MN $2,573,000.00 CLINOO17AA MP $250,000.00 CLINOO17AA MQ $691,42l.00 CLINOO17AA MR $0.00 DASG60-98-C-OOO 1 P00259 Page 17 of20 CLIN0017AA MS $700,000.00 CLIN0017AA MT $16,289,524.00 CLIN0017AA MY $39,921,199.75 CLIN0017AA MW $10,000,000.00 CLIN0017AA MX $124,795,358.00 1,715,871,307.27 CLIN0017AB KL 118,250.00 118,250.00 CLIN0017AC BZ 190,000.00 190,000.00 CLINOO17AD KN 0.00 CLIN0017AD KS 0.00 0.00 CLIN0017AE LL 173,798.00 173,798.00 CLIN0017AH KT 173,798.00 173,798.00 CLIN0020AA KN 0.00 DASG60-98-C-OOOI P00259 Page 18 of20 CLIN0020AA KQ 26,660.00 26,660.00 CLIN0021AA KW 0.00 0.00 CLIN0021AB KV 0.00 CLIN0021AB LB 0.00 CLIN0021AB KX 0.00 CLIN0021AB KY 0.00 0.00 CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00 0.00 CLIN0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLIN 0023 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN0023 LR $125,000.00 297,500.00 OO~S~~ DASG60-98-C-0001 P00259 Page 19 of20 CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CUN0024 KZ 25,000.00 CLIN0024 KW 20,000.00 CLIN0024 LP 83,200.00 203,708.00 CLINOO25 LE 1,173,850.00 CLINOO25 LM 1,080,404.00 CLINOO25 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,061.00 CLINOO27 LZ 1,751,384.00 1,751,384.00 CLINOO28 LM 329,972.00 CLINOO28 MA 2,982,442.00 CLINOO28 MG 6,262,095.00 CLIN0028 MU $7,864,499 17,439,008.00 CLIN 00300 I '" MX $52,974,283.00 DASG60-98-C-000 1 P00259 Page 20 of20 CLIN003002'" MX $719,132.00 CLIN 000303* MX $5,747.00 CLIN 000304'" MX $16,000,000.00 CLIN 000305* MX $16,000,000.00 CLIN 003006'" MX $38,000,000.00 eLIN 003007* MX 51,096,196.00 124,795,358.00 '" CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for perfonnance of SubCLIN 0017 AA. Infonnational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated un.der CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated. 8. In consideration of the modification agreed to herein as complete equitable adjustment for the following proposals submitted by Raytheon, the contractor hereby releases the Government from any and all liability under the contract for further equitable adjustments attributable to such facts or circumstances giving rise to the proposals for adjustment: JLENS System Capability Review (SCR) Proposal, submitted via Raytheon letter JLENS-SDDI2-016, dated 2 March 2012. (b)(3)(A) (i)&Title the Surveillance System (SuS) Proposal, submitted via Raytheon 10Sec letter JLENS-SDD-12-008, dated 16 February 2012. 130 (a) (b) JLENS 14 Day Endurance Test Proposal, submitted via Raytheon letter JLENS-SDD-12-026, dated 16 March 2012. JLENS Capability De-Scope Proposal, submitted via Raytheon letter JLENS-SDD-12-035, dated 9 April 2012. JLENS Deployment Transitiion Plan Proposal, submitted via Raytheon letter JLEN8-SDD-12-001, dated 23 January 2012. JLENS System Development and Demonstration (SDD) Spares, Proposal, submitted vai Raytheon letter JLENS SDD-12-012, dated 22 February 2012. AMENDMENT OF SOLICITATIONIMODIFICATION OF CONTRACT \MENDMENT/MODIFICATION NO. 4. REQUlSrnON/PURCHASE REQ. NO. 0260 6. ISSUED BY CODE 7. ADMINIS'lERED BY (Ifothor Iban itcm6) '------1 OCMARAYTHEON USASMOCIARSTRAT SOAPPl.E HILL ORNE SMOC·ROC MIST2FR2 POBOX11!OO TElM 8. NAME AND ADDRES';OF CONTRACTOR (No., Street, Co1Dlty, Statc and Zip Code) RAYTHEON COMPANY 31!0 LOV\8.L ST. ANDOVER MA D181D-4400 lOA. MOD. OF CONTRACf/ORDERNO. ~SG60-98-C-0001 "",A ahnvA nUnDeRd lolicitlllion is amonded .. let tbrth in Item 14. Thebour IIId datespeciied ilr receipt oroSe D i. not extended. OSrIlll.t acknowledge receipt ofthi. amendment prior to the hoW' lad date .peciJied io thOlolicitation or .. _ded by one ofth.. tbllowing mb.od.: (a) By oo ....l.ting Items 8 and H, IIId ",turning copiea ofthalDllnd"""t; (b) By acknowledging receipt ofthi. _dlIlOllt on each copy ofth. 01& aubnitted; or (c) By .epara/e.'.. t ... or telelJr&lll which includea arofon:nce to the solicitation and _dlIlOlt nuni>e 'YlUIJ1C1DIJ TO REFLECr THE ADMINISfRATlVE ~""""~'''''03(such as cbanges in paying TO THE AIJTHORITY OF FAR (Specify type of modification and authority) TffiAL: FAR 52.243-2, Changes and FAR 52.232-22 Urrlation of Funds E. IMPORT ANT: Contractor [R) is not, 0 is to sign this docl.II1cllt and return copies to the issuing office. 14. DBSCRIPT ION OF AMENDMENT IMODIFICAnON (Organized by UCF section hcadings, including solicitation/contract subject matter where feasible.) (b )(6) Modification Control Number: See SF3Q, block 14, continuation page. Except as herein,lll tClJU,ll and cooditions ofthe docum:nt ro&oDeod in Item 9A or lOA, as beman", chang.d, romIin. unchanged and in flll nree and ••1. 15A. NAME AND TITLE OF SIGNER (Type or print) :ONTRACfORIOFFEROR lSC. DATE SIGNED at.tborized to sign) 30-105·04 SfANDARD FORM 30 (Rev. 10·83) APPROVED BY OIRM 11·84 Prescribed by GSA ooaSq I FAR (48 CFR) 53.243 DASG60-98-C-OOOI P00260 Page 2 0(20 SBCTIONSF30BLOCKI4CO~ATIONPAGE The purpole or tills modification Is to: 1. Issue Change Order Modification P00260 for JLENS based on restructure letter JLENS-2012·03Idated 20 September, 2011. CeDing of contract will incJ'C8se by a total ofSS9,034,271. 2. This Change Order Modification will also incrementally fund this increase by $16,145,.226.39. SUMMARY OF CHANGES I. SECTIqN A - SOLICITATION/CONTRACT FORM The total cost of this contract was increased by $S9,034,271from $1,955,616,308,00 to $2,014,650,579.00. 2. SECTION B - SUPPLIES OR SERVICES AND PRICES SUBCLIN OOt7AA The target cost has increased by~ The tarset fee has increased Tho total target cost plUB fee ofthialine item has increased by 159,034,271 from $1,595,383,694 to $1,654,417,965. 11tJs includos an increase in target cost o~isting ofa inrn'OMUlfI in cost and a _crease in facilities capital cost of money, and an increase in target The target cost and tarlot fee set forth above and in the table below reflects the negotiated Section B values prior to any adjustments made resulting from estimated cost ovemms and share ratio impacts to the fee. Any dift'erences between the Estimated Cost values provided below and the Target Coat values provided above and shown on the table below are as a result of estimated cost overruns. Any dift'erenllCS between the Estimated Fee values provided below and the Targot Pee values provided above and shown on the table below are a result of reductions based on current sharo ratio impacts to the Target Fee and do not include any allocation for yet to be eamed incentives as sot forth in Section H-19. As of the date of this modification, the estimated cost and estimated fee are as follows: The Estimated Cost is $ facilities capi~ cost of money. .. -.-- The Estimated Fee is Tota,l Estimated Cost plus Fee Is S I ,776.902,132 .. Pursuant to FAR 16.405-1, the target cost and target fee will be finally detennined and adjusted after contract performance. The table below provides a swiunary of the target cost, target fee, and total: DASG60-98-C-OOO 1 POO260 Page 3 of20 CLIN MOD FCCM \ 17AA 1,594,280,516.00 ~~) 1,594,280,516.00 ~JL+) (}JX-~) 17AA ~)L*) P00259 cp)l~) 17AA POO260 .00 Cb'(4) CLIN0030 The total cost of this line item has increased by $16,000,000.00 from $124,795,358.00 to $140,795,358.00. SUBCLIN 003008 is added as follows: ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003008 GFEBS Funding for SubCLIN 0017 AA CPIF FOB: Destination ACRNMX $16,000,000.00 CIN: GFEBSOO lO2467oo0000 1 • As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding forperfonnance ofSubCLIN 00 17AA. The value ofCLIN 0030 equates to the amountofGFEBS funding obligated for perfonnance of SubCLIN 0017 AA and should not be considered additional contract value. Infonnational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, analyzed, or reported separately from SubCLINOO 17, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. B-17. INCENTIVE FEE FOR SUBCLIN 0017 AAlCLIN 0018 (SEE H-19): In accordance with FAR 52216-10, entitled "Incentive Fee", the total amount originally negotiated, adjusted in accordance with paragraph d. of this clause, for target cost and target fee for performance under SubCLIN 0017 AAlCLIN 0018 are set forth below: Target Cost 51,518,857,479 DASG60-98-C-OOO 1 P00260 Page 4 of20 Target Fee (b)(4) ~~ Incentive Arrangement Maximum$--- Fee: @li\ lb'1~ Minimum Fee: & (Share Ratio: Government/Contractor) Underrun: the amount by which the total allowable cost is less than the estimated cost until maximum fee is attained. Overrun: £ .r the amount by which the total allowable cost exceeds the estimated cost until (b )(4) ~'0 minimum fee is attained. FAR 52.216-10, INCENTIVE, paragraph (eX 1), is stated as follows: (e) Fee Payable. 8-18. ESTIMATED COST. ESTIMATED INCENTIVE FEE. MINIMUM INCENTIVE FEE. MAXIMUM INCENTIVE FEE. AND INCENTIVE ARRANGEMENT FOR SUBCLIN OOI7AA1CLIN 0018: SUBCLIN QO 17 AA - (Two SDO JLENS Systems) a. Estimated cost: (b )(4) (\;b b. Estimated fee: ~)Ltf- c. Minimum incentive fee: d. Maximwn incentive fee: $£ e. Total estimated cost and estimated fee: SI,776,902,132 3. SECTION G - CONTRACT ADMINISTRATION DATA ACCOWlting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $16,145,226.39 from $1,949,073,997.63 to $1,965,219,224.02. SUBCLIN 0017 AA: DASG60-98-C-000 1 P00260 Page 5 of20 MF: 21 12040 5L 5L68 Pl72419E555L 255Y 4MIJ730000 SOl0214MIJ730000114MJLEl4M5 was increased by $126,899.39 from $270,780,923.00 to $270,907,822.39 Estimated Cost, Estimated Fee, and Estimated total for the above increase of$126,899.39 is distributed as follows (b )(4) and includes an increase in estimated cost of I ,F:' f cost and of f~ci1ities capital Cbi; cost of money) and an increase in estimated fee of 3 lbu Estimated ~JUl Cost Estimated Fee Total MY: 21 12040 5L 5L68 PI72419E555L 2516 4MlMMICST3 S010214M1MMICST3114MJMM/4M5 was increased by $18,327.00 from $0.00 to $18,327.00 The contract ACRN MY has been added. Estimated Cost, Estimated Fee, and Estimated total for the above increase of $18,327 is distributed as follows and includes an increase in estimated cost cost and ~ffacilities capital cost of money) and an increase in estimated fee of••• Cost Estimated Fee Total 18,327 CLIN0030: SUBCLIN 003008: Funding on SUBCLIN 003008 is initiated as follows: ACRN:MX CIN: GFEBSOO1024670000ool Acctng Data: 0212012201320400000 1171722550030003242A.OOOOO 13.1.1 6100.9000021001 Increase: $16,000,000.00 Total: $16,000,000.00 Cost Code: A5XFI Estimated Cost, Estimated Fee, and Estimated total for the above increase of$16,OOO,OOO is distributed as follows and includes an increase in estimated cost of _ ( of cost and 2of facilities capital 006..595 DASG60-98-C-OOO 1 PO0260 Page 6 of20 cost of money) and an inCrease in estimated fee ot•••• (b )(4) Estimated Cost (b )(4) Estimated Fee Total IMPLEMENTATION OF AND EXPLANATION OF THE RELA TIONSIDP OF THE LIMITA nON OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS. subparagraph c., is revised to read as follows: SUBCLIN 0017 AA : THIS CUMULATIVE PRIOR MODIFICATION TOTAL· (1) Amount Required for Full Funding. Including Fee: (b)(4) ~ (2) Amount Allotted Under the LOF Clause for Payment of Costs: (9):.Y (3) Amount Separately Obligated for Payment of Fee: $ ~)~) ~l' (4) Total Amount Allotted and Obligated: $1,715,871,307.27 SI6,145,226.39 SI,732,016,533.66 (5) Net Amount Required for Full Funding $ 1,996,553.73 $ 42,889,044.61 S 44,885,598.34 • These figures take into consideration the negotiated total value of SubCLIN 00 17 AA (This does not include SubCLIN 17 AH) 4. SECTION H - SPECIAL CONTRACT REQUIREMENTS is revised as follows: Paragraph H-19, INCENTIVE FEE STRUCTURE AND PAYMENT FOR CLIN 0017. SYSTEM DEVELOPMENT AND DEMONSTRATION (SOD), subparagraph a., b., and c., are revised as follows: a. General. SubCLlN 0017AA, System Development and Demonstration (SOD), is a cost-plus-incentive-fee (CPIF) Line Item with cost and schedule incentives as described below. Paragraph H-19(b) applies only to the Cost Incentive and DAS060-9a-COOO1 POO260 PoP~'6f20 ,, "., , hrqrIph 8-19(0) oppilleo .>Diy .. melUd. • tIrJIIC COlt _ of.....,,) ond. lalPi'iiiCiiiiiiiW .....". b. Coot 1nccnIlvc. • 'I" (b)(4)~ "1 "''11_ ~m ~)J/ i!>:£.~ ; ~~ @YI: 8-19(eXI). Ili'j.q ...... (5) Notbinc ItUed in this cia&ale Ihall tab precedeoce over me claiM 52.216-10 - Inceatlve Foe contaioed in &i • "&t DlIMI" wiU be eatabliabed ... the IIrpt coC value "flU zone" over- which the c.ootruor wUl ICII: bib below 11'0 ~)b (b)(f (b)(4) 1>0 SDD S,. ...... t~ ~(fi l5>Xli ll')u.~ owcimum 1 )0 Orbit Critbl MoO'\) iiiil;~". FIIc:ol V", .II1II R.Iytbcca complclled the requirmDeot for thla o.t ZOM I _Final Ijl/.!J' cIoIomI_or~.. ftIe __ udlIz llionorebe _"...... _ 12 J.. ""Y' (b"X~) Q,o")dJ) . muimum. be )ewIopmonIaI blL.<{\ , Tat I witb lbecriteria .. tbr1h in Scctioa J.u.:imeat ooddod F1UZonD PatG:ciOlilCO I em.;. fur JLI!NS SDD ~ _8-19«). _01110112. (I' is bon>by _todpcI bylbo 110- "'" Rlylboon comp_1bo __I fur Ihlo fill """ ODd _ • "FIII_rr __YO Of OASG60-98-C-OOOl PO0260 Page 8 of20 ••••• or of the available . Final detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) Cd) of the maximum benefit of the "flat zone", earned by the conduct of the Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Fiat Zone Perfonnance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. (e) of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDO Contract, Section H-19(c), dated 08110/12. (It is hereby acknowledged by the government that Ra1eon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of i i or_ofthe available 2 Final detennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) "'NOTE: The ...... , ; •. .J. ....~...... ' • , , , I • • . (b)(3)(A) . . (i)&Title 10 (10 " ~ (f) . U of the maxunum benefit of the "flat zone", earned by the conduct of the Functional Sec 130 (a) (b) IJ; ]v . Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08110/12. increased from (b)(3)(A) (i)&Title 10 Sec (g) of the maximum benefit of the "flat zone", earned by the conduct of Developmental 130 (a) (b) li?x.. -(, Test 2 (DT-2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-:19(c), dated 08/10/12. • .-.... \I~V"JI (h) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Early User Test \Y J-.'-t (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10112. * (i) ~ of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional (,,;,/.--4) Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. • (3) For Earned Value and cost reporting purposes, the estimated cost value of $1,518,857,479 will be used. d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/perfonnance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision. 5. The following is an update to Modification P00259 showing a sununary offunding by ACRN through Modification POO260: FUNDING DASG60-98-C-OOOI P00260 Page 9 of20 AA 440,100.00 AB 2,2~8,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AI 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 OO~5q~ DAS060-98-C-Oool P00260 Page 10 of20 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1.975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10.199.288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ' 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 OO~(oOO DASG60-98-C-OOO 1 P00260 Page 11 of20 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LV $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 (X)cl&20 [ DASG60-98-C-000 I P00260 Page 12 of20 LZ $1,751,384.00 MA $2,982,442.00 MB $375,000.00 Me $2,283,48 LOO MD $8,573.00 ME $0.00 MF $270,907,822.39 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $ 16,289,524.00 MU $7,864,499.00 MV $39,921,199.75 MW $10,000,000.00 MX $140,795,358.00 MY $18,327.00 6. The following is an update to Modification P00259 showing a summary of funding by eLIN by ACRN through Modification P00260: OASG60-98-C-000 1 P00260 Page 13 0[20 FUNDING AMT CLIN TOTAL CLIN 0001 AA 440,100.00 CLIN 0001 AD 0.00 440,100.00 CLINOO03 AB 2,298,235.00 CLINOO03 AC 17,832,987.00 CLINOOO3 AD 0.00 CLINOOO3 AE 7,500,000.00 CLINOO03 AF 3,300,000.00 CLIN 0003 AG 17,192,400.00 CLIN 0003 AH 700,000.00 CLINOO03 AM 17,045,000.00 CLINOO03 AN 5,800.00 CLINOO03 AP 20,779,000.00 CLlN 0003 AS 0.00 CLlN 0003 AT 6,984,678.52 CLINOO03 AW 100,000.00 CLINOO03 AY 550,000.00 94,288,100.52 CLINOO05 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLIN 0005 BC 72,000.00 CLINOO05 BO 85,000.00 CLINOO05 BE 100,000.00 ()O~~O3 DASG60-9 8-C-000 1 P00260 Page 14 of20 CLIN0005 BF 100,000.00 CLIN 0005 BG 1,975,321.00 CLIN0005 BH 38,018,908.00 CLIN 0005 BL 0.00 CUN0005 BZ 0.00 65,025,107.00 CLIN0007AA BP 10,199,288.50 10,199,288.50 CLINOOO9AA AQ 45,106.00 CLIN 0OO9AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM l25,000.00 CLINOO09AA BN 21,315.00 447,966.00 CLINOO09AB AJ 200,000.00 CLINOOO9AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLIN 0009AB AR 35,000.00 CLINOO09AB BK 3,455.00 CLIN 0009AB BN 81,685.00 CLINOOO9AB BU 350,000.00 CLINOO09AB BV 9,000.00 ()O~u04 DASG60-98-C-OOO 1 P00260 Page 150[20 869,034.00 CLINOOl3 AU 7,970,000.00 CLINOO13 AX 3,396,000,00 CLINOOl3 AY 0.00 CLINOO13 AZ 19,412,000,OQ CLIN 0013 BJ 7,896,673.34 38,674,673.34 CLIN0017 BW 0.00 CLIN 0017 KM 0.00 0,00 CLIN 0017AA BY 3,880,000.00 CLIN 0017AA BX 1,146,000.00 CLINOO17AA BW 84,896,852.00 CLIN 0017AA BZ 0.00 CLIN 0017AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLIN 0017AA KQ 66,151.00 CLINOO17AA KS 0.00 CLINOO17AA KT 386,204,200.00 CLIN 0017AA KU 2,203,183.00 CLINOO17AA KY 0.00 CLIN 0017AA LC 200,000.00 CLIN 0017AA LD 7,943,648.00 CLIN OO17AA LE 0.00 OOd-laOS DASG60-98-C-OOO 1 P00260 Page 16 of2D CLIN OO17AA LH 400,000.00 CLIN 0017AA LJ 7,476.00 CLIN 0017AA LK 281,575,897.00 CLIN 0017AA LQ 235,566.00 CLIN 0017AA LS 6,069,616.00 CLIN 0017AA LT 530,377.00 CLINOOl7AA LV $9,100,000.00 CLIN OO17AA LV $1,957,265.00 CLIN OOl7AA LW $255,567.00 CLIN 0017AA LX $68,000.00 CLIN OO17AA LY $264,807,424.52 CLIN 0017AA MB $375,000.00 eLIN OOl7AA Me $2,283,481.00 eLIN 0017AA MD $8,573.00 eLIN 0017AA ME $0.00 CLINOO17AA MF $270,907,822.39 CLIN 0017AA MH $213,390.00 CLINOOl7AA MJ $858,495.00 CLIN 0017AA MK $56,076.00 CLIN OO17AA ML $116,044.00 CLINOOl7AA MM $1,618,600.00 CLIN OO17AA MN $2,573,000.00 CLIN 0017AA MP $250,000.00 CLIN 0017AA MQ $691,421.00 CLINOOl7AA MR $0.00 CO&loOto DASG60-98-C-000 1 P00260 Page 17 of20 CUN0017AA MS $700,000.00 CLIN 0017AA MT $16,289,524.00 CLIN 0017AA MV $39,921,199.75 eLIN 0017AA MW $10,000,000.00 CLIN 0017AA MX $140,795,358.00 CLINOOl7AA MY $18,327.00 1,732,016,533.66 CLIN 00 17AB KL 118,250.00 118,250.00 CLIN 0017AC BZ 190,000.00 190,000.00 eLIN OOl7AD KN 0.00 eLIN 0017AD KS 0.00 0.00 eLIN 0017AE LL 173,798.00 173,798.00 eLfN 0017AH KT 173,798.00 173,798.00 OO~(.QO'7 DASG60-98-C-000 I P00260 Page 180(20 CLIN0020AA KN 0.00 CLIN0020AA KQ 26,660.00 26,660.00 CLIN 0021AA KW 0.00 0.00 CLIN 002lAB KV 0.00 CLIN 002lAB LB 0.00 CLIN 0021AB KX 0.00 CLfN 002lAB KY 0.00 0.00 CLIN 0021AC KZ 0.00 CLIN0021AC LA 0.00 0.00 CLIN 0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLIN 0023 KY 25,000.00 CLINOO23 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN 0023 LR $125,000.00 00611908 DASG60-98-C-OOO 1 P00260 Page 190[20 297,500.00 CLIN 0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN 0024 KZ 25,000.00 eLIN 0024 KW 20,000.00 CLIN 0024 LP 83,200.00 203,708.00 CLIN0025 LE 1,173,850.00 CLIN 0025 LM 1,080,404.00 CLIN 0025 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,061.00 CLIN0027 LZ 1,751,384.00 1,751,384.00 CLIN 0028 LM 329,972.00 CLIN 0028 MA 2,982,442.00 CLIN 0028 MG 6,262,095.00 CLIN 0028 MU $7,864,499 17,439,008.00 DASG60-98-C-OOO 1 P00260 Page 20 of 20 CLIN 003001* MX $52,974,283.00 CLIN003002* MX $719,132.00 CLIN 000303 * MX $5,747.00 CLIN 000304* MX $16,000,000.00 CLIN 000305 * MX $16,000,000.00 CLIN 003006* MX $38,000,000.00 CLIN 003007* MX $1,096,196.00 eLIN 003008* MX $16,000,000.00 140,795,358.00 * CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated. (End of Summary of Changes) OO~lo(O AMENDMENT OF SOLICITATIONIMODIFICATION OF CONTRACT NO. EFFECTIve DAlE 4. REQUISmON/PURCHASE REQ. NO. 13-Nov-2012 6. ISSUED BY CODE 1.ADMINISlERED BY (lfotb.. lblll il.... 6) """';;"O"';='-----i DCMARAYTHEON USASMDCIAASTRAT 50 APPl£ Hi\.L DRIVE SMDC·RDC M/sT2FA2 PO BOX ISlO TEW 8. NAME AND ADDRESS OF CONTRACTOR (No., Street. COUDty, SUte and Zip Code) 9A. RAYTHEON COMPANY 350LOWEU.ST. ANDOVER MAOla'l).44oo 98. DATED (SEE ITEM II) Olh .....' ocknowtodg. receip' oflhi ...... dm:nl prio, to Ih. hour and dale 'p",iled in 'he sotici'ation o,.J _dod by on. ortbe.lltowlnH IIIdhods: (a) 9y co ....lelin~ 1t0lll5 8 and t S, and n:lumiaG ___copies oRh• ....,.d..... l; (b) By ocknowl.dllias roceipl oflhi ...... eImonl on each copy .fthe 01& .u_IIed; or (c) By •• panteleller 0' leteararftwhich includc. a ...... " 10 the loli 13. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Speciry authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA. "nn"'~JI'." (such as chllJlges in pDying (Scleciry type of modification and authority) ~L; FAR 52.232-22 E. IMPORT ANT: Contractor is not. 0 is required 10 sign Ihis document and reI urn copies to the issuing office. 14. DESCRIPTION OF AMENDMENT !MODIFICATION (Organized by UCF section headings. inch..!ing solicitation/contract subject matter where feasible.) MOdi'ficalion Control Number: 12••••• See SF30, block 14, contrrualion page. ST ANDARD FORM 30 (Rev. 10-83) Prescribed by GSA FAR (48 C'FR) 53.243 OO~{; {I DASG60-98-C-000 I P00261 Page 2 of 15 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES I. SECTION B - SUPPLlliS OR SERVICES AND PRICES CLIN 0030 The total cost of this line item has decreased by $2,000,000.00 from $140,795,358.00 to $138,795,358.00. ,., ,. As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for pertonnance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017AA, identified, accounted for, analyzed, or reported separately from SubCLINOO 17, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. 2. SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was decreased by $2,000,000.00 from $1,965,219,224.02 to $1,963,219,224.02. SUBCLIN 003008: NIX: 02120122013204000001171722550030003242A.0000013.1.1 6100.9000021001 A5XFJ (CIN GFEBSOO 102467000000 I) was decreased by $2,000,000.00 from $16,000,000.00 to $14,000,000.00 Estimated Cost, Estimated Fee, and Estimated total for the above decrease of $2,000,000 is distributed as follows and includes a decrease in estimated cost ( (' of cost and .f facilities capital cost of money) and a decrease in estimated fee of Estimated Cost Estimated Fee Total ($2,000,000.00) IMPLEMENT A TION OF AND EXPLANA nON OF THE RELA TIONSfllP OF THE LIMIT ATION OF FUNDS OO:tlo (a DASG60-98-C-000 1 P00261 Page 3 of 15 (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph C., is revised to read as follows: SUBCLIN0017AA : TillS CUMULATIVE PRIOR MODIFICATION TOTAL * (1) Amount Required for Full Funding, Lloj-l) Including Fee: SO ~ (2) Amount AlIotted Under the LOF Clause for Payment of Costs: lVJ~ct~ (3) Amount Separately Obligated for Payment of Fee: S lb\L~ (4) Total Amount Allotted and Obligated: $1,732,016,533.26 ($2,000,000.00) $1,730,016,533.26 (5) Net Amount Required for Full Funding $ 44,885,598.34 $ 2,000,000.00 $ 46,885,598.34 * These figures take into consideration the negotiated total value of SubCLIN 0017 AA (This does not include SubCLIN 17 AH) 3. The following is an update to Modification P00260 showing a summary of funding by ACRN through Modification P00261 : FUNDING AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 OOd-Lo{3 DASG60-98-C-000 1 P00261 Page 4 of 15 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 AM 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 BC 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 Bl 7,896,673.34 BK 260,000.00 DASG60-98-C-0001 P00261 Page 5 of 15 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 OOd-lt 15 DASG60-98-C·000 1 POO261 Page 6 of 15 LE 1,173,850.00 LF 10,000.00 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LV $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 MA $2,982,442.00 MB $375,000.00 Me $2,283,481.00 MD $8,573.00 ME $0.00 l'v1F $270,907,822.39 MG $6,262,095.00 OO:lu I ~ DASG60-98-C-OOO 1 P00261 Page 7 of 15 MH $213,390.00 MJ $858,495.00 tvJK $56,076.00 IvIL $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 l\.1R $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MV $39,921,199.75 MW $10,000,000.00 MX $138,795,358.00 MY $18,327.00 4. The following is an update to Modification P00260 showing a summary of funding by CLIN by ACRN through Modification P0026 I : FUNDING AMT CLIN TOTAL CLIN 0001 AA 440,100.00 CLIN 0001 AD 0.00 440,100.00 CLIN 0003 AB 2,298,235.00 DAS060-98-C-000 1 P00261 Page 8 of 15 CLIN 0003 AC 17,832,987.00 CLIN 0003 AD 0.00 CLIN 0003 AE 7,500,000.00 CLIN 0003 AF 3,300,000.00 CLIN 0003 AO 17,192,400.00 CLIN 0003 AH 700,000.00 CLIN 0003 AM 17,045,000.00 CLIN 0003 AN 5,800.00 CLIN 0003 AP 20,779,000.00 CLIN 0003 AS 0.00 CLIN 0003 AT 6,984,678.52 CLIN 0003 AW 100,000.00 CLIN 0003 AY 550,000.00 94,288,100.52 CLlN 0005 BA 24,527,878.00 CLINOO05 BB 146,000.00 CLIN 0005 BC 72,000.00 CLIN 0005 BD 85,000.00 CLlN 0005 BE 100,000.00 CLlN 0005 BF 100,000.00 CLIN 0005 BO 1,975,321.00 CLIN 0005 BH 38,018,908.00 CLIND005 BL 0.00 CLIN 0005 BZ 0.00 65,025,107.00 DASG60-98-C-OOO 1 P00261 Page 9 of 15 CLIN0007AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLINOO09AA BN 21,315.00 447,966.00 CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CUNOO09AB AL 45,000.00 CLIN 0009AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLINOO09AB BK 3,455.00 CLIN 0009AB BN 81,685.00 CLIN 0009AB BU 350,000.00 CLINOO09AB BV 9,000.00 869,034.00 CLIN0013 AU 7,970,000.00 CLIN 0013 AX 3,396,000.00 CLIN 0013 AY 0.00 CLIN 0013 AZ 19,412,000.00 CLIN 0013 BJ 7,896,673.34 OOG-~ 19 DASG60-98-C-000 I P0026 I Page 10 of 15 38,674,673.34 CLIN 0017 BW 0.00 CLIN 0017 KM 0.00 0.00 CLIN 0017AA BY 3,880,000.00 CLINOOI7AA BX 1,146,000.00 CLIN 0017AA BW 84,896,852.00 CLIN 0017AA BZ 0.00 CLINOO17AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLIN 0017AA KQ 66,151.00 CLIN 0017AA KS 0.00 CLIN 0017AA KT 386,204,200.00 CLIN 00 I 7AA KV 2,203,183.00 eLIN 0017AA KY 0.00 eLIN 0017AA LC 200,000.00 eLIN 0017AA LD 7,943,648.00 CLIN 0017AA LE 0.00 CLINOO17AA LH 400,000.00 CLIN 0017AA LJ 7,476.00 CLINOO17AA LK 281,575,897.00 eLIN 0017AA LQ 235,566.00 CLIN 0017AA LS 6,069,616.00 CLIN 0017AA LT 530,377.00 CLIN 0017AA LV $9,100,000.00 00 ~&d-O DASG60-98-C-000 1 P0026 I Page II of 15 CUN 0017AA LV $1,957,265.00 CLIN 0017AA LW $255,567.00 CLIN 0017AA LX $68,000.00 CLIN 0017AA LY $264,807,424.52 CLIN 0017AA MB $375,000.00 CLIN 0017AA MC $2,283,481.00 CLINOO17AA MD $8,573.00 CLlNOOl7AA ME $0.00 CLIN 0017AA MF $270,907,822.39 CLIN 0017AA MH $213,390.00 CLIN 00l7AA MJ $858,495.00 CLINOO17AA MK $56,076.00 CLIN 0017AA ML $116,044.00 CLIN 0017AA tvIM $1,618,600.00 CLINOO17AA MN $2,573,000.00 CLINOO17AA MP $250,000.00 CUNOOl7AA MQ $691,421.00 CLIN 0017AA MR $0.00 CUNOO17AA MS $700,000.00 CLINOOl7AA MT $16,289,524.00 CLlN 0017AA MY $39,921,199.75 CLINOO17AA MW $10,000,000.00 CLlNOOl7AA MX $138,795,358.00 CLIN OOl7AA MY $18,327.00 1,730,016,533.26 DASG60-98-C-OOO 1 P00261 Page 12 ofl5 CLIN0017AB KL 118,250.00 118,250.00 CLIN0017AC BZ 190,000.00 190,000.00 CLIN 0017AD KN 0.00 CLIN 0017AD KS 0.00 0.00 CLIN0017AE LL 173,798.00 173,798.00 CLIN0017AH KT \73,798.00 173,798.00 CLIN0020AA KN 0.00 CLIN0020AA KQ 26,660.00 26,660.00 CLIN0021AA KW 0.00 0.00 DASG60-98-C-OOO I P00261 Page 13 ofl5 CLIN 0021AB KV 0.00 CLIN 0021AB LB 0.00 CLIN 0021AB KX 0.00 CLIN 0021AB KY 0.00 0.00 CLIN0021AC KZ 0.00 CLIN 0021AC LA 0.00 0.00 CLIN 0022 KW 0.00 0.00 CLIN 0023 KX 60,000.00 CLIN 0023 KY 25,000.00 CLIN 0023 KV 65,000.00 CLIN 0023 LB 12,500.00 CLIN 0023 LF 10,000.00 CLIN 0023 LR $125,000.00 297,500.00 CLIN0024 LA l3,508.00 CLIN0024 LG 62,000.00 CLIN 0024 KZ 25,000.00 CLIN 0024 KW 20,000.00 CLIN0024 LP 83,200.00 DASG60-98-C-000 1 P00261 Page 14 of 15 203,708.00 CLIN 0025 LE 1,173,850.00 CLIN0025 LM 1,080,404.00 CLIN 0025 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,061.00 CLIN0027 LZ 1,751,384.00 1,751,384.00 CLIN 0028 LM 329,972.00 CLIN 0028 MA 2,982,442.00 CLIN 0028 MG 6,262,095.00 CLIN 0028 MU $7,864,499 17,439,008.00 CLIN 00300 1* MX $52,974,283.00 CLINOO3002* 1\1)( $719,132.00 CLIN 000303 * MX $5,747.00 CLIN 000304* MX $16,000,000.00 CLIN 000305 * MX $ I 6,000,000.00 CLIN 003006* MX $38,000,000.00 CLIN 003007* MX $1,096,196.00 CO~~~~ DASG60-98-C-OOO 1 P00261 Page 15 of 15 CLIN 003008* MX $14,000,000.00 138,795,358.00 * CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLlN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. For pruposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated. (End of Summary of Changes) Page Intentionally Left Blank Not a Contract Document Page Intentionally Left Blank Not a Contract Document Page Intentionally Left Blank Not a Contract Document Page Intentionally Left Blank Not a Contract Document Page Intentionally Left Blank Not a Contract Document Page Intentionally Left Blank Not a Contract Document AMENDMENT OF SOLICITATIONIMODIFICATION OF CONTRACT l. EFFEC"nVE DATE REQUISITION/PURCHASE REQ. NO. . ADMlNlSlERED BY (Ifother than it .... 6) t..:.:.;:;.;..="-___; OCMA RAYTHEON USASMDCIAASTRAT !IIAPPlE HIll. DRIVE SMDC·RDC MIS T2FR2 POBOX 1500 TEWKSBURY MA 01878 fiUNTSVJlI.EAL 35807·3801 8. NAME AND ADDRESS OF CONTRACfOR (No., Streel, COWlly. Stale and Zip Code) 9A. AMENDMENT SOLICITATION NO. RAYTHEON COMPANY 3!5IILO~ST. ANDOVERMAOI81().4400 98. DATED (SEE ITEM II) (SEE ITEM \3) n .....md solicit.tion is _dcd os set (nth in It .... 14. The ho.r and date spcciicd ilr ...,.ipt oro lir 0 i••• 1 ntendod. Oli:r I1IISlacknowledt:. receipt oflhi ...... dll"Cnt prior to Ih. ho.r and dlle 'pcci!cd in th. solicilltioo or as ...... dod by one oflhel>lIowi.llll:lbods: (a) By c:oJq)leting hems 8 and I S. and I'dumin" __ copJes o(the iU'IEIldnau; (b) By adcnowlcdging ~cejpl aflhis am:ndDall on each copy orthc 0 .... stlbnitted; or (c) By sopanl.lelter or I.I.g..... wbich i.clud... reference to th. solicitation IOd IIDmdJnCrIl nu.... .,.. FAILURE OF YOUR ACKNOWLEDOMENT1O BE RECEIVED ATlHE PLACE DESIGN A lED FOR THE RECEIPT OF OFFERS PRIOR 10 lliE HOUR AND DAlE SP ECIFIED MAY RESULT IN REJECTION OF YOUR OFFER. l(by vlnu. oflbi, _d.... t you desire to cbongc an olJ:r.lrcady ,ab"lled, such chanKe ny bellINI. by tel.gromor I",Ier. eacb te-Ie-edlnar letterrmkes reamce to Ihesolicill1ioD IIId tbis ~ndlll:llt,lDd IS ~ci¥t!d priorlD Ihe openinG hOlUlDd dilte specilcd. 12. ACCOUNTING AND APP ROP RIA nON DATA (I r required} 13. THISCHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA. L""""U,,"" \!RICn as changes in paying OTHER (Specify type of modification and aUlhority) E. IMPORTANT: Contraclor 0 isnot, is required to sign Ihis docwnent and return copies to Ihe issuing office. 14. DESCRIPTION OF AMENDMENTIMODIFICATION (Organized by UCF seclion headings, includingsolicilationlconlract subject matter where feasible.) Modification Control Nmnber: See SF30, block 14, contlnuaHon page. 0J/i0\ ~~ ___,'-.:. )1..') ST ANDARD FORM 30 (Rev. 10-83) Prescnbcd by GSA FAR (48 CFR) 53.243 DASG60-98-C·OOO I POO262 Page 2 of21 SECTION SF 30 BLOC'"<' . ~ CONTINUATION PAGE St:M M AR ~ ~) F CHA "I(·:~ S SECTION .:, SOLICIT n - IONiCONTRACI' FORM The foHowmg h.ave bee,. ":ded by full text: PURPOSE SECTION SF 30 BLOCK 4 COhfTlNUATION PAGE Tile purpost of this m r.di~c a ti O fl is to: I. Correct admin istr'::tive errors to Modification P()0260. 2. Summary of Changes for Modification P00260 should have read as follows: 3. All corrections ar..: shown in bold red. SUMMARY Of CHA~ G'£ S I. SECflO"l A - SOLl CI! ATION/CONT!lACT FORM Change Order Modification P00260 for JLENS based on restructure letter lLENS-20 12-03 I dated 27 September, 2012 Ceiling of conlract will increase by a tOla l of$59,034.271. The total cost or this contract was increased by $59,034,271 from $ I ,955,6 16,308.00 to $2,01 4,650,579.00. 2. SECTlO:-'; B - SUP !·~.E.S OR SER VICES AND PRICES SUBCLfN 0017AA Tho; tuget CC5i r::s increased by "~,ro"," """"~Ot~'''''''''''1I The targel fee hz.s increased byl••• The tetal tar g~, cost plus fee oftbis line item has increased by $59,034,271 from $ 1.595 ,3 83,694 to $1,654,41 7,';165. Th is includes all Inc rease in target cost o ~f ••••T~ consistillg of a • r increase ill cost and a ",re,,, ,"fa cilities capital cost of mOlley, and an increase III target fee The target cost and ~ a rget fee set forth above and in the table below reflects the negotiated Section B valUes prior to any adjustments made resulting from estimated cost overruns and share ratio impacts to the fee. Any differences between tht: Estimated Cost values provided below and the Target Cost values provided above and shown on the table below are as a result of estimated cost overruns. Any differences between the Estimated Fee DASG50·93·C'()OO! P;)0262 Page 3 of21 vallles prov;!l. ~'i below ~r.d 'he Target Fee values provided above and shown on the table below are a result o. reductions bllseci on cu 're~: ihare ratio impacts to the Target Fee and do not include any allocat ion for yet to be earned il1ccl.'i"ts as se, ri..' -6 in Section H-t 9. As of the date of this modification, the estimated cost and estimated fee are as foll ows: The Estimated CO:- The Estimatec ~~C is S••••• T ot ~ i Estimated r: '51 plus Fee is S 1.776,902, I 32. Pursuant to ?AR 16.405-1. the target cost and target fee will be finally determined and adjusted after contract perfonnance. The t'lble below p CUN (lJ\W (!:» UI,) t.b¥..1{) 17AA C':JX9-) ('p)(4,' (1;,1'0 CLIN 0030 T1;<,: total cost of his line item has increased by SI6,000,000.00 from S 124,795.35 8.00 to S 140, 795,35:UC. SUBCi...N 003003 is ::ldded as follows: ITEM NO SUPPLIES/SER .... '::ES Q UANTITY UNIT UN IT PRICE A.W: " 003008 GFEBS Funding 1cr SubCLIN OO l 7AA CPIF FOa. Destination AC R.'J MX $16,OOO.O~, " CIt\. GFEBSOO : ')24S7000000 [ DA:-:;G6 '}3-C -I}'jl)! P00262 ,'age loi2 • AS stated ' •...f:. difiea : . -'002! I, CLll" 0030 has been establishecl fo r the so le purpose of obligatmg GPESS fur,ding for .:.:'(Ntnan';.o 0'" S':bCL I:-" OO ! 7AA The value o!"CLfN 0030 equates to the amount of GFE.S S fur.dlng obiigatco fo: ::~ 'iorm31 ,.: '. $ ut;CL/:-' DO \7 AA an d should no t be considered additional eontTllct. v3Iut:. lnforma1ior;a; SuoCLf:-:s~,dc r CUN 0030 will be established each ti me additional GFEBS funding is ohlig3ted CLN 0030 (V";; IS Sub·-; '';$ "'II! not be ~egregated from SubCLfN OOI7AA, id entified, accounted for, anaIYJ'd. or reponed ~~,:~~ ately ;"J"" :-'ubCUNOGI7, l'1dudlng F, VMS. All sr.:ope remains unu~r SubCLlN OO] 7AA with a:.sociated jr~~"'I\"e c.. ~,;~' Jl\d flat lones 8 -: 7, ,;-';CEt. ·; "'; FE!: [OK SUBCL[N OOt7ANCLIN 0018 (SEE H-19): 1. i;c oord;. :'~'-"it.i FAR 52.216'10, entitled "Incentive Fee", the total amount originally ot:goliated, adjusted in ac cordance ·"It<". ~aragta ph d. of this clause, fur target COSI and target fee fo r performance under Sub<..UN 00 17 ANCLil'- 00 18 are S~! forth below: ,r,~e ntive .'" ~ - 'Igcmcrrt: ·\lfax:iUlum F~e: Minimum Fee: "r,tjcrrun ' f the amount by which the tocal allowable oost is less than the estimated cost until max:i mum fe ~ :S lItminea. OllemJn: the arnoun, by wh ich the total allowable cost exceeds the estimated COlI t ); nli! minimwr. fee is '!.ttai ned. FAR. 52.216·10, r:-.;CENTIVE, paragraph (eX! ), is staled as follows: (e) F'!c Pa.yaole. (b)(4) { \ The ree ;.y~ble under this ~ntnlCl shall be the ""."" dollar that (b)(4) the tolal aHo .... RIlle cost :3 less than the estimated cost or decreased roc " ~'l' iiOiii;;u~"th. total allowable (b)(4) cost exceeds ! ~e ~t imll.~d ··ost. In no event :lhall the fee be greater ;;.,,,, (M;u;,""," r•• ). , less than. .,ercent (Mir.;'num fee) ~fth.:: ~tjm a :ed cost. (b)(4) .I:J- i ~ E srlMAT~D COST. ESTIMATED (NCENTJVE FEE. MllilMUM INCENTIVE FEE. MAXIMUM ;NCEN!r\iC :;EE, AND INCENTIVE ARRANGEMENT FOR SUBCLIN 00 I 7ANCLCN 00 18: S1i3CU NOO I k ,. (Two SPD ILENS Systems) l':>)(~, c. ....I. nimun: ·~r,;~r,tjve fee: Cbi~) fb ) l't CXJ~3'5 DASG60·98·C-OOO 1 P00262 Page 5 0[ 21 e. L~ta l estJr-J -!". ' :;os;: and estimated ftt: $1,776,902,132 3. SECTIOi' G - CQj\:71..\CT ADMlNISTR.. Summary fer ':le Pay r.ll;"".~ .. ) ffice As a " SUBCLIN 00' i AA: MF: 21 I 2040 5L 3i.68 PI724 19E5S5L 25S Y 4MIJ7]OOOO 50 1021 4MI1730000i I4MJLE/4MS was increased by $:26,899 39 from $270.780,923.00 to $270,907,822.39 Estimated Cost, Estimatd Fee, and Estimated ;;'n.'"'~';'i' ,~O:f '~~~:=; .' d; ;;Stributed as follows (b)(4) and includes an increase ~st i mated • and facilities capital (b)( 4) cost of mOrley) and an i ncr~ ase in estimated (b)(4) Esti:nated Cost (b)( 4) Estimated -;: ee Total $ I Z;' , S ~9J 9 MY: 2, 1204051. 5i..58 PI724 19E555 L 251 6 4M IMM[CSTJ S0 1021 4M 1MMICSTJ/14MJMW4M5 was increased by $18,327.00 from $0.00 to $18,327.00 The contract ACRe'.' MY has been added. Estimated Cost, Estima ted Fell, and Estimated total for the above increase of S 18,]27 is distributed as follows and includes an [:l.c rease in e' t mat.'dil'ilOii"lI0iif b S_fcostand '-'ffacilities capital cost of money) and (b)( 4) Ib' an increase ir. es timated f~e of /;') (b)(4) Cost Estimated ~~e (b)(4) Total CLlNOO]O; • SUBCLIN OG30 08: Funding on S(;8CLfN 00:')08 is initiated as follows: DASG60-98-C-OOOI POOl.2 Page6 of 21 ACRl'\; MX CIN: GFEB SOOI 024670000001 Ac.:tng Dw.: 02 120 \::201320400000 t 171712SS0030003242A.OOOOO13.1.1 6100.9000021001 Incrust: S[ 6,000.0;)(l ao Tocal: $16,000,000 .00 Cost Code: A:lXFJ Estimated Cosl. EstimlrttO. Fee, and E!timatcd ~ ,""' ,~ ;,~~ ofSI6.000,OOO is distributed as foUo\Ol1i and includes an il'LCrease ;n ~ 5timatcd cost • • roo... ", ~ ffaci l ities capital C(lSl of money) and an increase in estimmd "'. .' IMPLEMEr-o'TATION OF ANDEXPLANAnON OF THE RELAnONSHIPOf 1HE UMITAll0N OF FUNDS CLOF) CLAli5E TO FEE OBLIGATIONS, s ~h c., is revised to read as follows: SUBCLIN 0011AA : nus CUMULATIV -~ MODIFICATION TOTAL- ( I ) Amou;r, Requirl:d fc Full Funding, lnclud;ng Fee: SI.7l7,867.861 $ 59,034,271 S 1,716,902,132 (2) Amount Allotted. Tj r.der the LOF Clause few Paym.ent of Cous: (3 ) Amount Separatt.:y Obliaated for Payment QfFee: (4) Total A:nount Allc;;:ed and Obligated: 51,715,871,307.27 S16,J4S,226.39 Sl,7J2,016,533.t; (5) Net Amount Req ui7ed ror Full Funding S 1 , ~-:'1:J - S-42;U9;04it'.~611--';'-"' ;M5 i 5 9 8~ uP '4,". i't'(, .sti' . l o1 ~ -(I'" ~ 4 (" ,r; , , .,f. 1: 4 DASG6C-98-C·()OO l POQ::!62 Page 7of:, " These fig · . 'J.ke int: "'sideration the negotiated total value of SubCLIN 00 17 AA (This does not indud-e S .... bCU N [7A;·:) 4. S ECT I C~I ,.¥ - SPEC',. COi\. TRACT REQUlREMENTS is revised as follows : Paragrapn j-'. 9. INCE?\T;'1E FEE STRUCTURE Al'\'O PAYMENT FOR eLIN OO ! 7. SYSTEM DEVELOPY;J,T &'11; )Sy{ONSIRATION (SODl, subparagraph a., b., and c., are revised as fellows: SubCLIN OO! 7 AA, Systel"" Development and Demonstration (SOO), is a cost-plus-incentive-fee (C PIF) Line Item with cost ar. c schedule i;:c~nti ves as described below. Paragraph H· [9(b) applies only to the Cost Incentive and Paragraph H-! 9(c) app lie~ only to the Schedule Incentive. The price amount of51,654,417,965 includes a target cost ofi capital cost of rno:lty: dnd a tar:;e. ·r.centlve is ~ ftarget cost I cost of money. b. C;5t Incent"!': (I ) The target fee payab le un der SubCLIN ~ of the estimated cost less facilities capital cosl of IJut( money ( ,,1 amount equal 10 _ ('oj. 4' , (2) The ma..' (5) Noth ing stated in this dallse shall take precedence over the clause 52.216-10 - Incentive Fee co ntained in this contract. c. S';hedule and Performance Incentive. ~~~~~~~~The'~'fl~'~ t~z~oo~:ot"~Wfil"flat zone";j ' oveb~o~,~r stawhichblish theed atcontractor the target will cost eam value taiget ofS feeI,5IS.BS7,379 is for eligib leWI coststh the from the set forth below ate conducted. (Note: As of the effective~ date of Modifkation maximum lat zone" has been acknow!edg~c as earned. ) P I th e maximum benefit of the "flat zone", earned by the conduct of the SOD System Functional Review "''L T 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Ri'IYithi'loioiOO.~IiPII'ttc d the rcquircmenl for this flat zone and earned the "Flat Zone" schedule incentive of i inal cctennination of incentive fee payment utilizing the "Flat Zone" amount will be made at the DrI.'jGG -"3·(.AI(!" I'lhI2,)~ ~'!!!"l:!oC2' .:.r. ,', SIU!" <: ..:on .• b) ••••__ L ~ • ~ ;n3.ximur.1 oent',it oftfl" "nJ: ZOll.(', ealned by tile conduct of SOD Cr, ;( (n'lnl ',,;cslgn rc.v -':LT 2. .1. ~r ~i:;cill Yt'3r 2009. L,t; is ht'reby acknowledgeo by the !!o'emrr.ent Ihat {aytilco[1 ~;;.Hj:'.e t ed - ~ '~qu i-er ' J' ,Cjos na! ror.e and elf1ed the " 1: lat Z\Jn~" schedule incentive of Final 'eh'f,!],I1'1I" !11<.<:' ~. I~:t)nttnt u::h,/;mg the "Flal tOIl ~" amount will be made at the conclusior. ·f '.he ,. ILL ~.;.t:< I';'" I anu : -:01)9 . .."...... tc) 1)1...... ' . tne maximull ht:llelit or the " nat 1-un""', c3.rn.::d by the .:onductofthe Devc opnlental T cst I (oT-. t, accor~'"' . , wim ,he cnter:a kt forth in Section J attachment emitled Flat Zone Perforwance Critena for fL::-G SO!:: )'ltract, Sectiun H.19(c), dated OSI I0f12. (It is hereby acknowledged by the govemmcnt '~"j'I"I!i"iiiihi"l-t' ~e 'l1p[et~ . e (e (d) ~~t he maximum benefit of the " flat zone", earned by the conduct of the Elecrtonag'letic Er,vironmenl<" EfTeciS. 0:'-estin g in accordance with the criteria set forth in S~ction J ilttachment crltlttcd flat Zone 'Ei f.>c rformancc (- ,; teria f<1. ! ·,'+5 SDD Cuntra<;:t, Seellon H-19(c), dated 0811 0/1 2. ~ e) 1-_ ~"the maximum bem:fit of the "flat zone", ~afned by the tonduct of the 1 11te J"'dt~ Fire Control Eve"- ;, a cco r:l~"" with the criteria SCI forth In Section J attachment entitl.:d Flal Zulli: ~e r r<1n nance Criteria for L 2'>I"S SOD -::' ').~tr'l.C I , Section H·19(c), dated 081 10112. (It is hereby acknowl",dged by the gOHmmcnt :;4 • • ~"~ ~ reliUlrement for this flat lOne and earned a "Fl at Lo ne" sciledule incentive of I ·he available Final detenmnatlon of inceutivc f« payment uti!lung the L\,'L~: 11 ade at the conclusion of the contract.) *NOTE: (b)(3)(A) lbl") (i)&Title 10 Sec 130 (t , __~ oithe maximum benefit of the Unat zone", earned by the conduct of tile Functional Uo\L~ (,)(b) Configuration Audit (FCAj.1 in accordance with thc cntcrla set forth in Settion J attachn:enl mutled Flat tone r:, >:'NS SOD Contract, Section H·19(c), dated 08/ 10/1 2. · Note: (!;)1-~ (b)(3)(A) (i)&Title H 10 Sec 130 (g) the maximcm benefit of the " flat zone , earr,ed by tho: conduct of rJeve'opmcllta! (,)(b) \.I9)U fest 2 COT ·2) in accorcarce with tile criteria ~ t fon:h in Section J anacl\ment entitled Flat Zone Perform~rlce Crncria:or r:.E.~ S SD!; "~;::::Itract , S«:1ion H·I9(cJ. dated OS/ IOfI2. ~ (11) ~ fth<:: maxilllu m bt:ue{ic o rth~ " fl at mne", earned by the conduct of the Eart" User Test l\?)G (previously jefined as l..':'l. ted Uscr Test) in aCCOTdan.:e with the criteria sel forth in Section 1 anachm':J" ~1I1itled Flat Zone P e~:~~ manc e C"l'e ri~ for /LENS SOD Contract, Section H·19lc), daled 0811 0112 . • (i) , ~ ~\he maximum b-enefit o rtne "fiat lone". earned by the conduct of the Fina: 1" H1ction:;. o,H' CunfiguTaliv'l Audit (Fe;, lin accordance with the criteria set forth in Seclion J attachment entitled flat (-une Po;: rforman(;e - :te ri a fo :.£~S SDD Contract, Section H-19(c). dated 08110/12, • (3) for £a nt.~\l Value ~ " Gost reportin g purposes, Ihe estimated cost val ul:' of .,•••••• Wlll be used. DASG 61_~ ·98-C-OOO I P00262 °age 9 of21 d. Cnanges issued under FAR 52.243-2, Changes - Cost Reimbursement In the event :l"" a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the perfonnance and schedule incenti ve may be considered a pan of the equitable adjustment. In the event that any Options to CLiN 00 17 are added and exerclsed, the incentive fee for cost and schedulelperformance applicable to the Option wilt oe incofro:ated in accordance with the incentive f« structure of this provision. 5. The ronowmg is all update to Modification PQ0259 showing a summary of fu nding by ACRN through Modification P00260: FUNPIt-G AA 440,WO.00 AB 2,298,235.00 AC J 7,832,987.00 AD 0.00 A£ 7.500,000.00 AF 3,300,000.00 AG 17,1 92,400.00 AH 700,000.00 "1 200,000.00 AI( 85,000.00 AL 45,000.00 AYI 17,045,000.00 AN 5,800.00 AF 20,779,000.00 AQ 105,000.00 AI( 35,000.00 AS 0.00 AT 6,984,678.52 OO~(pyo DASG60-98··C-OOO 1 P002b2 Page 10 of21 7,970,000.00 <\, 0.00 ,~ 100,000.00 \X 3,396,000.00 550,000.00 19,412,000.00 24,527,878.00 146,000.00 SC 72.000.00 K) 85 ;000.00 8"2 ]00,000.00 B17 100,000.00 R(' .< J 1,975,321.00 38,018,908.00 81 7,896,673.34 BK 260,000.00 .; J. , ~~ 0.00 BM 125,OOOO[) 8"\ 103,000.00 Dnu, 1O,199,28UO Be 350,000.00 [3 9,000.00 84,896,852.00 X 1,146,000.00 3,880,000.00 190,000.00 K.L 118,25000 OOd.{, L( I DASG60-98-C-000 1 P00262 P'tgel1of2! 192.793.00000 0.00 92,811.00 0.00 0.00 386,377,998.00 2,203.183.00 KV 65,000.00 IN 20,000.00 f' v ,',. , 60,000.00 KY 25,000.00 KL 25,000.00 13,508.00 LB t2,500.00 LC 200,000.00 ID 7,943,648.00 i,173,850.00 10,000.00 62,000.00 J()O,OOO.OO 7,476.00 LK 'S28 l,575,897.()O $173,798.00 $i,410,376.00 5630,06 t .00 p $33,200.00 $235.566.00 DASG60-98-C-OOO I P00262 Page 12 r>f21 $125,000.00 $6,069,616.00 , L $530,377.00 S9,i 00,000.00 $1,957,265.00 $255,567.00 :568,000.00 $264,807,424.52 LZ $1,751,384.00 $2,982,442.00 $375,000.00 $2,283,481.00 'vID $8,573.00 !\11:. $0.00 5270,907,822.39 $6,262,095.00 'ill-j $213,390.00 $858,495.00 $56,076.00 ML $ t 16,044.00 MM $1,61S,600.00 $2,573,000.00 'vIP $250,000.00 $691,42[,00 $0.00 'viS $700,000.00 $[6,289,524.00 DASG60-9S-C·OOO I POO262 Page 13 of21 M'J 57,864,499.00 "" S39,92I, I99.75 MW S 10 ,000,000.00 MX 5140,795,358.00 MY SI8,J27.00 6. The foll owing is an update to Modification P00259 showing a summary of funding by CLfN by ACRi'1 through Modification P00260; f1&'D(NG AMI CLIN TOTAL CLIN 0001 440,100.00 CLIN 0001 0.00 440,100.00 CLIN 0003 -'" 2,298,235.00 e LlN 0003 ,'\C 17,832,987.00 CLlN 0003 , ) 0.00 CLIN 0003 ,- 7,500,000.00 CLIN 0003 AI 3,300,000.00 CU N 0003 >\'-T 17,192,400.00 CLIN 0003 ,.; 700,000.00 CLIN 0003 A~.1 17,045,000.00 CU N 0003 A 5,800.00 CLIN 0003 AP 20,179,000.00 CU NOOO ) \. 0.00 CLlN 0003 AT 6,984,678.52 DASG60-98-C-OOOI P00262 Page 14 of21 CUN OOO : .v 100,000.00 CLiNOOO J 550,000.00 94,233,100.52 CLfN 0005 '" 24,521,878.00 CUN 0005 d.J 146,000.00 CLIN 0005 B:: 72,000.00 CLIN0005 3D 85,000.00 CLlNOO05 .... ::: 100,000.00 CLINOOO:: 3, 100,000.00 CLIN 0005 B.:J 1,915,321.00 CUNOOO5 B:t 38,0 18,908.00 C ... fNOQOS: , 0.00 CLIN 0005 Bl 0.00 65,025,101.00 CLIN 0001AA S" 10,199,288.50 10,199,288.50 CLiN OOOS AA CLJ:l'\ 0OO9A A \V 0.00 eLIN 0009AA B< 256,545.00 eLIN 0009AA B;"! 125,000.00 (LIN 0009AA Bi' 21.315.00 441,966.00 • DASG6 CLIK 0009",8 200,000.00 elI!\" 0009AB , 85,000.00 CLIN OOO~AB ,. 45,000.00 eLIN 0OO9A.B , ) 59,894.00 CUN 0009AB '-' 35,000.00 CUN 0009AB i3;\ 3,455.00 eLIN 0009.'1.8 "' 81,685 .00 CLIN 0OO9AB ,. 350,000.00 eLIN 0OO9AB ::; 9,000.00 869,034.00 CLIN 0013 AC 7,970,000.00 CUNCOll AX 3,396,000.00 eLIN DOl] AY 0.00 CUN 0013 ., 19,412,000.00 . CLINOOIJ o ., 7,896,673.34 38,674,673 .3 4 (LIN 0017 0.00 eLIN OO[~ 0.00 0.00 (LIN OOl7AA " ],880,000.00 CUNOO17AA ".,'. 1,146,000.00 C1INOO17AA ?., 34,896,852.00 , CUNOO 11AA J? 0.00 Cb~~y~ • DASG6U·98·CJ)(IOI POO262 Pa6C 16of:l C;"f.\I 001 AA , \92,793,000.00 G.'[N 001 ,V\ 0.00 Ci...lN 001 ~."'- .... , 66,151.00 CLlNOO17AA 0.00 CLIN OO(1A"" 386,204,200.00 CLIN OOI~.~.'\ 2,20),183.00 CLiNOOI":.I>..A 0.00 CLINOO l 7AA 200,000.00 CLiNOO l 7AA 7,943,648.00 C".... fN 00 17 AA 0.00 CLINOOI1AA 400,000.00 CLINOO,-,-\.A 7,476.00 CLIN 00: 7 •.l.A 281.575,897.00 Ct.!NOQI7.'v, 235,566.00 eLrN OO!7AA l 6,069,616.00 C!...IN 0011AA T 530,377.00 CUN oo\7AA L $9,100,000.00 CLIN 0017AA $1,957,265.00 CUNOOl7AA I \V $255,567.00 CLIN 0017AA , $68,000.00 CLfNOOl7AA L S264,807,424.S2 CL I}JOO17AA ' , S375,OOO.00 CLfNOOl7AA $2,283,481.00 eLf.'! 00 I '": A:\ .) $8,573.00 (LIN 0017AA $0.00 CLiN 00 17AA .' F $270.907,822.39 DASG6(\·99-C·(lCC, pe~)":IJ~ P~~O!:l7cf:! :L r-". (>1: I - , , 5213,390.00 , CLI"'\ 001 -' $858,495.00 . CU'" 00 -, , $56,076.00 :U'>. ;') \ ' - $116,044.00 )\" ;0' -, , , $1,6 18,600.00 ':1.1'-1 nOli \ \ ',' " $2,573,000.00 CU'-i OW - \.\ ',Ip 5250,000.00 CI P\ on " 'J $691 ,421.00 'L'~IJOI -, 50,00 " eLi).. 00 1 • \ \. ,-, S700.000.00 ,.. I' 00 1 \.\ \' SI6.289,524.00 1.1"'\ OO'7A ~ "\ 539,921.199.75 , u)..oo~,...... \ ~ 510,000,000.00 1"\.001- , -, S~795,J58,OO f" " '" Ill'; OUI \ ,'\. .\I \- $I8,m.oo ------ 1 .7 ll';0 1 ~533.66 0<,<' I! 8,25000 118,250,00 190,000.00 190,000,00 DASG60-98-C-OOO ; POO262 Page 18 of21 c" ... fN OOI?AD 0.00 CLIN 00171\0 0.00 0.00 CLIN 0017AE 173,798.00 173,798.00 (LIN 00 I-t....O:; 173,798.00 173,798.00 (LIN oo20."A 0.00 CLIN0020AA 26,660.00 26,660.00 (UN 002iP."'" \ 0.00 0.00 CLIN 002 lAS 0.00 CUN0021AB Lo 0.00 CLIN002:Aii 0.00 CUN0021AB 0.00 0.00 CLN 002:AC 0.00 CUN 002 1A( \ 0.00 0.00 DASG60-98·C·OOOj PQ(}262 Page 19 ofl, CLrN 002:" 0.00 0.00 c.... fl\ 00:· .' , 60,000.00 CLIN 002J .( 25,000.00 CLiN 002j :<. / 65,000.00 CliN 0023 .8 12,500.00 CL,N 002: , 10,000.00 l:UN (}I)2. , S 125,000.00 297,500.00 CLfN 0024- 13,508.00 CLf'I' 0024 62,000.00 CLIN 002 4 i<..l 25,000.00 CLIN 0024 '<' .\; 20,000.00 CLIN 0024 , 83,200.00 203,708.00 CUN0025 1, 173,850.00 CLiN 0025 1,080,404.00 CLIN 0025 0.00 2,254,254.00 CLf)I 0026 , 630,061.00 630,06 1.00 OO,U5D DASG60-98-C-OOOI POO262 Page 20 of2! CLN OC:" 1,751,384.00 1,751 ,3 84.00 cu~ Q02~ 329,972.00 CLIN 002f 2,982,442.00 6,262,095.00 $7,864,499 17,439,008.00 CUN OOlC') i ' <'IX $52,974,283.00 CLTNOO300: ·x $719.132.00 CLfN oomn:; . ... ; S5,747.OO CUNOOO;, 'X $16,000,000.00 CUN 00031)5" 'AX $16,000,000.00 CLIN 0030G6' .\It. "'( $38,000,000.00 CLIN 003(1f\7· ~X S I ,096, 196.00 CLiN 603008· vp. SI6,OOO,000.00 140,795.)58.00 • CLIN 0030 nas been established for the sole purpose of obligating GFEBS funding for performance ofSubCUI'o 00 17 AA. Informational SuoCLINs IUlder CLIN 0030 will be established each time additioanl GFE BS funding is obligated. Fer proposes oftltis funding update, funding obligated under eLIN" 0030 ~ill also be reflected Wldcr SubCLlN 00 17 AA and silould not be counted twice with regards to the total contract funding obligated. DASG6<. -')8-C-C1O POr,2S: ,-----.-~-··-·------·------·------TC__::_:_:_==______~--,------'. CO"TRACT lD CODE AMENDMENT OF SOLICITATION/1\'10DIFICATION OF CONTRACT 4 12. AME'IDME:-JTt'VIODIFICA nON "10 . EFFEC11VE DA TE 4. REOUIsmO"tPURCHASE REO NO RJ0263 0010303589 I, ISSliED BY 7 ADMINISTI;:RED BY (Ifotherrhan ;temo) '------1 DCMA RAYTHEON USASMDCIARSTRAT 50 APPlE HILL DRIVE SMDC·RDC MIS T2FR2 PO BOX 1500 TEWKSBURY MA 01876 HUNTSVIlLE AL 35807-3801 8. NAME AND ADDRESS OF CONTRACTOR (No., Street, County, State and Zip ('--ode) A. AMENDMEt-.T RAYTHEON COMPANY 350 LOWELL ST ANDOVER MA 0181 (}.4400 lOA. MOD. OFCONTRACT/ORDER NO. ~SG60-98-C0001 111t: ahov~ nunb~red solicitation is arrended as set fOrth in Item 14. 1lle hour and date specified lOr-receipt ofOti':r 0 is cxtend~d, 0 is not extended. Otkr 1T1lSt acknowledge n.. "Ccipt ofthis arrenulTl:nt pnor to the huur and date specifh.:u in the solicitation or as arremled by one ofthe Dilowing In::thods: (a) By cOIll'leting Items 8 and 15, and returning copies ofthe arrendrrent; (b) By acknowledging receipt ofthis arrendrrent on each copy ofthe offer 5ubrritted; or(c) Ry separate letteror te1egramwhich includ~nce to the ,"olicitation and arrendrrrnt nurrbers. FAlT,lJRE OF YOUR ACKNOWL EOGME~TTO BE RECErVED ATTIlE PLACE DFSIGNATED FOR TIlE RECElPTOF OFFERS PRIOR TO THE HOURAND DA TE SPECIFIED MAY RESULTlN REJECllON OF YOL:R OFFER Ifby virtue ofthis am:ndrrent you desire to change an ofi:r already submitted, such change may bc ITBdc by telegmmor letter, provIded each telegrnmor letter rmkes rei;cence to the solicitation and this arrendrrent, and 15 received pnor to the opening hour and date specified 12. ACCOUNT ING AND Alry PROP RIA TION DAT A (If required) See Schedule 13. THIS [TEM APPLIES ONLY TO MODIFlCATlONSOF CONTRAerSiORDERS. IT MODIFIES T HE CONT RACf 10RDER NO. AS DESCRIBED IN IT EM 14. A. THISCHAl'lGE ORDER [S lSSlJED PURSUANT TO: (SpecifY authority) THE CHANGES SET FORTH [N ITEM 14 ARE MADE [N THE CONTRAer ORDER NO. IN ITEM lOA. CONT RACT 10RDER IS MODIFIED TO REFLEer THE ADMIN1SfRATIVE ,",nLn.l·'U<'~ (such as changes in paying .) SET FORTH [N ITEM 14, PURSUANT TO THE AUTHORITY OF FAR THlS SUPPLEMENT AL AGREEi'VIENT [S ENTERED INTO PURSUANT TO AUTHORITY OF: (SpecifY type of modification and authority) FAR 52.232-22 Increrrental Funding E. IMPORT ANT: Contractor [R] is not, 0 is required to sign this dlcwnent and retWll copies to the issuing office. 14. DESCRIPTIOI'\" OF AMENDMENT IiVIODlFlCATION (Organized by UCF section headings, including solicitation/contract subject matter where feasible.) (b)(6) Modification Control Number: 1...... • The purpose of this rmdification is to increrrentally fund a..IN 0017AA via a..IN 0030 ACRN MZ in the armunt of $21,000,000.00. ACRN KM for SLlN 0017AA in section G is incorrect and should be disregarded. Funded arrount total as a result of thiS rrodification in section G is incorrect and should be disregarded. herein, all tCITIli and conditions ofthe docurrent rererenct!d in ltem9A or lOA, as hereto lOre changed, remnns unchanged and In full /Orce and etrct. ~ 158. CONTRACTOR/OFFEROR 15C. DATE SIGNED 16C. DAT(bj~ 14-Feb-2013 (1oX0 30-105-04 Sf ANDARD FORIvl30 (Rev. 10-83) APPROVED BY OJRM 11-84 Prescribed by GSA ooau53 FAR (48 CFR) 53.243 UAe>vOV-'1/l-'-.--VVV I P00263 Page 2 of4 SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES SECTION A - SOLICITATION/CONTRACT FORM The following have been added by full text: PURPOSE CLIN0030 * As stated in Modification P00251, CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for perfonnance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Infonnational SubCLINs under CLIN 0030 will be established each time additioanl GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. AIl scope remains under SubCLIN 00 i 7AA with associated incentive events and fiat zones. The following have been deleted: PURPOSE PURPOSE PURPOSE PURPOSE SECTION B - SUPPLIES OR SERVICES AND PRICES SUBCLIN 003009 is added as follows: U.t\.':)VOV-~/)-L-VVV 1 P00263 Page 3 of 4 ITEM NO SUPPLIES/SERVICES QUANTITY UNIT UNIT PRICE AMOt.JNT 003009 $0.00 GFEBS Funding for SubCLIN 0017 AA CPIF FOB: Destination PURCHASE REQUEST NUMBER: 0010303589 TARGET COST $0.00 TARGET FEE $0.00 $0.00 TOTAL TGT COST + FEE MINIMUM FEE $0.00 MAXIMUM FEE $0.00 SHARE RATIO ABOVE TARGET SHARE RATIO BELOW TARGET ACRNMZ $21,000,000.00 CIN: GFEBSOO 103035890000 I SECTION E - INSPECTION AND ACCEPTANCE The following Acceptance/Inspection Schedule was added for SUBCLIN 003009: INSPECT AT INSPECT BY ACCEPT AT ACCEPT BY N/A N/A N/A Government SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result of this modification, the total funded amount for this document was increased by $21,000,000.00 from $1,922,617,489.68 to $1,943,617,489.68. SUBCLIN 0017AA: KM: 21 72040 5L 5L68 Pl7419E555L 255Y 4M7J730000 SOlO21 4M7J730000174MJLE/4M was increased by $192,793,000.00 from $0.00 to $192,793,000.00 The contract ACRN KP was changed to KM. The Cost Code' has been added. SUBCLIN 003009: Funding on SUBCLIN 003009 is initiated as follows: ACRN:MZ CIN: GFEBSOO 103035890000 1 OO<1lP 55 UA~vOV-':II:5-L-VVV 1 P00263 Page 4 of4 Acctng Data: 02120 132014204000001 17 1722550030003242A.0009263. 1. 1 6100.9000021001 Increase: $21,000,000.00 Total: $21,000,000.00 Cost Code: A5XFJ (End of Summary of Changes) MOD00263 SECTIOl\i SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES 1. SECTION B - SUPPLIES OR SERVICES AND PRICES CUN0030 The total cost of this line item has increased by $2 1,000,000.00 from $138,795,358.00 to $159,795,358.00. * * As stated in Modification P00251, CLL'J" 0030 has been established for the sale purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. The value of CLIN 0030 equates to the amount of GFEBS funding obligated for performance of SubCLIN 0017 AA and should not be considered additional contract value. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. CLIN 0030 and its SubCLINS will not be segregated from SubCLIN 0017 AA, identified, accounted for, invoiced, analyzed, or reported separately from SubCLIN 0017, including EVMS. All scope remains under SubCLIN 0017 AA with associated incentive events and flat zones. SUBCLIN 003009 is added as follows: ITEM NO SUPPLIES(SERVICES QUANTITY UNIT UNIT PRICE AMOUNT 003009 GFEBS Funding for SubCLIN 0017 AA CPIF FOB: Destination PURCHASE REQUEST NUMBER: 0010303589 ACRNMZ $21,000,000.00 CIN: GFEBSOOI03035890000 1 2. SECTION G - CONTRACT ADMINISTRATION DATA Accounting and Appropriation Summary for the Payment Office As a result ofthi::; modification, the total funded amount for this document was increased by $21,000,000.00 from $1,963,219,224.00 to $1,984,219,224.00. SUBCLIN 003009: Funding on SUBCLIN 003009 is initiated as follows: ACRN:MZ CrN: GFEBSOO 103035890000 I Acctng Data: 0212013201420400000 I 171722550030003242A.0009263.1.1 6100.9000021001 OO~lo51 Increase: $21,000,000.00 Total: $21,000,000.00 Cost Code: A5XFJ Target Cost, Target Fee, and total for the above increase of $21 ,000,000 is distributed as follows and includes an increase in target cost of cost and 'facilities capital cost of money) and an increase in target fee Target Cost ~ Target Fee -==t-. Total [MPLEMENT ATION OF AND EXPLANATION OF THE RELATIONSHIP OF THE LIMITATION OF FUNDS (LOF) CLAUSE TO FEE OBLIGATIONS, subparagraph c., is revised to read as follows: SUBCLIN 0017AA: THIS CUMULATIVE PRIOR MODIFICATION TOTAL * (1) Amount Required for Full Funding, Including Fee: $1,776,902,132 $ 0 $ 1,776,902,132 ,,-,, ~£) All10unt Allotted Under the LOF Clause for Payment of Costs: (Pt4 (3) Amount Separately Obligated for • Payment of Fee: $ (b~~) (4) Total Amount Allotted and Obligated: $1,732,016,533.66 421,000,000 $1,753,016,533.66 (5) Net Amount Required for Full Funding $ 46,885,598.34 ($21,000,000) $ 25,885,598.34 * These figures take into consideration the negotiated total value of SubCLrN 0017 AA (This does not include SubCLIN 17 AH) 3. The following is an update to Modification P00255 showing a summary of funding by ACRN through Modification P00263: ACRN FUNDING AA 440,100.00 AB 2,298,235.00 AC 17,832,987.00 AD 0.00 AE 7,500,000.00 AF 3,300,000.00 AG 17,192,400.00 AH 700,000.00 AJ 200,000.00 AK 85,000.00 AL 45,000.00 ANI 17,045,000.00 AN 5,800.00 AP 20,779,000.00 AQ 105,000.00 AR 35,000.00 AS 0.00 AT 6,984,678.52 AU 7,970,000.00 AV 0.00 AW 100,000.00 AX 3,396,000.00 AY 550,000.00 AZ 19,412,000.00 BA 24,527,878.00 BB 146,000.00 Be 72,000.00 BD 85,000.00 BE 100,000.00 BF 100,000.00 BG 1,975,321.00 BH 38,018,908.00 BJ 7,896,673.34 BK 260,000.00 BL 0.00 BM 125,000.00 BN 103,000.00 BP 10,199,288.50 BU 350,000.00 BV 9,000.00 BW 84,896,852.00 BX 1,146,000.00 BY 3,880,000.00 BZ 190,000.00 KL 118,250.00 KM 192,793,000.00 KN 0.00 KQ 92,811.00 KR 0.00 KS 0.00 KT 386,377,998.00 KU 2,203,183.00 KV 65,000.00 KW 20,000.00 KX 60,000.00 KY 25,000.00 KZ 25,000.00 LA 13,508.00 LB 12,500.00 LC 200,000.00 LD 7,943,648.00 LE 1,173,850.00 LF 10,000.00 CO&~59 LG 62,000.00 LH 400,000.00 LJ 7,476.00 LK $281,575,897.00 LL $173,798.00 LM $1,410,376.00 LN $630,061.00 LP $83,200.00 LQ $235,566.00 LR $125,000.00 LS $6,069,616.00 LT $530,377.00 LU $9,100,000.00 LV $1,957,265.00 LW $255,567.00 LX $68,000.00 LY $264,807,424.52 LZ $1,751,384.00 MA $2,982,442.00 ME $375,000.00 MC $2,283,481.00 MD $8,573.00 ME $0.00 MF $270,514,880.00 MG $6,262,095.00 MH $213,390.00 MJ $858,495.00 MK $56,076.00 ML $116,044.00 MM $1,618,600.00 MN $2,573,000.00 MP $250,000.00 MQ $691,421.00 MR $0.00 MS $700,000.00 MT $16,289,524.00 MU $7,864,499.00 MV $39,921,199.75 MW $10,000,000.00 MX $159,795,358.00 4. The following is an update to Moditlcation P00255 showing a summary of funding by CLIN by ACRN through Modification P00256: FUNDING AMT CLIN TOTAL CLIN 0001 AA 440,100.00 CUN 0001 AD 0.00 440,100.00 CLIN 0003 AB 2,298,235.00 CLlN 0003 AC 17,832,987.00 CLlN 0003 AD 0.00 CLINOO03 AE 7,500,000.00 CLIN 0003 AF 3,300,000.00 CLIN 0003 AG 17,192,400.00 CLIN 0003 AH 700,000.00 CLlN 0003 AlV1 17,045,000.00 CLIN 0003 AN 5,800.00 CLIN 0003 AP 20,779,000.00 CLIN 0003 AS 0.00 CLIN 0003 AT 6,984,678.52 CLIN 0003 AW 100,000.00 CLIN 0003 AY 550,000.00 94,288,100.52 CLIN 0005 BA 24,527,878.00 CLIN 0005 BB 146,000.00 CLIN 0005 BC 72,000.00 CLIN 0005 BD 85,000.00 eLIN 0005 BE 100,000.00 CLlN 0005 BF 100,000.00 CLIN 0005 BG 1,975,321.00 CLIN 0005 BH 38,018,908.00 CLIN 0005 BL 0.00 CLINOO05 BZ 0.00 65,025,107.00 CLINOO07AA BP 10,199,288.50 10,199,288.50 CLINOO09AA AQ 45,106.00 CLINOO09AA AV 0.00 CLINOO09AA BK 256,545.00 CLINOO09AA BM 125,000.00 CLlNOO09AA BN 21,315.00 447,966.00 CLINOO09AB AJ 200,000.00 CLINOO09AB AK 85,000.00 CLINOO09AB AL 45,000.00 CLINOO09AB AQ 59,894.00 CLINOO09AB AR 35,000.00 CLIN 0009AB BK 3,455.00 CLIN 0009AB BN 81,685.00 CLINOO09AB BU 350,000.00 CLIN 0009AB BY 9,000.00 C()clb~l 869,034.00 CLIN 0013 AU 7,970,000.00 CLIN 0013 AX 3,396,000.00 CLINOO13 AY 0.00 CLI~0013 AZ 19,412,000.00 CLNOO13 BJ 7,896,673.34 38,674,673.34 CLIN 0017 BW 0.00 CLIN 0017 KM 0.00 0.00 CLIN 0017AA BY 3,880,000.00 CLIN 0017AA BX 1,146,000.00 CLIN 0017AA BW 84,896,852.00 CLINOO17AA BZ 0.00 CLINOO17AA KM 192,793,000.00 CLIN 0017AA KN 0.00 CLIN 0017AA KQ 66,151.00 CLIN 0017AA KS 0.00 CLIN 0017AA KT· 386,204,200.00 CLIN 0017AA KU 2,203,183.00 CLIN 0017AA KY 0.00 CLIN OOl7AA LC 200,000.00 CLIN 0017AA LD 7,943,648.00 CLIN 0017AA LE 0.00 CLIN 0017AA LH 400,000.00 CLINOOl7AA LJ 7,476.00 CLIN OOl7AA LK 281,575,897.00 CLIN 0017AA LQ 235,566.00 CLIN 0017AA LS 6,069,616.09 CLINOO17AA LT 530,377.00 CLIN 0017AA LV $9,100,000.00 CLIN 0017AA LV $1,957,265.00 CLIN 00I7AA LW $255,567.00 CLINOOl7AA LX $68,000.00 CLINOO17AA LY $264,807,424.52 CLIN 0017AA MB $375,000.00 CLIN 0017AA Me $2,283,481.00 CLIN 0017AA MD $8,573.00 CLINOO17AA ME $0.00 CLINOO17AA MF $270,514,880.00 CLINOO17AA MH $213,390.00 CLINOO17AA MJ $858,495.00 CLINOO17AA MK $56,076.00 CLIN 0017AA ML $116,044.00 CLIN 0017AA MM $1,618,600.00 CLIN 0017AA MN $2,573,000.00 CLIN 0017AA MP $250,000.00 CLIN 0017AA MQ $691,421.00 CLIN 0017AA MR $0.00 CLIN 0017AA MS $700,000.00 CLIN 0017AA MT $16,289,524.00 CLIN 0017AA MV $39,921,199.75 CLINOOl7AA MW $[0,000,000.00 CLIN 0017AA MX $140,795,358.00 CLIN 0017AA MY $18,327.00 CLIN 0017AA MZ $21,000,000.00 1,751,016,533.66 CLIN 0017AB KL 118,250.00 118,250.00 CLIN0017AC BZ 190,000.00 190,000.00 CLIN 0017AD KN 0.00 CLIN 0017AD KS 0.00 0.00 CLINOOI7AE LL 173,798.00 173,798.00 CLIN 0017AH KT 173,798.00 173,798.00 CLIN0020AA KN 0.00 CLIN 0020AA KQ 26,660.00 26,660.00 CLIN 0021AA KW 0.00 0.00 CLIN 002lAB KV 0.00 CLIN0021AB LB 0.00 CLIN0021AB KX 0.00 CLIN 002lAB KY 0.00 0.00 (x)~~(o3 CLIN0021AC KZ 0.00 CLIN0021AC LA 0.00 0.00 CLIN 0022 KW 0.00 0.00 CLIN0023 KX 60,000.00 CLIN0023 KY 25,000.00 CLIN0023 KV 65,000.00 CLIN0023 LB 12,500.00 CLIN0023 LF 10,000.00 CLIN 0023 LR $125,000.00 297,500.00 CLIN0024 LA 13,508.00 CLIN0024 LG 62,000.00 CLIN 0024 KZ 25,000.00 CLIN0024 KW 20,000.00 rn CLI1'~ 0024 Lr 83.200.00 203,708,00 CLIN0025 LE 1,173,850.00 CLIN 0025 LM 1,080,404.00 CLIN0025 MA 0.00 2,254,254.00 CLIN0026 LN 630,061.00 630,06l.00 CLIN0027 LZ 1,751,384.00 1,751,384.00 CLIN 0028 LM 329,972.00 CLIN0028 MA 2,982,442.00 CLIN 0028 MG 6,262,095.00 CLIN0028 MU $7,864,499 17,439,008.00 CLIN 003001 * MX $52,974,283.00 CLIN003002* MX $719,132,00 CLIN 000303* MX $5,747.00 CLIN 000304* MX $16,000,000,00 CLIN 000305* MX $16,000,000.00 CLIN 003006* MX $38,000,000.00 CLIN 003007* MX $1,096,196.00 CLIN 003008* MX $14,000,000.00 eLIN 003009* MX $21,000,000.00 159,795,358.00 * CLIN 0030 has been established for the sole purpose of obligating GFEBS funding for performance of SubCLIN 0017 AA. Informational SubCLINs under CLIN 0030 will be established each time additional GFEBS funding is obligated. For purposes of this funding update, funding obligated under CLIN 0030 will also be reflected under SubCLIN 0017 AA and should not be counted twice with regards to the total contract funding obligated. (End of Summary of Changes) Page Intentionally Left Blank Not a Contract Document oa,;Z660 AMENDMENT OF SOLICITATIONIMODIFICATION OF CONTRACT PAGES 10 NO. llul""ruK'LH'''~REQ. NO. 6. ISSUED BY CODE L!.!::'..:..:=:....----1 .ADMINISTERED BY (Ifolherll.... il 8. NAME AND ADDRESS OF CONTRACTOR (No., SlTeet, County, Stale and Zip Code) 9A.AM NO. RAYTHEON CQNPANY 350 LOYtSl. ST. ANDOI/ER "'AOl8'0' ...00 98. DATED (SEE IT EM I!) O"IIIISlI.knawlcdsc rccclpi oflhi. IIII:I1d"""l priOriO Ih. hour and d.,especllcd in Ih. SOUcillllion or u am:nded by one oflb, ..Uowlall_hod.: (I) By 00""letln8 II ... 8 Ind 15 •• ad Rlumlol __copies oflhCln1Olldmcnl; (hJ By IckoowlqinllltCclpl oflhis .....dlllt.' Dn .Icb copy orlhe a .....builled; .r(c) By ••panlc loUer Drldearamwhich iDclud .....hace 10 Ih •• olicilllloD and amomdlR!1l1 nuldtm. FAILURE OF YOUR ACKNOWLEDGMENTlO BE RECEIVED ATlH E PLACE DESIGNA -reO FOR me RECEIPT OF OfFERS PIUOR TO mE HOUIlAND DATE SPECIFIED MAY RESUL TIN REJl!CnON Of YOUR OFFER. Ilby vlrtuc .flhi. 'lImd"""'l you desi", I. chanse Ill •• liready subuiUed.such Cblllie!MY be ...de by 'olOllramor leller, provided .Ich 1tlellTIDIo, leller nakes "'e .... celo Ihuolicililion ond Ihls ...... dnznl.llld '" ....elved prior 10 Iheopenlog b•• rlllddllespccifed. 12. ACCOUNTING AND APPROPRIATION DATA (If required) 13. THIS CHANGE ORDER IS ISSUED PURSUANT TO: (Specify authority) THE CHANGES SET FORTH IN ITEM 14 ARE MADE IN THE CONTRACT ORDER NO. IN ITEM lOA. CHANGES (such as chanse! in paying . OTHER (Specify type ofmodilication and authority) E. IMPORT ANT: CQRlrac:lor 0 is DOt, ~ is required to silP1lhis document and return copies to the isslling office. 14. DESCRIPTION OF AMENDMENT !MODIFICATION (Organized by UCF seCI ion headings. including solicitation/contract subject matter where feasible.) Modification Control NlIII\ber: ...... See ConUnuatlon Page Iii_~~~~ __iiiiii~i :"""'-6C-.-OA-T-E SJ-GN-ED---1 (10 yo) • t MAR ZUll b1o) sr ANDARD FORM 30 (Rev. 10·S3) Prescribed by GSA FAR(48 eFR) 53.243 DASG60-9 8-C-OOO 1 P00264 Page 2 of 10 SECTIO!,; SF 30 BLOCK 14 CONTI:-.lUATION PAGE The following items are applicable to this modification: SECTION SF 30 BLOCK 14 CONTINUATION PAGE SUMMARY OF CHANGES SECTION A - SOLICIT A TION/CONTRACT FORM The following have been added by full text: PURPOSE The purpose of this modification is: 1. Settlement of P00260 Change Order Modification per the USD, AT&L Nunn McCurdy directed restructure of JLENS contract DASG60-98-C-OOOI submitted in letter JLENS-2012-031. The target cost, target fee, and total contract value will not be adjusted from Change Order modification P00260 and subsequent modifications that make corrections or add incremental funding through modification P00263. 2. It is understood that P00260 Change Order amount of $59,034,271 shall not change from $59,034,271.00. 3. Attach GFE list dated 01124/2013 in section J of the contract. 4. Attach Contractor Furnished Property (CFP) list dated 01124/2013 which includes Cooperative Engagement Capability (CEC) Hardware, and Revised additional test spares in section J ofthe contract. Note: Engineering units are acceptable for delivery so long as all components are form, fit and function equivalent. 5. Attach revised DD250 Plan dated 02-11-2013 in section J of the contract. 6. Attach revised Functional Configuration Audit (FCA) Plan dated 02/14/2013 in section J of the contract. 7. Attach revised Master Test Plan dated 02/0412013 to section J of the contract. DASG60-98-C-OOO I P00264 Pagc30flO (b)(3)(A) 8. The requirement to nder this (i)&Title 10 Sec change order is 130 (a) (b) (ROR) is (b)(3)(A)(i)&Title 10 will remain at Sec 130 (a)(b) (nX 4: values are included in the $59,034,271.00 change order P00260, llD)L'\- but are to be documented in the modification for baselining purposes). 10. Aerostat Accident Recoup Direction The Aerostat Accident shall be considered settled within this restructure settlement with no further intent by the Government to take further action in this matter. In consideration for this accident Raytheon shall provide (2) JLENS compliant Tethers in the amount of $2,316,819.00, as well as the Governments cost avoidance and other consideration. Agreement by Raytheon to this settlement relinquishes all claims for equitable adjustment by Raytheon, and the Government denies the increase to the Contract Budget Baseline (CBB) as requested by Raytheon. In consideration of the foregoing, the Government hereby releases Raytheon from any and all liability under the contract for further claims or liability attributable to the Aerostat Accident. 11. Upon execution of this contract modification, Raytheon will commence re baselining the work to go including the FY'13 restructure as part of the SDD (CLIN 0017 AA). Raytheon will incorporate the changes for the restructured baseline in accordance with its documented process guidelines and procedures. 12. Flat Spot Opportunity Incentive Criteria c. Schedule and Performance Incentive. (1) A maximum •••••"flat zone" will be established at the target cost value of ••••••with the conduct of milestones below. The "flat zone" over which the contractor will earn target fee is for eligible costs from 0 •••••• (b)( 4) once the program milestones set forth below are conducted. (Note: As of the effective date of Modification P00260, the maximum 'flat zone" has (b)( 4) liv'£' been acknowledged as earned.) (a) 7_0 of the maximum benefit of the "flat zone", earned by the conduct of the SDD System Functional Review NL T 2nd Quarter, Fiscal Year 2007. (It is hereby acknowledged by the government that Raytheon completed the requirement for this DASG60-98-C-OOO I P00264 Page 4 of 10 flat zone and earned the "Flat Zone" schedule incentive of'•••••• Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 5 March 2001 ,,__ -(b)\LP) l\D )L~) (b) of the maximum benefit of the "flat zone", earned by the conduct of SnD Orbit Critical Design review NLT 2nd Quarter, Fiscal Year 2009. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned the "Flat Zone" schedule incentive of ••• Final (b)(4)U~ determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract. Reference letter, dated 12 January 2009,•••••••• l\r, 1~) Ll-:> )Clij (c) Yo of the maximum benefit of the "flat zone", earned by the conduct of the Developmental Test 1 (DT-l) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H- 19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of r 2fo of the available & I Final determination of incentive (b)C4-) fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) (d) $_ .....0 of the maximum benefit of the "flat zone", earned by the conduct cbl(4j ofthe Electromagnetic Environmental Effects (E3) Testing in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (e) .g d,....-0 of the maximum benefit of the "flat zone", earned by the conduct of the Integrated Fire Control Event in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. (It is hereby acknowledged by the government that Raytheon completed the requirement for this flat zone and earned a "Flat Zone" schedule incentive of. or"l0 of the available • ): Final determination of incentive fee payment utilizing the "Flat Zone" amount will be made at the conclusion of the contract.) *NOTE: The potential has been (i)&Title 10 Sec (f) 53 *~o of the maximum benefit of the "flat zone", earned by the 130 (a) (b) (b)c+) conduct of the Functional Configuration Audit (FCA) #1 in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. *Note: The potential has been increased from DASG60-98-C-OOOI P00264 10 ~)Y-~ to movement of the _ncentive fo (b)(3)(A) ~!!!E:tio~===='ue (i)&Title 10 Sec 130 (a)(b) (g) .-' ~ of the maximum benefit of the "flat zone", earned by the ~J)(4 conduct of Developmental Test 2 (DT -2) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. * •••1 /0 of the maximum benefit of the "flat zone", earned by the conduct (b )(4) (1:1)( I of the Early User Test (previously defined as Limited User Test) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SDD Contract, Section H-19(c), dated 08/10/12. * (i) ~ Sio of the maximum benefit of the "flat zone", earned by the conduct of the Final Functional Configuration Audit (FCA) in accordance with the criteria set forth in Section J attachment entitled Flat Zone Performance Criteria for JLENS SOD Contract, Section H-19(c), dated 08/10/12. * (3) For Earned Value and cost reporting purposes, the estimated cost value of ••••Iwill be used. d. Changes issued under FAR 52.243-2, Changes - Cost Reimbursement In the event of a change issued under FAR 52.243-2, Changes - Cost Reimbursement, it is agreed that changes to the performance and schedule incentive may be considered a part of the equitable adjustment. In the event that any Options to CLIN 0017 are added and exercised, the incentive fee for cost and schedule/performance applicable to the Option will be incorporated in accordance with the incentive fee structure of this provision. SECTION J - LIST OF DOCUMENTS, EXHIBITS AND OTHER ATTACHMENTS The following have been modified: J.:l. SECTlO]\: J - LIST OF DOCUMENTS, EXHIBITS A~D OTHER ATT ACHME]\:TS The following have been modified: DASG60-98-C-OOO 1 P00264 Page 6 of 10 5. SECTION J - LIST OF ATTACHMENTS: Section J is changed as shown below: #OF PAGES Contract Security Classification Specification (DO Form 254), 14 May 09 11 Revision II (Added per Modification POO 187) (DO Form 254 mailed via US Postal Service) Contract Security Classification Specification (DO Form 254), 14 Apr II 13 Revision 13 (Added per Modification P00235) JLENS Software Source Code Specifically Negotiated License, 04 Sep 08 8 License Number JLENS-SWLA-O 1 (Added per Modification POOI66) CLIN 0017: JLENS System Development and Demonstration 30 Nov 06- 37 (SOD) Program Statement of Work (Revised by Revised 20 Feb 07 Incorporating CSDR Plans dated 20 Febr 2007 in Appendix C per Modification POOI36) JLENS System Development and Demonstration Revised 06 Apr 09 38 (SOD) Program Statement of Work (Added per Modification POOI87) JLENS System Development and Demonstration Revised 09 Mar 10 36 (SOD) Program Statement of Work, Revision 2 (Added per Modification P00207) JLENS System Development and Demonstration Revised 01 Sep 11 36 (SOD) Program Statement of Work, Revision 3 (Added per Modification P00239) JLENS System Development and Demonstration Revised 26 Sep II J6 (SOD) Program Statement of Work (Added per Modification P00240) (b)(3)(A)(i)&Tillc 10 Sec 130 (a)(b) Contract Data Requirements List (DO Form 1423) 01 Dec 06 63 Exhibit A with Distribution List & Data Item Nos. BOOI through B062 (Replace Data Item Nos. 8026 and B027, only Revised 05 Apr 07 Per Modification POO 1J6) (Replace Data Item Nos. B048 and B049, only Revised 24 Oct 07 Per Modification POO 143 & to add statement in Section A of Modification POOI4J) (Replace Data Item No. BOJJ only, per Revised II Jul 08 Modi fication POO 16/) DASG60-98-C-Ooo 1 P00264 Page 7 of 10 Contract Data Requirements List (DO Form 1423) Revised 07 May 09 2 Exhibit A, Data Item Nos. B001 and B0 14 (Added per Modification roo 187) Contract Data Requirements List (DO Form 1423) Revised 20 Mar 09 60 Exhibit A, Data Item Nos. 8 002 through 8062 (less 8014 ) (Added per Modification POOIS7) Contract Data Requirements List (DO Form 1423) Revised 30 Aug II 2 Exhibit A, Data Item Nos. BOOI and 8014 (Added per Modification P00239) Contract Data Requirements List (DO Form 1423) Revised 31 Jul 12 Exhibit A, Data [tern Nos. 8004 (Addcd per Modification P002S7) "Added statement below to address weekends/Holidays: 24 October 07 (In Mod POO143) "Per a mutual agrcement between Raytheon and JLENS Product Office all Contract Data Requirements Li st (CORL's) (DO Form 1423) are due on the next business day after the required due date if the due date falls on Saturday, Sunday or a Govemmcnt Holiday. In addition, for any CDRL with a requirement to resubmit within 10 days or less after receipt of comments, where Raytheon receives the comments on a Friday, the timeframe for rcsubmittal will begin on thc neit business day. Statement added in Mod P00143 on 24 Oct. 2007. GFEiGFP/GF$ List for SOD 28 Nov 06 2 Replaced wi th Rev. B List 15 Oct 07 6 "'Add items below Revised 22 Ocl 07 For record-keeping purposes (Pcr Mod PO0143) Replaced wi th Revision C List 09 Mar 09 12 (Per Modification POO l 83) Replaced with Rcvision 0 List 23 Feb 10 11 (Per Modification P00207) "'Per the D CMA is authorized rent free use on a non-interference use of (b)(4) the equipment listed below on JLENS Fire Control Radar Prime Contract DASG60-98-C- 0001 for the period from 19 April 2007 through 30 September 20 11 . OO~.!o'73 DASG60-98-C-OOOI P00264 Page 8 of 10 Hereby added in Mod POO 148 for tracking purposes; Originated in Basic Contract: Government Furnished Equipment - Spiral 1 20 Jun 03 I List (Spiral I Equipment Transferred to Government 25 Mar 07· 34 pages Contract DASG60-00~ 1149 (attached) (Revised 21 Nov 07)- 34 pages _ (b)(6) (b)(4 ) -NOTE: Items 1-1 060 transferred to Contract DASG60-00-e.OO91 per revised GFE list daled 21 Nov 07. Items 1061 - 1116 GFE items retained on Contract DASG60-98-C-OOOI for Spiral 2 per aFE list dated 25 Mar 07. J LENS Performance Specification, MIS-PRF-5S628. 27 Jun 08 136 Revision A (Added by rererence per Modification POO168) Annex A to the JLE NS Performance Specification, 27 lun 08 \0 MIS-PRF-5S628, Revision A (Added by reference per Modification P00168) JLENS SOD 00250 Plan II DeeM , (Added per Modification P00207) Engineering Change Proposal (Eep) MI-N3893. 15Novi0 Revision 2, CORL B039-005b " Engineering Change Proposal (ECP) MI-N3894, 18 Aug 10 16 CORL B039-006 Engineering Change Proposal (ECP) MI-N3895. 28 Sep 10 '0 CORL 8039-007 Engineering Change Proposal (ECP) Jl1359 20 lun 11 7 (Added per Modification POO240) Flat Zone Performance Criteria for JLENS SOD 01 Nov 11 4 Contract, Section H- 19(c) (Added per Modification P00242) Revised Flat Zone Performance Criteria for lLENS SOD 02 Aug 12 7 Contract, Section H-19(c) (Added per Modification P00257) Test Spares List Undated 8 (Added per Modification POO247) SubCLIN 0017AA The following added by reference per Modification PO00264 DASG60-98-C-OOO I P00264 Page 9 of 10 'Government Furnished Equipment list (GFE) 24 Jan 13 1 ..... Contractor Furnished Property list (CFP) 24 Jan 13 1 (Includes Cooperative Engagement Capability (CEC Hardware) " SDD DD250 Plan 11 Feb 13 4 ... Functional Configuration Audit (FCA) Plan 14 Feb 13 28 FY13 Master Test Plan, H492257 Rev b 04 Feb 13 62 " Flat Spot Opportunity Incentive Spreadsheet N/A 7 , FY13 Final Test Spares List 04 Mar 13 6 CLIN s 0023 and 00024 JLENS Simulation Support 28 January 2008 2 pages SOW dated 28 January 2008 For JDEP, Nimble Fire and Simulation Suppon Tasks (Added per Mod POO 160) CLIN 0025 JLENS Integrated Fire Control Demonstration Program 14 Jan 08 3 Statement of Work, Revision 3 (Added per Modification POOI65) JLENS Integrated Fire Control Demonstration Program 25 Jul 08 11 Program and Technical Clarification Description, incorporated herein by reference (Added per Modification POOI65) JLENS Integrated Fire Control Demonstration Program 14 Sep 09 3 Statement of Work, Revision 5 (Added per Modification P002! I) lLENS Integrated Fire Control Demonstration Program 30 Mar 10 26 Program and Technical Clarification Description, incorporated herein by reference (Added per Modification P00211) Contract Data Requirements List (DD Form 1423) 16 Oct 01 19 Exhibit B, Data Items Nos. BOO 1 through B004, with Data Item Descriptions (Added per Modification POO \65) Contract Data Requirements List (DO Form 1423), 16 Jun 10 6 CLIN 0028, Exhibit B, Data Item Nos. BOOI through 8006 (Added per Modification P002Il) DASG60-98-C-OOO I P00264 Page 10 of 10 CLfN 0027 JLENS System Integration Lab (SIL) Undated 6 Equipment List (Added per Modification POD 196) Revision to System Integration Lab (SIL) 02 Aug 10 6 Equipment List (Added per Modification P00217) (End of Summary of Changes) (b) (3) (A) (i)& Title 10 Sec 130 (a) (b) (b) (3) (A) (i)& Title 10 Sec 130 (a) (b) (b)(3)(A)(i)&Title 10 Sec 130 (a) (b) (b) (3) (A) (i)& Title 10 Sec 130 (a) (b) (b) (3) (A) (i)& Title 10 Sec 130 (a) (b) (b)(3) (A)(i)&Title 10 Sec 130 (a)(b) (b) (3) (A) (i)& Title 10 Sec 130 (a) (b) (b) (3) (A) (i)& Title 10 Sec 130 (a) (b) (b)(3)(A)(i)&Titlc 10 Sec 130 (a)(b) (h)(3)(A)(i)&Title 10 Sec 130 (a) (h) (b)(3)(A)(i)&Title 10 Sec 130 (a)(b) (b)(3)(A)(i)&Title 10 Sec 130 (a)(b) (b)(3)(A)(i)&Title 10 Sec 130 (a)(b) (b)(3)(A)(i)&Title 10 Sec 130 (a)(b) G <:( cx::: I oZ u CI CI V) Y" (b)(3)(A) (b)(4) FLAT SPOT INCENTIVE CRITERIA FOR SDD CONTRACT, SECTION H-19(C) (b)(3)(A) (b)(4) (b)(3)(A) FLAT SPOT INCENTIVE CRITERIA FOR (b)(4) ~a:: Iz a u £:) £:) Vl . -Vl (b)(4) I a Q.. Vl 5u.. (b)(4) FLAT SPOT INCENTIVE CRITERIA FOR \jS SDD CONTRACT, SECTION H-19(C) (b)(3)(A) (b)(4) (b)(4) w > (b)(4) I Z w U Z aI- 0- Vl Su.. (b)(4) (b)(4) (b)(4) (b)(3)(A)(i)&Titie 10 Sec 130 (a)(b) (b)(4) iI (b)( 3)(A) (i)&Titlc to Sec 130 (a) (b) (b)(3)(A) (i)&Title HJ Sec 130 (a)(bJ (b)(3)( A) (iJ&Title \() Sec 130 (a) (b)(4) (b) (b)(3)(A) (i)&Tillc 10 Sec 130 (a) (b) (b)(4) (bj(3)(A) (i)&Tilll.' 10 Sec \30 (a) ,bl (b)(4) (b)( 3)(A) (ij&T itlc 10 Sec 130 (a) (b) (b)(3) (A) (i)&Titlc 10 Sec I ) U (a) (b) (b)(J) (A) (i)&Titlc 10 Sec UO (al (b) (b)(4) (b)(3) (A) (i)&Title 10 Se, 130 (a) (b) (b) (3) (A) (j)& Title 10 S<, 130 (.) (b) (b)(4) (b)(4) (h)(4) (b)(3)(A) (i)&Titlc 10 See 130 (a)(b) (b)(3)(A) (i)&Titie 10 Sec 130 (a)(b) (h)(3)( A) (i)&Title 10 Sec 130 (a) (b) (b)(4) Raytheon (b)(3)(A) (i)&Titic 10 Sec 130 (a)(b) (b)(3)(A) (i)&Tille 10 Sec 130 (a) (b) (b)(3) (A) (i)&TiUe IOSee 130 (a) (n) (b)(4) Page 12 of62 OOd-'7DJ... CAGE Code 057 16 Doc H4 92 257 Rev - 4 February 20 13 (h)(3) IA) (i)&Title 10 Sec 130 (a) Ib) (b)(3)(A) (i)&Tille 10 Sec 130 (a)(b) (b)1 3)(A) (i)&Titlc 10 Sec 130 (a)(b ) (b)(4) lbyw; \.klfo. lut-) Co'/}; (?l~) (bl (4) ) 30 (a)(b) (b)(4) :, I (b)(3)(A) (i)&Title 10 Se,130(a) (b) (3)(A ) (b)14) (i)&Title 10 St.'C 130 (a)(b) (b)(4) (i)&Title 10 Sec 130 (a)(b) (" )(3)(A) (i)&Titie 10 Sec 130 (a) (b) (b )(3)(A) (i)&Titlc \0 Sec 130 (a) (b) (bJ(4) (b)(3)(A) 10 See 130 (a)(b ) (b)(3) (A) (i)&Titlc IOSee no (a ) (b) (b)(3)(A) (i)&Title III See 130 (a)(b) (b)(4) (b)(J,)( A j (ij&Title 10 Sec 130 (aj (bl (b l('1 (b)(3)(A) (i)&Title 10 Sec 130 (a) (bl (b)(3)(A) (i)&Titlc 10 Sec 130 (a) (bl (b)(4) 130 (i)&Titlc 10 Sec 130 (a)(b) (i)&Til lc (b)(3)(A) (i)&Titic 10 Sec 130(a) (hi (b)(4) (b)(3)( AI (i)&'Ti tle 10 Sec 130 (a) (bl (b)(J)(A) (i)&Tille 10 Sec 130 (iI) (1I) (h)(J)(A) (i)&Titlc 10 Sec 130 (a) (hi (h)(3)(A) (i)&Title 10 See 130 (a)(b) (h) (4) (b)(3)(Al (i)&Titlc 10 Sec 130 (al (b) (b )(3) (A) (i)&Titic 10 Sec 130 (a) Ibl (b)(3)(A) (i)&Tillc 10 Sec 130 (a)(bl (b)(4) (iJ&·fi". I. 130 (a)(b) (b)(3)(A) (i)&Tille 10 Sec 130 (a) (b) (b)(3)(A) (i)&Title 10 Scc 130 (a)(b) (Il)(J)(A) (i)&Titie 10 Sec 130 (a)(b) (b)(J)(A) (i)&-Titlc 10 Sec 130 (a) (b) (b)(4) (b)(3)(A) (i)&Titlc 10 Sec 130 (a)(b) (b)(3)(A) (i)&Titlc 10 Sec 130 (a) (b) (b)(3)(A) (i)&TitJe LO Sec 130 (a)(b) (b )(3)(A) (i)&Title 10 Sec 130 (a) (b) OOJ')/~ (b) (4) OOdl:L1 (h)(3)( A) (i)&Titic 10 130 (a) (b) (b)(4) (b)(3)(A) (i)&Titl c \0 Sec 130 (a)(b) (hJ(4) (b)(3)(A) (i)&Title 10 Sec 130 (a) (b) (h )(3)(A) (i)&TitJe 10 Sec 130 (,,)(b) (b)(4) (h)(4) (bIl3I1A) (i)&Titic JO Sc, 130 (3 ) (') (')(4) (b)[7)( E) (b )(3)[A) (i)&Titlc 10 Sec 130 (a) (bl (b)(J) (A) (i)&Tillc 10 Sec 130 (a)(b) (b)(4) (b)(3)(A) (i )&Tille IOScc130 (a)(b) (b)(3)(A) (i)&Titie 10 Sec 130 (a)(b) (b)(3)(A) (i)&Titlc 00;2'131 (b)(4) (bj(3)(A) (i)&Titlc 10 SCI,: L30 (a)(b) (b) (4) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(4) Page 48 of 62 COD.'133 (b)(3)(A) (i)&Title IOxe 130 (a)(b) (b)(3)(A) (i)&Tllle IO S« 130 (a)(b) (b)(3){A) (i)&Titie 10 51!' 130 (a) Ib) Ib)(4) (b )(3) (AI (i)&Tille IU Sec 130 (a) (bl (b)(3)(A) (i)&Title 10 Sec 130 (a)(b) (b)(3)(A) (i)&Titlc lOSe<: 130 (al (bl (b)(4) (b)(3)(A) (i)&Titic 10 Se, 130 (a)(b) (b)(3) (A) (i)&Titlc 10 Sec 130 (a) (b) (b)(3)(A) (i)&Title 10 Sec 130 Cal (b) (h)(4) (b)(3)(A) (i)&Title 10 Sec 130 (a) Ib) (b)(J)(A) (i)&Titlc 10 Soc 130 (al Ib) (b)(3)(A) (i)&Title 10 Sec 130 (a) Ib) Ib)(4) (h)(3)(A) (i)&Title 10 See 130 (a) (b) (b) (3I1 A) (i)&Titic 10 See 130 (a) (b) (b)(3) (A) (i)&Till e 10 Sec 130 (a) (b) (b)(4) (b)(3) (A) (i)&Title 10 51:' 130 (a) (b) (b){3)(A) (i)&Titlc 10 SCI; 130 (a)(b ) (bJ(4) -OJ~'74Y (h)(3)(A) (i)&Title \0 Sec 130 (a) (bl (b)(3)(A) (i)&Titlc 10 Sec 130 (a)(b) (b)(3)(A) (i)&Titlc 10 Sec J 30 (a) (bl (b)(4) (b)(3)(A) (i)&Title 10 SC( 130 (a) (h) (b)(3) (A) (i)&Title 10 Se( 130 (a) (h) (h)(3)(A) (i )&Title iO SC( 130 (a) (h) (b)(4) (b)(3)(A) (i)&Tillc 10 Sec 130 (a) (b) (b )(3)(A ) (i)&Titlc 10 Sec 130 (a) (b) (b)(3)(A) (i)&Titlc 10 Sec 130 (a) (b) (b)(4) (b)(3) (A) (j)&Tille 10 Sec:: 130 (a) (b) (b)(3) (A) (i)&Till c 10 Sec 130 (a) (b) (b)(3) (A) (i)&Titl e 10 Sec 130 (a) (b) (b)(4) (b)(3) (A) (i)&Ti tie 10 S" 130 (a)(b) (b)(3) . (AI (i)&Tit Ie 10 Se, 130 (a) (bl (b)(3) (AI (i)&Titl e IV Sec 130 (a) (hi (b)(4) (h)(3)(A) (i)&Tillc 10 Sec 130 (a)(b) (b)(3)(A) (i)&Tille 10 Sec 130 (a)(b ) (b )(3) (A) (i)&Title 10 Sec 130 (a) (h) (b)(4)